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A b s t r a c t  
 
The Structural Maintenance of Chromosomes (SMC) proteins play a number of 
crucial roles in the metabolism of chromosomes. The Smc5-Smc6 complex is the least 
well understood of the complexes formed by SMC proteins. Hitherto, the Smc5-Smc6 
complex has been linked to protein post-translational modification by sumoylation 
and restart of collapsed replication forks by homologous recombination between sister 
chromatids (SCR). However, a detailed characterization of the roles of the Smc5-Smc6 
complex is missing.  
 
The objective of this study is to characterize the function of the Smc5-Smc6 
complex in DNA repair by SCR, and to identify sumoylation substrates of MMS21, a 
E3-sumoligase subunit of the Smc5-Smc6 complex. 
 
Recent studies suggest that DNA single-strand nicks are transformed to double-
strand breaks in a replication-dependent manner, and this triggers SCR. I developed an 
assay for the activation of SCR based on the expression of a site-specific nickase. 
Unfortunately, a stable site-specific nick was observed in only 30% of the population. 
This percentage was insufficient for the study of the molecular role of the Smc5-Smc6 
complex during SCR. However, this assay could be used to confirm and further 
characterize the activation of SCR upon replication-induced DNA damage. 
 
To study the role of sumoylation within the Smc5-Smc6 activity, I have 
developed a proteome-wide approach for the in vivo identification of sumoylation-sites 
by mass spectrometry. This technique can be used for the identification of MMS21 
substrates and for the mapping of their sumo-acceptor lysines. The mapping of sumo-
acceptor sites allows the generation of sumo-specific mutant proteins that can be used 
to study the function of sumoylation. More than 360 sumo-acceptor lysines, belonging 
to 245 different proteins, were identified. In vivo sumoylation at these lysines was 
verified by MS-independent methods. In addition, I developed a SILAC-based mass 
spectrometry assay for the quantitative study of site-specific sumoylation.  
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1.1. Genome stability 
 
 The maintenance of genomic stability is fundamental to cell survival in both 
yeast and higher eukaryotes. The major causes of genome instability are DNA damage 
and errors made during DNA replication. Genomic instability drives tumourigenesis in 
humans, and is one of the main focuses in clinical science research.  
  
 DNA damage can arise through two main tracks. First, exogenous or 
environmental agents as UV light, ionizing radiation and a wide range of genotoxic 
chemicals can cause DNA lesions. UV-B light causes crosslinking between adjacent 
pyrimidines bases. These pyrimidine dimers introduce conformational changes in the 
DNA structure that can prompt replication errors and cell cycle arrest. UV-A light 
generates free radicals, which can interact with DNA producing oxidative damage. This 
kind of damage is implicated in mutagenesis, carcinogenesis and ageing. Ionizing 
radiation causes breaks in the DNA strand, increasing the risk of rearrangement and 
replication fork blocks.  
 
 The second main source of DNA damage is common metabolic processes in the 
cell. For instance, reactive oxygen species, a normal product from oxidative respiration 
and lipid metabolism, are the major source of oxidative damage (Cadet, Berger et al. 
1997). Other processes like replication, or DNA repair itself can present a risk to 
genomic stability too. Replication defects and stalled replication forks promote 
mismatches, gaps and breaks in the DNA strand. Repair mechanisms, which in normal 
circumstances aim to restore DNA integrity, can be error-prone thus introducing 
mutations during the process. These activities can lead to mismatches and 
establishment of mutations, loss of heterozygosity between homologous alleles, loss or 
gain of genomic information, and chromosomal rearrangements (Hoeijmakers 2001; 
Friedberg 2003).  
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1.1.1 DNA repair 
 
Eukaryotic cells have developed a number of DNA repair mechanisms that aim 
to maintain DNA stability. DNA damage involves detectable structural changes in the 
DNA molecule. These changes trigger the activation of repair and damage-avoidance 
pathways together with DNA damage checkpoints. DNA repair pathways are under 
rigorous control and commonly are highly specific to the nature of the damage and the 
cell cycle stage (Hoeijmakers 2001). 
 
 Initially, specialized proteins (i.e. ATM, ATR) recognize the site of the lesion, 
these are referred to as DNA damage sensors (Shiloh 2003). Activated sensors start a 
DNA damage response (DDR) that involves transcriptional and post-translational 
regulation. Immediately after DNA damage is recognized, checkpoint proteins are 
recruited and activated. Checkpoint activation prompts a wide variety of cellular 
responses including stabilization of the replisome, regulation of transcription and the 
cell cycle, chromatin remodelling, recruitment of DNA repair machinery and, in higher 
eukaryotes, senescence and apoptosis (Harrison and Haber 2006; Branzei and Foiani 
2008; Jackson and Bartek 2009). Checkpoint signalling is normally transmitted and 
amplified by kinase cascades.  
 
 DNA damage can affect one DNA strand or both. In the case where only one 
of the DNA strands is damaged, the complementary strand is an ideal template for 
error-free repair (Hanawalt and Haynes 1967). Some examples of this type of DNA 
repair are base excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR) and lesion bypass.  
 
 While BER and NER are the most prominent repair pathways during G1, and 
although they are not restricted to this phase, mismatch repair and lesion bypass are 
crucial repair pathways during replication. These pathways ensure the accurate 
replication of the genome so an identical copy of the genome is transmitted to the 
daughter cells; hence genomic stability is kept through generations. 
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 Mismatch repair recognizes and repairs biosynthetic errors in freshly replicated 
DNA, thereby improving dramatically the fidelity of DNA replication (Jiricny 2006). 
Repair by lesion bypass is divided into translesion synthesis (TLS) and template switch 
(TS). TLS involves a polymerase switch, in which an error-prone polymerase is 
incorporated into the replisome to allow replication across a damaged region (Lehmann 
AR. et al., 2007). TS repairs single strand gaps left by the replisome. The gap is filled 
using the undamaged strand from the sister chromatid as a template in an error-free 
process similar to homologous recombination (Hoege C. et al., 2002). 
 
 Lesions where both DNA strands are damaged, e.g. double strand breaks 
(DSBs), are potentially far more challenging to DNA stability, as there is no 
complementary strand that can be used as a template. In accordance with this, a single 
unrepaired DSB is able to fully activate the checkpoint response and to stop the cell 
cycle (Paques and Haber 1999). In eukaryotes, DSBs can be repaired by two different 
pathways: homologous recombination (HR) or non-homologous end joining (NHEJ), 
error-free and error-prone respectively (Figure 1). 
 
 NHEJ is a mechanism by which the two ends of the break are ligated again. 
NHEJ is initiated by the loading of the Ku heterodimer to the free ends. The presence 
of the Ku heterodimer prevents nucleotide resection at the ends. Then, the ligase IV 
(Dnl4 in budding yeast) links the two free ends. NHEJ repair can lead to errors. The 
free DNA ends could be linked to an incorrect partner, especially if there is more than 
one DSB (Hefferin and Tomkinson 2005). The NHEJ pathway is the most common 
option in mammals cells and in budding yeast when there is no homologous sequence 
available (i.e. G1 in haploids cells). 
 
 DSB repair by HR is characterized by 5’-3’ resection of the DNA strand ends 
and the use of a homologous DNA sequence as a template. To begin with, the DSB 
ends are bound by the MRX (Mre11-Rad50-Xrs2) complex (Lisby, Barlow et al. 2004). 
This complex, together with the Sae2 endonuclease initiates degradation from the 5’ 
end of the DNA. Long 3’ single strands are then generated by the activity of the 
helicase Sgs1 and nucleases Exo1 and Dna2 (Mimitou and Symington 2008; Zhu, 
Chung et al. 2008). The newly exposed single strand DNA (ssDNA) is coated with 
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RPA. Rad51 is loaded then in a Rad52-dependent manner, helping the search for a 
homologous sequence and the recombination event (Shinohara and Ogawa 1998). HR 
can occur between three different sequences: sister chromatids, homologous alleles in 
diploid cells, and non-allelic homologous repeats. The choice of the homologous 
template largely depends on the cell cycle and the availability of a sister chromatid. 
Indeed, sister chromatid recombination (SCR) seems to be the preferred pathway for 
HR both in yeast and mammals. A sister chromatid is only available from S to G2-M 
phase and provides the only error-free pathway by HR (Kadyk and Hartwell 1992; 
Johnson and Jasin 2000; Gonzalez-Barrera, Cortes-Ledesma et al. 2003).  
 
 
 
 
Figure 1. Repair of a DSB by 
homologous recombination (HR) and 
non-homologous end join (NHEJ). In 
NHEJ, after recognition by the Ku 
heterodimer, the free ends are simply 
joined together. In HR, resection 
initiated by the MRX complex, 
exposes single strand DNA. Then, 
proteins like RPA, Rad51 and Rad52 
bind the ssDNA and help in the search 
for homologous sequence and the 
recombination event (strand 
invasion).  
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1.2. SMC proteins 
 
SMC proteins are highly conserved chromosomal ATPases that play a number 
of crucial roles in the metabolism of chromatin and chromosomes as well as in DNA 
repair. Eukaryotic SMC proteins are present in three distinct protein complexes 
containing a heterodimer of SMC proteins and additional non-SMC subunits (Figure 
2). 
 
 
 
 
 
 The most studied complex is cohesin, due to its role in sister chromatid 
cohesion (Ivanov and Nasmyth 2005). It contains Smc1 and Smc3 and two additional 
subunits, Scc1 and Scc3. In addition to cohesion, cohesin is required to mediate repair 
of chromosomes by sister chromatid recombination (Sjogren and Nasmyth 2001), and 
has a role in transcription (Mannini, Menga et al. 2010). 
 
The second SMC complex is condensin, known to play a role in the 
architecture of mitotic chromosomes. Condensin contains the Smc2-Smc4 heterodimer 
as well as three additional subunits; Brn1, Ycs4 and Ycs5. The main phenotypes 
observed in condensin mutants are the lack of chromosome condensation during 
mitosis and the presence of DNA bridges between segregating chromatids (Strunnikov, 
Hogan et al. 1995).  
Figure 2. SMC proteins are 
found in three different 
protein complexes; 
condensin, cohesin and Smc5-
Smc6 complex. These 
complexes contain a 
heterodimer of SMC proteins 
and additional non-SMC 
subunits.  
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Finally, the third SMC complex, Smc5-Smc6, is the least well understood. It 
contains the Smc5-Smc6 heterodimer and at least six additional subunits, termed Nse1-
Nse6. All Smc5-Smc6 Nse subunits are essential for cell viability and mutations in 
many of these genes cause DNA damage sensitivity. In addition to the as yet unknown 
essential function, the Smc5-Smc6 complex participates in a number of DNA repair 
related functions (Fujioka, Kimata et al. 2002; Harvey, Sheedy et al. 2004). Moreover, 
different studies implicate the Smc5-6 complex with the restart of collapsed replication 
forks, rDNA integrity and maintenance of telomeres. 
 
Replication forks can stall or even collapse at sites of unrepaired DNA damage 
(Branzei and Foiani 2005). Collapsed replication forks have the potential to generate 
DSBs and compromise the accurate completion of genomic replication (Kogoma 
1996). Studies in mammalian cells suggest that the major mechanism by which 
replication forks can be restarted is HR (Arnaudeau, Lundin et al. 2001). The Smc5-6 
complex has been suggested as part of this HR pathway. A possible role for the complex 
in this pathway could be to facilitate RAD51-dependent strand invasion and exchange 
(Torres-Rosell, Machin et al. 2005).      
 
The Smc5-Smc6 complex is also necessary for the correct segregation of 
repetitive regions. Accordingly, binding of Smc5-Smc6 subunits is increased in 
repetitive DNA regions such as the rDNA or telomeres. In addition, mutations of the 
genes SMC5 and SMC6 result in defective segregation of the rDNA (Torres-Rosell, 
Machin et al. 2005). The Smc5-Smc6 complex, in this context, might have a role in 
ensuring the proper segregation of chromatids during anaphase by preventing the 
appearance of sister chromatid junctions.  
 
This possibility is supported by observations of mitotic non-disjunction in 
Smc5-Smc6 mutants. The reason behind the non-disjunction phenotype are two fold: 
presence of recombination intermediates and lack of complete replication (Torres-
Rosell, De Piccoli et al. 2007). 
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1.2.1 SMC5-SMC6 complex in genome stability 
 
 
The inhibition of the Smc5-6 complex in budding yeast and humans prompts 
defects in processes where HR is required. In both organisms, the Smc5-Smc6 complex 
is recruited to DNA DSBs to help in their repair by homologous recombination 
between sister chromatids (De Piccoli, Cortes-Ledesma et al. 2006; Potts, Porteus et al. 
2006). 
 
In humans, Smc1-3 (cohesin) is Smc5-6-dependently recruited to DSBs. 
Interestingly, although SCR is notably reduced by the knockdown of the Smc5-6 
complex, repair by NHEJ and HR other than SCR is not affected (Potts, Porteus et al. 
2006). Similarly, studies in budding yeast showed that the Smc5-6 complex is recruited 
to HO-induced DSBs in an Mre11-depended manner. However, no recruitment is 
observed to HO-induced DSBs which are not repaired by HR due to the lack of sister 
chromatid (Lindroos, Strom et al. 2006).  
 
Even though the Smc5-6 complex has a critical role in DSB repair, its specific 
role during HR remains unclear. The Smc5-Smc6 complex might help with the 
chromatid interconnections created during the repair process, which implies that it has 
a structural role during the HR process itself. This conclusion would link the Smc5-6 
complex with cohesin, which is known to hold sister chromatids together to mediate 
DSB repair. Further supporting this possibility, the localization of cohesin and the 
Smc5-Smc6 complex in undamaged chromosomes overlaps. This localization is altered 
in the absence of the cohesin subunit Scc1 and Scc2 (Torres-Rosell, Machin et al. 2005; 
Lindroos, Strom et al. 2006). In addition, the yeast mutant Smc6-9 mutant presents a 
high level of Gross Chromosomal Rearrangements (GCRs). These GCRs are produced 
by the use of donor other than the sister chromatid during HR (De Piccoli, Cortes-
Ledesma et al. 2006).  
 
In fission yeast, the Smc5-Smc6 complex is also required during HR. In this 
context, the Smc5-Smc6 complex affects the processing of the recombination-
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dependent DNA structures formed upon replication fork collapse (Ampatzidou, 
Irmisch et al. 2006), and it is needed for the efficient recruitment of RPA and Rad52 to 
stalled replication forks. The Smc5-Smc6 complex also acts as a positive regulator of 
recombination at DNA repetitive regions like rDNA (Irmisch, Ampatzidou et al. 2009).      
 
Despite being a major repair pathway, the precise molecular mechanism of SCR 
has yet to be described, as has the part played by the Smc5-6 complex. The main reason 
behind the poor understanding of this process is the lack of an in vivo model for the 
study of SCR in detail.  
 
During SCR, repair of the damaged double strand relies on the undamaged 
sister chromatid. Normally, recombination assays use inducible DSBs catalyzed by 
sequence specific endonucleases. However, this will cause both sister chromatids to 
become cut, therefore creating a situation not suitable to be repaired by SCR (Figure 3).  
 
 
Figure 3. Current studies based on an inducible endonuclease  (      ) do not create a DNA 
structure suitable to be repaired by SCR. The DSB created by the endonuclease can either (A) 
collapse the replication fork (       ) if the cut is made in a unreplicated sequence, or (B) cut both 
sister chromatids. On the other hand, (C) single strand nicks transformed into a DSB in a 
replication-dependent manner are likely to be repaired by SCR.  
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In order to circumvent this problem, an alternative suboptimal recognition site 
for the HO-endonuclease has been attempted. This site promotes cleavage of only one 
DNA strand. Experiments suggest that these single strand nicks are transformed into 
DSBs in a replication-dependent manner and then repaired by SCR in dividing cells 
(Gonzalez-Barrera, Cortes-Ledesma et al. 2003; Cortes-Ledesma and Aguilera 2006). 
However, the cleavage efficiency at this recognition site is too low to perform any 
detailed study of the repair mechanism. A replication-dependent DSB was created in 
less than a 10 % of the population (Cortes-Ledesma and Aguilera 2006). 
 
Currently, there is mounting evidence that single strand nicks and gaps in the 
DNA could be transformed into DSBs in a replication-dependent manner.  This is 
probably an effect of uncoupled replication fork progression. In addition, replication-
dependent DSBs have been proposed as the most common substrate for SCR 
(Kuzminov 1999; Branzei and Foiani 2005; Lettier, Feng et al. 2006; Caldecott 2008).    
 
At the present time, there are experimental methods that generate single strand 
nicks and gaps, or that impair replication fork progression, e.g. hydroxyurea or 
camptothecin treatment. However, none of them are site specific, making the study of 
the molecular mechanism behind SCR very difficult (Hsiang, Lihou et al. 1989; Rouse 
2004; Altieri, Grillo et al. 2008; Duro, Vaisica et al. 2008).  
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1.3. Post-translational modifications and their role in genome stability 
 
 Post-translational modifications (PTMs) are covalent modifications of one or 
more residues of a given protein by addition or removal of a modifying group. In 
particular, PTMs are a key mechanism to increase the complexity of the proteome, and 
hence of the organism, relative to the size of the genome. 
 
PTM events in a protein might determine its interactions with other proteins, 
enzymatic activity, localization or conformation. For instance, every single step in the 
DNA damage response is tightly regulated by PTMs. Proteins involved in sensing 
DNA damage, recruitment of repair factors, or in the signal cascade for global cellular 
changes, are all targets of one or multiple PTMs. Example of this are the histones post-
translational modification (acetylation, phosphorylation, methylation, ubiquitination 
and sumoylation) required for the chromatin response to DNA damage, and the kinase 
cascade (involving phosphorylation) initiated by the DNA damage sensors ATM/ATR. 
Some of the most significant modifying groups are summarized below. 
 
Phosphorylation (Figure 4C) is the reversible addition of a phosphate group (PO43-) to a 
tyrosine, serine or threonine. The consequence of phosphorylation is normally a 
conformational change in the structure of the protein which leads to a difference in its 
activity. This modification is a regulator of many enzymatic activities and it is a key 
element for intracellular signalling (Cohen 2001).  
 
Acetylation (Figure 4B) is a common reversible modification of residues by 
addition of an acetyl functional group. Among other functions, acetylation regulates 
protein stability in most of human proteins by modification of the N-terminus alpha-
amine, and regulates the protein-DNA interaction of histones (Xiong and Guan 2012). 
 
Methylation (Figure 4G) is a common regulator of gene expression based on 
the addition of up to three methyl groups to a protein residue, typically arginine or 
lysine. The most studied substrate of methylation has been histones (Lake and Bedford 
2007).  
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Acylation (Figure 4E), or the attachment of fatty acyl groups to a protein 
residue, is a mediator of protein-protein interactions and regulator of protein cellular 
localization. 
 
 Glycosylation (Figure 4A) is the reversible site-specific attachment of glycans to 
either a nitrogen of asparagine or arginine residues (N-linked) or to a hydroxy oxygen 
of serine, hydroxylysine, threonine, tyrosine or hydroxyproline residues (C-linked). 
Glycosilation regulates protein folding and activity, gene expression, and cell-cell 
recognition.  
 
 Sulphation (Figure 4I) is the attachment of a sulphate group to a tyrosine 
residue. This modification modulates the strength of protein-protein interactions and 
protein-ligand interactions.  
 
 Disulphide bonds (Figure 4F) are formed between the thiol groups of cysteine 
residues. These bonds are critical for the folding and stability of some proteins and can 
also regulate intermolecular crosslinks.  
 
 Ubiquitin and ubiquitin-like proteins (UBLs) (Figure 4D) are small peptides 
containing an ubiquiton fold, a common 3D structure. Modification by covalent 
attachment of ubiquitin or UBLs is ATP-dependent and in most cases reversible. The 
consequences are modifier- and substrate-dependent. 
 
Non-standard amino acids (Figure 4H) are also formed as a post-translational 
modification. These include the hydroxylation of proline or lysine, carboxylation of 
glutamic acid, and the pyroglutamic acid, among others. The presence of these non-
standard residues is often of major importance for the activity of the protein.  
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Figure 4. Most significant post-translational modifications (Seo and Lee 2004; 
Walsh, Garneau-Tsodikova et al. 2005, for review on protein post-translational 
modifications). 
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1.4. Protein modification by ubiquitin-like modifiers 
 
 Small polypeptides can also act as protein modifiers. They become attached to a 
target protein by a covalent link. These modifications are generally reversible and ATP-
dependent.  
 
 The first polypeptide found to be a protein modifier was ubiquitin (discovery 
awarded with the Nobel Prize in Chemistry in 2004). Ubiquitin is a small (76-residue), 
omnipresent, and highly conserved protein found in all eukaryotes. Its conjugation 
process requires ATP-dependent activation and aims to attach ubiquitin to a specific 
target protein. Ubiquitin becomes attached by a covalent link between its C-terminus 
and the ε-amino group of a lysine residue at the target protein. The ubiquitin pathway 
is governed by a myriad of different enzymes which confer the characteristics of target 
specificity and high regulation. Commonly, ubiquitin forms chains, although mono-
ubiquitin modification has also been found in some substrates. Chains are lengthened 
by adding one or more additional ubiquitins to a lysine residue present at an ubiquitin 
already attached to the target-protein.   
 
 Protein modification by ubiquitin was first thought to work essentially as a 
degradation signal for proteins. For this purpose, a chain of at least four ubiquitins is 
needed to indicate that the target-protein must be degraded. Degradation is carried out 
by the 26S proteasome, which will recognize the ubiquitin chain. Today it is known 
that the ubiquitin pathway plays a broader role within the cell, for example protein 
modification by ubiquitin is a crucial regulator of the maintenance of genome stability, 
DNA repair, and checkpoint response.     
 
 Since the discovery of ubiquitin many other distinct ubiquitin-like proteins 
(UBLs) have been described as protein modifiers. UBLs include SUMO(Smt3), 
Nedd8(Rub1), Urm1, Ucrp, Fub1, Atg8 and Atg12 among others. UBLs share with 
ubiquitin a similar three-dimensional structure, the β-grasp fold. However, UBLs might 
or might not have a high sequence similarity with ubiquitin, and the charge distribution 
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and surface residues can be markedly different. These characteristics underpin the 
distinctive roles played by the different UBLs. 
 
 Hitherto, all UBLs for which a covalent link with their target-proteins has been 
proved share the same C-terminus residue, a glycine. Most commonly, UBLs become 
attached to the target protein by creating an amide bond between the carboxyl group 
of the glycine situated at their C-termini and a lysine side chain from the target 
protein. A growing number of exceptions are being discovered where UBLs are 
attached to a different residue rather than lysine, e.g. to a cysteine residue or to the free 
α-NH2 group at the C-terminus residue of the target protein. 
 
Similarities among UBLs are not only to be found in their structure but also in 
their enzymatic pathway. Most UBLs are synthesized as an inactive precursors. 
Presursor UBLs are cleaved by an UBL-protease so that a glycine at the C-terminus is 
exposed. After the cleavage, UBLs are activated by an E1-activating enzyme. E1 
enzymes create a high-energy ATP-dependent bond with the UBL at its C-terminus. 
The UBL modifier is then transferred from an E1 to an E2-conjugating enzyme. The 
E2 enzyme alone or with the assistance of an E3-ligase enzyme performs the last step, 
by which the UBL modifier becomes attached to the target protein (Figure 5). 
 
 
 
 
 
 
Figure 5. UBLs conjugation pathway. 
A UBL inactive precursor is cleaved at 
the C-terminus before being activated 
by the E1 enzyme. E2 and E3 enzymes 
are responsible to attach the UBL to 
the target protein.  
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 UBLs such as ubiquitin are found in all eukaryotes and are involved in many 
cellular processes such as regulation of cell cycle, transcription, protein localization and 
DNA damage repair. In the following sections a more detailed description of some of 
these UBLs will be presented.     
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1.5. Protein modification by SUMO 
 
 The small ubiquitin-related modifier (SUMO), discovered in 1996 (Shen, 
Pardington-Purtymun et al. 1996), is the UBL that more research attention has 
captivated and for which more conjugation targets are known. The SUMO proteins are 
reversible protein modifiers present in all eukaryotes and highly conserved between 
species. The SUMO conjugation pathway, also called sumoylation, aims to covalently 
attach SUMO to a given substrate and it is involved in a myriad of cellular processes, 
among them, transcription, nuclear transport, signal transduction, chromosome 
segregation, replication and DNA repair (Johnson 2004; Geiss-Friedlander and 
Melchior 2007; Gareau and Lima 2010). Sumoylation is essential for viability in most 
eukaryotic organisms so far studied, including A. thaliana (Saracco, Miller et al. 2007), 
S. cerevisiae (Johnson, Schwienhorst et al. 1997), C. elegans (Fraser, Kamath et al. 
2000), D. melanogaster (Apionishev, Malhotra et al. 2001), vertebrate cells in culture 
(Hayashi, Seki et al. 2002) and mice (Nacerddine, Lehembre et al. 2005).   
 
 Members of the SUMO family share little homology with ubiquitin in surface-
charge distribution or amino acid sequence (≈18%). However, they present a similar 3D 
structure, in particular at the C-terminal folded domain (Bayer, Arndt et al. 1998; 
Mossessova and Lima 2000). In addition, all members of the SUMO family share a 
similar region at its N-terminus not present in any other UBL.    
 
 A single SUMO gene is found in S. cerevisiae (SMT3), C. elegans (SMO-1) and 
D. melanogaster (SMT3), whilst several SUMO genes are present in vertebrates and 
plants. Four genes in the human genome, SUMO1-SUMO4, encode for proteins of the 
SUMO family. Of these proteins, SUMO2 and SUMO3 are substantially alike (97% 
identical) and only share 50% of sequence similarity with SUMO1. Accordingly, 
SUMO1 and SUMO2/3 seem to be functionally distinct and their conjugation 
pathways have different substrates (Saitoh and Hinchey 2000; Vertegaal, Andersen et 
al. 2006). No role has been yet identified for SUMO4 and even its ability to be 
conjugated in vivo remains unproved (Owerbach, McKay et al. 2005).  
	   30	  
1.5.1 Conjugation pathway 
 
 SUMO is a small protein (≈11kDa) encoded as an inactive precursor. The 
nascent SUMO needs to be cleaved at its C-terminus to expose a Gly-Gly motif 
necessary for SUMO conjugation to target proteins. This cleavage is mediated by 
SUMO-specific isopeptidases (SENP family in mammals and Ulp1 in S. cerevisiae). 
The mature form of SUMO can now be activated in an ATP-dependent manner by an 
E1-activating enzyme. A single E1 has been described for most organisms, a 
heterodimer formed by Aos1-Uba2 (Sae1-Sae2 in mammals) (Johnson, Schwienhorst et 
al. 1997). Using ATP, the C-terminal carboxyl group of SUMO forms a thioester bond 
with a Cys residue of Uba2.  
 
Subsequently, SUMO is transferred to Ubc9, which is thought to be the only 
existing SUMO-conjugating enzyme. Ubc9 presents high sequence similarity and a 
similar folded structure to ubiquitin E2s. However, the presence of a single E2-enzyme 
in sumoylation is a substantial difference with ubiquitination, where many different E2 
proteins are expressed conferring target-specificity. A thioester bond is formed between 
the C-terminal carboxyl group of SUMO and a Cys residue of Ubc9.  
 
Finally, SUMO is transferred from Ubc9 to a lysine side chain of the target 
substrate. In this reaction, SUMO creates a covalent isopeptide bond through its C-
terminal glycine. E3-ligase enzymes normally ease this reaction, although E3-
independent sumoylation can occur (Figure 6).  
 
 
 
Figure 6. Sumoylation pathway. 
SUMO is synthesized in an inactive 
form that has to be cleaved at the C-
terminus followed by an ATP-
dependent activation. Ubc9 and E3 
ligases are responsible for attaching 
SUMO to the substrate. 
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The most common group of E3-ligases present a common SP-RING motif key 
to their SUMO-ligase function (Hochstrasser 2001). SP-RING E3-ligases directly 
interact with the substrate and Ubc9, and non-covalently with SUMO. In mammals, 
SP-RING ligases include members of the PIAS family (Sharrocks 2006). In S. 
cerevisiae, three mitotic SP-RING E3 have been described, Siz1, Siz2 and Mms21 
(Zhao and Blobel 2005); and one meiotic, Zip3 (Cheng, Lo et al. 2006). Other types of 
E3-ligases present in mammals include the nuclear pore protein RanBP2/Nup358 
(Pichler, Gast et al. 2002) and the polycomb group Pc2 (Kagey, Melhuish et al. 2003). 
In addition, three more proteins have been reported as E3-sumo ligases in mammals; 
the histone deacetylase HDAC4 (Zhao, Sternsdorf et al. 2005), the topoisomerase I-
binding RING finger protein TOPORS (Weger, Hammer et al. 2005) and the Ras 
homologue enriched in striatum RHES (Subramaniam, Sixt et al. 2009). 
 
Most frequently, sumo-acceptor lysines are mono-sumoylated, but SUMO 
chains (polySUMO) can be formed by the repeated action of the sumoylation pathway 
described above. In S. cerevisiae, the formation of SUMO chains (prevented in the 
Smt3 KallR) is not essential for normal growth (Bylebyl, Belichenko et al. 2003), 
although it is needed for sporulation after meiotic division (Cheng, Lo et al. 2006). 
 
Sumoylation is a reversible modification due to the action of SUMO-specific 
isopeptidases (some of which are involved in the maturation of nascent SUMO). These 
enzymes belong to a single gene family that encodes Ulp1 and Ulp2 in S. cerevisiae, 
and the sentrin-specific proteases (SENP1-3 and SENP5-7) in mammals (Hay 2005). 
After cleavage and deconjugation, SUMO might be recycled for another sumoylation 
cycle. 
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1.5.2 SUMO-target sites 
 
 A consensus motif for sumoylation was proposed soon after the mapping of the 
first SUMO-modified lysine residues. The acceptor lysine seemed to be contained in 
the ψKxE motif (where ψ is a large hydrophobic amino acid and x any amino acid) 
(Rodriguez, Dargemont et al. 2001). This consensus motif together with a particular 3D 
structure in the substrate allows the binding of Ubc9 and the consequent transfer of 
SUMO (Bernier-Villamor, Sampson et al. 2002). 
 
 In addition to the simple 4 amino acids consensus motif, two more extended 
versions have been identified. The first extended motif to be described was the 
phosphorylation-dependent sumoylation motif (PDSM), which consists of the core 
motif followed by a phosphorylated serine and a proline amino acid (ψKxExxpSP) 
(Yang and Gregoire 2006). The second extended motif is the negatively charged 
amino-acid-dependent sumoylation motif (NDSM), consisting of the core motif 
succeeded by two or more acidic amino acids (Yang, Galanis et al. 2006).   
 
 Although the SUMO consensus motif is found in many substrates, some 
exceptions for this motif have been already described, e.g. the K164 in PCNA (S. 
cerevisiae). The sumoylation of K164 in PCNA is dependent on the PINIT domain of 
the E3 sumo ligase Siz1 (Yunus and Lima 2009). However, It is still unclear how Ubc9 
recognizes other sumo-modified lysines contained within no consensus motifs. 
Whether these unorthodox motifs mimic the 3D structure present at the SUMO 
consensus motif, or they are no more than rare exceptions remain to be answered. This 
evidence also opens the door for speculation about the existence of a still unknown 
further E2-like enzyme in the SUMO pathway. 
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1.5.3 Non-covalent interactions 
 
 SUMO interaction with substrates is not only about covalent attachments. 
SUMO can interact non-covalently with proteins containing a hydrophobic motif 
flanked by acidic or serine amino acids, the SUMO-interacting motif (SIM/SBM) 
(Kerscher 2007; Stehmeier and Muller 2009). SUMO interaction with the SIM motif 
has been proved responsible for the recruitment of downstream effectors and for the 
modification in the activity and localization of substrates. In addition, SIM motifs are 
also present within the ubiquitination and sumoylation apparatus. Some SUMO-E1 
and E3s contain SIMs although the biological relevance of this is still unclear (Lois and 
Lima 2005). SIMs are also found in SUMO-targeted ubiquitin ligases. In this affair, 
SIMs allow the interaction of these ubiquitin ligases with proteins containing 
conjugated SUMO or SUMO-like domains (Heideker, Perry et al. 2009).    
 
 
1.5.4 Consequences of sumoylation 
 
 Substrate modification by SUMO can entail three main consequences, namely; 
concealing an existing binding site, creation of a novel interface for an interacting 
partner or conformational changes in the substrate (Figure 7). However, functional 
consequences of sumoylation are target-specific and might reach any single aspect of 
the substrate; stability, localization, activity, increased or decreased interaction with 
other proteins, with DNA or other macromolecules.  
 
Figure 7. Consequences of sumoylation. Figure modified from (Meulmeester and Melchior 2008) 
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Sumoylation is highly dynamic modification. In fact, most of the substrates 
studied so far have a very low (<5%) steady-state sumoylation. However, sumoylation 
can have a substantial effect upon these substrates. This phenomenon has been named 
the “SUMO enigma” (Hay 2005). Data so far obtained suggests that these might be 
achieved by quick cycles of SUMO attachment and cleavage. 
 
 
1.5.5 Cross-regulation with other PTMs 
 
 Sumoylation is also dynamic in its interaction with other PTMs. Sumoylation 
of some substrates present phosphorylation-dependent regulation. The effect of 
substrate phosphorylation can be an increase of sumoylation, as for the proteins HSF1 
and MEF2, both containing a PDSM (Hietakangas, Anckar et al. 2006). However, 
negative effects have been also described, as for c-Jun, c-Fos, IκKα and p53 (Desterro, 
Rodriguez et al. 1998; Müller, Berger et al. 2000; Bossis, Malnou et al. 2005). 
Moreover, SUMO-substrates have been found within the cell phosphorylation 
apparatus (e.g. the kinases FAK, GSK3β, HIPK2 and ERK5), as well as components of 
the SUMO-pathway are targets of phosphorylation (e.g. the E3-ligases Pc2, PIAS1, 
TOPORS and RanBP2) (Wilkinson and Henley 2010).  
 
Other PTMs also found in relationships with sumoylation are ubiquitination 
and acetylation. The inhibitor IκBα was the first example of ubiquitin/SUMO crosstalk 
ever described. A truly antagonist effect is observed in this case, ubiquitination of IκKα 
eases its degradation while sumoylated-IκBα is protected from proteolysis (Desterro, 
Rodriguez et al. 1998). In the case of the tumour suppressor p53, upon ubiquitination, 
an E3-sumoligase is recruited and therefore sumoylation is boosted (Carter, Bischof et 
al. 2007).  
 
The PCNA (proliferating cell nuclear ­antigen), a crucial factor for the 
resolution of stalled replication forks, is also an important example of ubiquitin/SUMO 
crosstalk. PCNA is modified by both ubiquitin and SUMO. Mono-ubiquitination at 
the K164, dependent on the E2-E3 enzymes Rad6-Rad18, drives translesion synthesis 
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by activation of damage-tolerant DNA polymerases (Hoege, Pfander et al. 2002). 
Meanwhile, the E2 complex Ubc13/Mms2 and the E3 Rad5 can create a poly-ubiquitin 
chain. Poly-ubiquitinated PCNA is involved in a recombination-related error-free 
damage bypass, which also requires modification by SUMO (Ulrich 2005; Branzei, 
Vanoli et al. 2008). However, sumoylation of PCNA seems to be independent on DNA 
damage. The E2-E3 enzymes Ubc9-Siz1 cooperate to attach SUMO to the K164 (also 
target of mono-ubiquitination). In addition, K127 can also become sumoylated 
(Parker, Bucceri et al. 2008; Windecker and Ulrich 2008). In budding yeast, 
sumoylated PCNA recruits the Srs2 helicase to replication forks so that deleterious 
recombination events are inhibited (Pfander, Moldovan et al. 2005; Watts 2006). 
 
A growing number of examples of a competitive crosstalk mechanism are also 
found between sumoylation and acetylation. The tumour suppressor HIC1, the 
transcription factors MEF2A and Sp3 and the co-activator p300 can be either 
acetylated or sumoylated at the same target lysine. (Sapetschnig, Rischitor et al. 2002; 
Bouras, Fu et al. 2005; Shalizi, Gaudilliere et al. 2006; Stankovic-Valentin, Deltour et 
al. 2007). 
 
 
1.5.6 Substrates of sumoylation 
 
SUMO substrates are widely present in the cell. However, a great proportion of 
substrates are somehow related to nuclear functions, e.g. transcription, chromosome 
organization, nuclear transport and DNA repair.  
 
Indeed, transcription factors are one of the largest groups of SUMO substrates 
so far indentified (Verger, Perdomo et al. 2003; Gill 2005). Substrates are to be found 
in the gene-specific and general transcription machinery, including activators, 
coactivators, repressors and corepressors (Rosonina, Duncan et al. 2010). Sumoylation 
has an additional effect in transcription through modification of members of the PML 
nuclear bodies. These are nuclear structures involved in apoptosis, tumour suppression, 
response to viral infection, DNA stability and transcription. The core component of 
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PML nuclear bodies, the PML protein, is sumoylated at three sites and contains a SIM 
motif. Both sumoylation of PML and its SIM motif are necessary for the recruitment 
of other members and normal formation of PML nuclear bodies (Regad and Chelbi-
Alix 2001; Shen, Lin et al. 2006). In addition, numerous proteins that localize to PML 
nuclear bodies are also sumoylated. Some of these proteins are in fact components of 
the SUMO conjugating pathway (Seeler and Dejean 2003). 
 
Sumoylation substrates were first described in nuclear transport related proteins. 
For instance, RanGAP1 is the most abundant SUMO-1 target in vertebrates. The 
localization of RanGAP1 to the nuclear pore complex (NPC) is essential for nuclear 
import assays in vitro (Mahajan, Delphin et al. 1997). Further sumoylation of members 
of the NPC seems to affect nucleocytoplasmic transport regulation (Pichler, Gast et al. 
2002). In addition, some mutants of the SUMO pathway in yeast are defective in 
nuclear import (Stade, Vogel et al. 2002). 
 
Sumoylation regulates chromosome cohesion through modification of Top2 
and other centromeric factors (Bachant, Alcasabas et al. 2002; Azuma, Arnaoutov et al. 
2005). Sumoylation also regulates genome stability by regulation of the DNA-damage 
response and a number of DNA repair mechanisms. For instance, the regulation of the 
enzyme TDG through SUMO-conjugation and its SIM motif is crucial for the 
initiation of BER (Ulrich 2005). The XPC protein (xeroderma pigmentosum group C), 
a crucial factor in DNA repair by NER, is also a SUMO-substrate. Modification of XPC 
by SUMO might influence its stability and functionality (Wang, Zhu et al. 2005). In 
yeast, sumoylation also targets PCNA and regulates its role in recombination-
dependent repair during replication (see above).  
 
DSB repair by HR and NHEJ are also targets of sumoylation. Important 
components of the HR pathway, including the Rad52 and Rad54 recombination factors 
and the DNA helicases WRN and BLM (Sgs1 in S. cerevisiae), are SUMO-targets 
(Shen, Pardington-Purtymun et al. 1996; Golebiowski, Matic et al. 2009; Rog, Miller 
et al. 2009). During NHEJ, the Ku70-Ku80 heterodimer bound to the DSB ends and 
the XRCC4 factor required for elongation are sumoylated (Yurchenko, Xue et al. 2006; 
Yurchenko, Xue et al. 2008).  
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In addition, a number of tumour suppressors and oncogenes in mammals are 
known to be modified by SUMO, including PML, Mdm2, c-Myb, c-Jun, p53, p63, 
p73 and the retinoblastoma protein (Rb) (Baek 2006; Seeler, Bischof et al. 2007). 
 
 
Despite the overwhelming number of studies on the role of sumoylation in 
nuclear processes, SUMO substrates are not just nuclear. They are also found in the 
cytoplasm, organelles and membranes. Sumoylation seems to regulate the 
mitochondrial fusion and fission dynamic through the SUMO-protease SENP5 and the 
SUMO-target DRP1 (Harder, Zunino et al. 2004; Zunino, Schauss et al. 2007). The 
endoplasmic reticulum (RE) protein PTP1B, part of the receptor tyrosine kinase 
signalling, has been also identified as SUMO-substrate. Sumoylation of PTP1B 
increases upon insulin treatment, and successively PTP1B activity is reduced (Harder, 
Zunino et al. 2004).  
 
Non-nuclear substrates of sumoylation also include proteins related to the 
plasma membrane. The regulation of the potassium channel Kv1.5 at the plasma 
membrane is affected by sumoylation (Benson, Li et al. 2007), as well as the potassium 
channel Kv2.1 in pancreatic cells (Dai, Kolic et al. 2009). Some other substrates of 
sumoylation found in the plasma membrane are the kainite receptor and the 
metabotropic glutamate receptor-8.  
 
In addition, evidence suggests an important role of sumoylation in cell 
differentiation and development. Sumoylation plays a role in the regulation of both 
pluripotency and self-renewal of human embryonic stem cells (hESCs) by targeting 
two important transcription factors SOX2 (Van Hoof, Munoz et al. 2009) and Oct4 
(Wei, Schöler et al. 2007). SUMO-dependent regulation is also to be found during the 
development of the three germ layers: ectoderm, mesoderm and endoderm. Examples 
of it are the C/EBPα factor for hepatic differentiation (Sato, Miyake et al. 2006), the 
Pc2 for normal cardiac development (Kang, Qi et al. 2010) and GluR6 in the nervous 
system differentiation (Martin, Nishimune et al. 2007).    
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1.5.7 Sumoylation in clinical science 
 
 The relevance of sumoylation to human health increases as the sumoylation 
pathway is better understood and more SUMO-substrates are found.  
 
Albeit mechanistically unclear, sumoylation is required for tumour suppression, 
telomere homeostasis and senescence. These cellular processes are physically and 
functionally interconnected. Telomere dysfunction (e.g. failure in the maintenance of 
telomere’s length) prompts the recruitment of DNA repair factors and the subsequent 
formation of TIF (telomere-induced foci). As a consequence of this, the p53 tumour 
suppressor pathway is activated and with it cellular senescence. SUMO conjugates to 
some DNA repair factors and p53 itself (explained above) and SUMO substrates are 
likely to be found at TIF. Sumoylation seems to regulate p53-dependent transcription 
and to be connected through this way with a pro-senescence activity (Bischof and 
Dejean 2007). In S. cerevisiae, depletion of enzymes part of the sumoylation 
machinery results in longer telomeres, and SUMO is conjugated to a number of 
telomere-related proteins (Rap1, Cdc13, Pif1, Yku70 and Yku80) (Hang, Liu et al. 
2011).  
 
 Besides, sumoylation plays a role in the defense against tumourigenesis by 
modification of the tumour suppressors 53BP1 and BRCA1 and regulation of the 
cascade signalling after DSB (Bartek and Hodny 2010). Further study of this SUMO 
function could lead to the identification of tumour suppressors within the SUMO 
machinery itself. Accordingly, deregulation of the SUMO machinery has been found 
in some tumours types, e.g. head and neck (Ronen, Malone et al. 2009), breast (Wu, 
Zhu et al. 2009), thyroid oncocytic (Jacques, Baris et al. 2005) and prostate (Cheng, 
Bawa et al. 2006). In addition, SUMO-conjugation seems to be enhanced in metastatic 
cells, and controls the transcription repressive function of reptin during metastasis 
(Baek 2006).      
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 Osteoarthritis and rheumatoid arthritis are usual forms of human arthritis and 
aim of many studies. This arthritis presents a mal-function of the NFκB pathway and 
with it an over-expression of pro-inflammatory mediators. Sumoylation seems to exert 
a fine-tuned regulation on the NFκB pathway by stabilizing the inhibitor IκBα, a 
SUMO-target, which leads to an inhibition of NFκB-dependent transcription 
(Desterro, Rodriguez et al. 1998). Other sumoylated members of the pathway are IL-1R 
and IRAK1, for which the consequences of sumoylation are still not clear (Yan, Davis 
et al. 2010). Sumoylation would therefore have an anti-inflammatory effect. 
 
 Sumoylation regulates neuronal excitability, signalling and development, and 
its deregulation has been linked with a wide range of neurodegenerative disorders, 
including Huntington’s disease, spinocerebellar ataxias, Alzheimer’s disease and 
Parkinson’s disease. SUMO seems to be present in protein aberrant protein aggregates 
characteristic many of these disorders, and a number of diseases-related proteins are 
SUMO-substrates. In addition, sumoylation seems to have a neuroprotective role 
during ischaemia and other cell stress conditions (Anderson, Wilkinson et al. 2009; 
Wilkinson, Nakamura et al. 2010). 
 
 Another consequence of sumoylation of clinical relevance is linked with its role 
in regulation of ion-channel function. Sumoylation regulates excitability in native 
beta-cells at the pancreas by inactivation of the potassium channel Kv2.1, and affects 
the activity of the potassium channel Kv1.5, required for the electrical responses across 
the cardiovascular system (mentioned above). In addition, alterations in sumoylation 
of lamin A sumoylation seems to be behind some cardiomyopathies (Zhang and Sarge 
2008).   
 
Moreover, sumoylation, together with the other UBLs, crucially affects viral 
infection processes. The SUMO pathway is able to target viral proteins and doing so 
modify viral replication. Hence, it is expected that through time the viral machinery 
adapted to use sumoylation to influence its own replication.  SUMO substrates related 
to transcription and replication have been found in influenza A virus, adeno-, herpes- 
and papillomavirus, as well as viral proteins that, albeit not sumoylated, can interact 
with SUMO and Ubc9 (Isaacson and Ploegh 2009; Pal, Santos et al. 2011).    
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Figure 8. Sumoylation roles in cell metabolism and human diseases. 
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1.5.8 SMC5-SMC6 in sumoylation 
 
 
The Smc5-6 complex has been linked to post-translational modification of 
proteins through one of its subunits, MMS21, an E3 sumoligase. 
 
    Mms21(Nse2 in fision yeast) was first identified in a genetic screen for DNA 
damage-sensitive mutants in budding yeast (Prakash and Prakash 1977; Prakash and 
Prakash 1977). Later, Mms21 was demonstrated to be a component of the Smc5-6 
complex (Andrews, Palecek et al. 2005; Potts and Yu 2005). Mms21 contains a 
putative SP-RING domain common to other E3 ligases that confers SUMO ligase 
activity. Moreover, it is an essential gene in fission and budding yeast (Andrews, 
Palecek et al. 2005; Zhao and Blobel 2005)  
 
Hitherto, only a few proteins have been identified as targets of Mms21 
sumoylation, among them, the Smc5-6 complex subunits Smc5, Smc6, Nse3, Nse4, 
and Mms21 itself (Andrews, Palecek et al. 2005; Potts and Yu 2005; Zhao and Blobel 
2005; Pebernard, Schaffer et al. 2008).  
 
Mms21 is an important regulator of DNA repair, and assists the Smc5-6 
complex in its HR-mediated functions (Lee and O'Connell 2006). Budding yeast 
defective for the Mms21 sumoligase activity suffer from GCRs, a phenotype similar to 
the one observed in SMC5-6 mutants. This suggests a role for Mms21 in genome 
maintenance and stability (Hwang, Smith et al. 2008).  
 
Mms21 sumoligase activity is also found to be important in the restart of 
collapsed replication forks and in the maintenance of repetitive DNA regions. In 
budding yeast, the lack of Mms21 sumoligase activity affects telomere clustering, 
silencing and length regulation (Zhao and Blobel 2005), and  increases the number of 
collapsed replication forks after MMS treatment (Branzei, Sollier et al. 2006). In the 
absence of Mms21 sumoligase activity, fragmented and irregular shaped nucleoli are 
observed, suggesting faulty rDNA maintenance (Torres-Rosell, Machin et al. 2005; 
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Zhao and Blobel 2005). The pertinent targets of the Mms21-dependent sumoylation in 
relation to fork collapse and repetitive DNA maintenance are unknown to date.  
 
Interestingly, Nse1, another assential subunit of the Smc5-Smc6 complex, 
might also play an important role in post-translational protein modification. Nse1 
contains a vRING domain, suggesting a possible E3 ubiquitin ligase activity (Doyle, 
Gao et al. 2010). Mutations at this domain have shown DNA repair defects associated 
with the Smc5-Smc6 function in DNA stability (Pebernard, Perry et al. 2008). 
 
Despite active research, many questions remain unanswered in relation to the 
role of the Smc5-Smc6 in sumoylation and of the Mms21 in DNA stability. All 
progress done so far is mainly based on studies where either Ubc9 (the only E2 
conjugating enzyme known) or Mms21 are mutated. When sumoylation activity is 
impaired at the level of these sumoligases consequences in the cell metabolism are far 
too general. A general description of the possible role of Mms21 in DNA repair, restart 
of collapsed replication forks, or rDNA and telomeres maintenance can be suggested. 
However, this can explain little about how all this activities are carried out or regulated 
by the sumoligase activity of Mms21.    
 
An accurate description of proteins sumoylated in Mms21-dependent manner 
is needed. Only substrate-specific studies can provide robust understanding on the 
particular functions of Mms21 within the Smc5-Smc6 complex activity and on the role 
of sumoylation in the response to DNA instability.  
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1.6. Peptide sequencing  
 
 
 Protein sequencing started more than half century ago with the arrival of the 
Edman degradation method. This technique, developed by Peer Edman, is based on the 
stepwise cleavage of amino acids from the amino terminus of the protein (Edman, 
1949). Cleaved amino acids are subsequently identified using techniques such as 
chromatography or electrophoresis. The Edman degradation method, albeit a 
breakthrough at that time, had very important limitations. The identification of amino 
acids is less accurate as the length of the peptide increases and with it the number of 
cleavage steps. Yet, the major limitation is the need of a free N-terminus for the 
cleavage to take place. Should the N-terminus be modified (e.g. acetylated) or hidden 
within the body of the protein, the Edman reaction is blocked. 
   
 During the 1990s a new technique came to the aid of peptide sequencing, mass 
spectrometry (MS). This method had serious advantages with respect to Edman 
degradation, which was quickly dislodged. MS is more sensitive in the sequencing of 
proteins and it can be used with blocked or modified proteins. Besides, MS does not 
entail the use of a homogenous purified protein sample, and it can fragment peptides 
in seconds rather than hours (Wilm, Shevchenko et al. 1996). 
 
   
1.6.1 Mass Spectrometry (MS) 
 
Mass spectrometry is an analytical technique used to determine the chemical 
composition of a wide range of samples and molecules. During MS, molecules or 
fragmented molecules are ionized. These ions are then separated in compliance with 
their mass-to-charge ratio (m/z) by a transit through electromagnetic fields in a 
vacuum system. In fact, MS is not a mass analyzer per se, but an m/z analyzer.  
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m/z is dimensionless, where m stands for the mass of the ionized molecule or 
particle and z represents the number of elementary charges of the ionized molecule. 
The importance of this value resides in the fact that the m/z defines the movement that 
an ionized particle describes in a vacuum when exposed to an electric and magnetic 
field. Different paths traced by different ionized particles can be detected, and this 
information can be used to deduce the nature of the sample.    
 
Although the application of MS to protein sequencing took off during the 
1990s, this technique was first used for analysis of amino acids and peptides already in 
the late 1950s (Andersson 1958). In later years, other advances helped MS to become 
central technology for the study of proteins. Some of the most noticeable advances 
were the application of matrix-assisted laser desorption/ionization for peptides analysis 
by F.Hillenkamp and M.Karas (Karas, Bachmann et al. 1987), and the invention of 
electrospray ionization and soft laser desorption by J.B.Fenn and K.Tanaka respectively 
(Tanaka, Waki et al. 1988; Fenn, Mann et al. 1989). Today, further technological 
breakthroughs like the utilization of Orbitrap (Makarov 2000) and hybrid mass 
spectrometers have set MS as a leading tool in the field of proteomics, in particular in 
the study of primary structures of proteins, protein complexes and protein post-
translational modifications (PTMs). 
 
 The basic procedure used in a mass spectrometry experiment aimed to detect 
and sequence proteins from a large and complex protein sample is explained below.  
 
After protein sample preparation, proteins are fragmented into peptides. The 
digestion is normally done with trypsin, a stable and highly active sequence-specific 
protease. Trypsin cleaves proteins at the C-terminus side of arginine and lysine 
residues, creating a pool of peptides with a basic residue at the C-terminus of the 
peptide and of a mass range adequate for MS analysis.  
 
Peptides are preferred over proteins for MS analysis for a number of reasons. 
Mass spectrometers have a higher sensitivity for peptides than for proteins, and the 
possible presence of several isoforms makes determining the mass of the protein 
extremely challenging.  In addition, protein properties like solubility and “stickiness” 
	   45	  
could interfere with the MS analysis. Most importantly, even if the mass of proteins 
can be resolved, information about the sequence of amino acids is most efficiently 
obtained from peptides smaller than 20 residues.  
 
 Before being introduced into the mass spectrometer, peptides go through a 
microscale capillary high-performance liquid chromatography (HPLC) column. In 
them, a solvent gradient of increasing organic content is used to elute peptides 
according to their hydrophobicity. From the column, peptides are eluted in the smallest 
volume possible so the signal intensity in the mass spectrum (proportional to the 
peptide concentration) is increased. When a peptide exits the column, it travels 
through a needle and, at the end of it, the liquid is vaporized and the peptide ionized 
(process called electrospray ionization, (Fenn, Mann et al. 1989)).  
 
 Inside the mass spectrometer, electrosprayed ionized peptides are guided in 
vacuum by electric fields. Firstly, the mass-to-charge (m/z) ratios of the peptides are 
determined. A mass spectrum is generated with and account of the signal intensity 
(high of peaks) of the ionized peptide at each value of the m/z scope. Once the m/z 
value and intensity of all peak is measured, particular ionized peptides (corresponding 
to the most abundant peaks) are selected for their sequence to be analyzed. This process 
is called tandem MS (MS/MS or MS2). During tandem MS, isolated ionized peptides 
are broken apart by collision with an inert gas. Then, the m/z values of the resulting 
fragments (also called product ions) are measured. The mass spectrum that results from 
tandem MS is a collection of values from the fragmentation at different amide bonds 
of a particular ionized peptide. Product ions are called b-ions if the charge remains at 
the N-terminus or y-ions if the charge is at the C-terminus. The mass difference 
between consecutive product ions in the spectrum is of one amino acid. Hence, it is 
possible to resolve the amino acid sequence of the ionized peptide by looking at the 
mass differences between peaks.  
 
  Unfortunately, the tandem MS spectrum is often incomplete, and the presence 
of peaks which do not belong to the series can complicate the analysis. In practice, 
incomplete spectra can often be correctly interpreted by experts. In addition, tandem 
MS results (which the exception of de novo sequencing) often go through a database-
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matching process in which a full spectrum is not needed for identification. Fully or 
partially sequenced peptides are searched against a protein sequences database. Since 
only a minimal fraction of all the possible amino acid sequence are represented in 
nature, a partially sequenced peptide might be sufficient to match it with a unique 
protein sequence from the database. There are a number of search engines commonly 
used for the database-matching process, i.e. Sequest, Mascot and Andromeda.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 9. Mass spectrometry analysis and mass spectra. Peptides loaded into the mass spectrometer are 
ionized so their m/z ratios can be calculated. This calculation generates the mass spectrum. Most 
abundant peptides (most intense peack of the spectrum) are fragmented. The m/s values of the 
resulting fragments are used to determine the sequence of the fragmented peptide (tandem MS).    
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It is worth noting that, Database-matching identification can only be used 
when working with organisms for which the whole genome has been sequenced, so that 
all proteins are known.     
 
Many different algorithms have been so far implemented for database 
identification. Among them, Peptide Sequence Tags (Mann and Wilm 1994), 
autocorrelation (Eng, McCormack et al. 1994), probability-based matching (Perkins, 
Pappin et al. 1999) and graph theory (Yan, Zhang et al. 2011). 
 
 Peptide identification after database-matching is reported in terms of a 
probability score. In case of large protein samples, assigning a realistic probability score 
to each peptide can be challenging. Different techniques might be used in order to 
avoid a high false positive rate in this case. Significant database identification scores can 
be calculated by searching the tandem MS spectrum against a randomized database 
where all sequences have been reversed (Peng, Elias et al. 2002). The probability of 
correct identification for any chosen cut-off score can be calculated using statistical 
procedures (Keller, Nesvizhskii et al. 2002; Nesvizhskii, Keller et al. 2003; Nesvizhskii 
and Aebersold 2004). In addition, an independent analysis of the results obtained by 
mass spectrometry is sometimes possible. For instance, PTMs detected by MS can 
often be confirmed by immunoblotting. 
  
 
1.6.2 Quantitative mass spectrometry 
  
 Quantification of the peptides, not only identification, is sometimes needed in 
proteomic studies. However, mass spectrometry analysis as described above is not a 
quantitative method. The signal intensity from ionized peptides is not a direct measure 
of the amount of protein in the sample. Signal intensities are also influenced by the 
protease digestion, peptide solubility or peptide ionization efficiency. In practice, the 
signal intensity from different peptides belonging to the same protein can be very 
different. Nevertheless, the factors that introduce variability in the signal intensity are 
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reproducible. The signal intensity of the same peptide can be used as an indicator of the 
relative amount of that protein when two similar experiments are compared.   
 
 Relative quantification of mass spectrometry data, however, is most correctly 
done using stable isotopes. This technique makes it possible to compare and quantify 
the relative differences between two protein samples (i.e. samples obtained under 
different growth or metabolic conditions). In this process, only one of the protein 
samples is labelled with stable-isotopes (2H, 13C, 15N or 18O). When both protein samples 
are mixed, the two forms of the same molecule, labelled and unlabelled, have an 
identical behavior during MS analysis. The only difference between both forms will be 
a mass shift of the molecule cluster in the mass spectrum. The ratio of the two signal 
intensities is directly proportional to the relative amount of protein present in the 
samples.  
 
 
 
 
 
 
 
 
 
 
Figure 10. Quantification by 
SILAC. Mass spectrometry can 
quantify the relative amount of 
proteins (☐, Δ, Ο) between two 
samples. One sample contains 
proteins with heavy isotopes-
labeled aa (red). The other sample 
contains normal proteins (white). 
Proteins are extracted and 
purified together. Both forms of a 
given peptide (light and heavy) 
will behave similarly in the mass 
spectrometer. In the mass 
spectrum, the heavy form shifts to 
higher m/z from the light form.  
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Stably labelled amino acids can be added to the culture media, and can be 
allowed to fully incorporate into the proteome of the cell population. This approach, 
called SILAC (stable-isotope labeling in cell culture), has been successfully used in both 
microorganism cultures (de Godoy, Olsen et al. 2006; Choudhary, Kumar et al. 2009) 
and cell cultures of high eukaryotes (Ong, Kratchmarova et al. 2002; Wagner, Beli et al. 
2011). Full incorporation of labelled amino acids avoids what otherwise would be a 
source of uncertainty in the quantitative results. Cells growing in normal media are 
used as a control sample. Both labelled and control cultures are normally mixed prior to 
protein extraction and purification to avoid variability due to the extraction and 
purification technique.    
 
 The accuracy of the quantitative results mainly depends on the resolution of the 
mass spectrometer and the signal intensity of the measured molecules. The accuracy of 
the results for each experiment can be estimated by calculating the standard deviation 
from the intensity ratios of peptides that quantify the same protein. For more robust 
quantitative results, the experiment can be duplicated in reverse, namely, by the 
interchange of the labeling between the two conditions.        
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1.7. Mass spectrometry analysis of post-translational protein 
modifications  
 
 
 MS is a useful tool in the study of post-translational modifications (PTMs). MS 
analysis is highly specific (with single aa sequencing resolution) and allows detection of 
large-scale samples. PTMs change the mass of the modified protein. MS can detect this 
mass shift and tandem MS can map the modified amino acid. However, analysis of 
PTMs can be challenging; modified peptides are normally present in low amounts 
compared with unmodified ones. This can hide modified peptides in the background 
spectrum not allowing them to be analyzed by tandem MS. Moreover, the tandem MS 
spectra from modified peptides are more complex, and the software algorithms which 
interpret them do so losing accuracy in the database search matches. 
 
 In particular, the MS detection of substrates modified by UBLs is key for the 
understanding of the biological relevance of these modifiers. So far, the use of MS for 
this purpose has prompted both successes, as it is the quantitative survey of 
ubiquitination sites (Wagner, Beli et al. 2011), and disappointment, the lack of 
proteome-wide mapping conjugating sites of any other UBL in budding yeast. 
 
The reasons for the still poor success in the MS detection of UBL-modified 
peptides are named above: low concentrations of modified peptides in the input sample 
and a complex tandem MS fragmentation of modified peptides. Protein samples low in 
UBL-modified peptides are normally due to the low ratio of modified/unmodified 
protein in vivo for some UBL, and to the loss of attachment between the UBL and the 
protein during the protein extraction and purification. Trypsin digestion prior to MS 
analysis leaves an amino acid side chain (belonging to the UBL) at the modified 
peptides of up to 5aa. During tandem MS, these “branched” peptides are fragmented in 
a complicated pool of modified and unmodified molecules, and amino acids belonging 
to the side chain can be mistaken for amino acids from the main peptide sequence. As a 
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consequence, tandem MS spectra are difficult to interpret, the database search 
complexity increases and reliability in the results is lost.  
 
The success in the in vivo mapping of ubiquitination sites is in part because two 
intrinsic characteristics of ubiquitin help overcome the limitations mentioned above. 
Ubiquitination is found “ubiquitously” through out the proteome, making possible 
purifying a protein sample rich in modified peptides. Ubiquitin-modified lysines keep 
an aa side chain of only 2 residues (diGlycine) after trypsin digestion. Tandem MS 
spectra from the modified peptides can be managed by common software algorithms.   
 
 
1.7.1 Identification of SUMO-substrates and conjugation sites 
 
 The identification and quantification of sumoylation by MS is especially 
challenging. Most of the in vivo modified proteins have a very low steady-state 
sumoylation and conjugated SUMO is very likely to be lost during the protein 
extraction and purification. Hence, input protein samples for MS are likely to contain 
a very low concentration of sumoylated peptides. In addition, SUMO-modified lysines 
keep an aa side chain (5 residues in case of Smt3) after trypsin digestion which belongs 
to the SUMO modifier. During tandem MS, this aa side chain generates overlapping 
fragment ions with the ones from the target protein peptide. Standard database 
matching algorithms find difficult to assign correct sequences to this complex ion 
spectrum.  
 
 An increase in the concentration of sumoylated peptides has been achieved by 
expression and purification of His6-SUMO in human cells (Tatham, Rodriguez et al. 
2009; Galisson, Mahrouche et al. 2010; Matic, Schimmel et al. 2010) and His6-Smt3 in 
yeast (Wohlschlegel, Johnson et al. 2004), and by cysteine-target purification of 
SUMO-1 (Blomster, Imanishi et al. 2010). Furthermore, non-standard database search 
tactics have been developed e.g. ChopNSpice (Hsiao, Meulmeester et al. 2009) and 
SUMmOn (Pedrioli, Raught et al. 2006), which can deal with complex tandem MS 
spectra generated by sumoylated peptides.  
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In some studies, the aa sequence of the C-terminus of SUMO itself has been 
modified in an attempt at reducing the complexity of the tandem MS spectrum. This 
variation in the sequence does not prevent SUMO conjugation to target proteins. 
However, it reduces the complexity of the tandem MS spectrum and, therefore, 
simplifies the database search matching. This approach has been implemented in studies 
of sumoylation in both human cultured cells (Galisson, Mahrouche et al. 2010; Matic, 
Schimmel et al. 2010) and budding yeast (Wohlschlegel, Johnson et al. 2006). 
 
Despite all these efforts and promising advances in human cells, MS studies in 
budding yeast so far have been limited to the recognition of SUMO-modified proteins. 
The detection of SUMO acceptor lysines in complex samples remains elusive. As a 
consequence, many studies of sumoylation were limited to the study of phenotypes 
observed after modification of Ubc9 and E3-ligases and in protein knockouts. 
However, these studies do not offer an accurate description of the biological relevance 
of sumoylation. The consequences of modifying the SUMO-machinery or of 
knockouts are far from being sumoylation-specific. Only the mapping of acceptor 
lysines in target proteins allows protein-specific/sumoylation-specific studies.  
 
Identification of acceptor lysines by site-specific mutagenesis is expensive and 
time-consuming, in particular in big proteins with many “possible” acceptor lysines to 
be mutated. A proteome-wide mapping of sumoylation sites by MS would be a 
breakthrough in the functional study of sumoylation. 
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1.8. Project introduction 
 
 
 The Smc5-Smc6 complex is required for key mechanisms affecting the 
metabolism of the chromatin and chromosomes, including DNA replication, 
chromosome segregation and DNA repair forks by homologous recombination 
between sister chromatids. One of the components of the Smc5-Smc6 complex is the 
sumoligase Mms21. This enzyme is one of the only three E3 sumoligases in budding 
yeast. The sumoligase activity of Mms21 is essential for the regulation of the 
performance of many proteins involved in the same functions that the Smc5-Smc6 
complex. However, the molecular mechanisms involved in many of the Smc5-Smc6 
complex functions, i.e. DNA repair, are poorly understood. The role of sumoylation 
within these functions is in most of the cases unknown. 
 
The objective of this study is to further characterize the function of the Smc5-
Smc6 complex in DNA repair by sister chromatid recombination (SCR), as well as to 
identify sumoylation substrates of Mms21. 
 
Recent studies suggest that DNA single-strand nicks are transformed to double-
strand breaks in a replication-dependent manner, and this triggers SCR. I aim to 
develop an assay for the activation of SCR based on the expression of a site-specific 
nickase. This technique should generate a DNA lesion such that only a single sister 
chromatid is cut. Under these conditions the cell will rely on the intact sister chromatid 
as a repair template.  
 
The synchronous activation of site-specific SCR in a large proportion of the 
population should allow a detailed study of the molecular mechanism involved in SCR, 
and the role of the Smc5-Smc6 complex within it. ChIP (Chromatin 
Immunoprecipitation) analysis could be used for the description of proteins recruited to 
the damaged site and the DNA structures generated during SCR might be studied by 2-
dimensional gel electrophoresis. 
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To study the role of sumoylation within the Smc5-Smc6 activity, I aim to 
develop a proteome-wide approach for the in vivo identification of sumoylation-sites by 
mass spectrometry. I aim to create a biologically functional version of the SUMO 
modifier of budding yeast, Smt3, which will be efficiently purified and easily analyzed 
by mass spectrometry. In addition, I aim to describe a SILAC-based mass spectrometry 
assay for the quantification of site-specific sumoylation.     
 
This technique could be used for the identification of Mms-21 sumo-substrates 
and for the mapping of their sumo-acceptor lysines. The mapping of sumo-acceptor 
sites is crucial for the generation of sumo-specific mutants that can be used to study the 
function of sumoylation in these substrates.    
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C h a p t e r  2 .   
M A T E R I A L  A N D  M E T H O D S  
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2.1. Chemicals  
 
 Unless otherwise stated, all chemicals and reagents were obtain from: 
Invitrogen, GE Healthcare, Bio-rad, New England Biolabs, Promega, Roche, Sigma, 
Fisher Scientific and Qiagen. 
 
 
2.2. S. cerevisiae strains, plasmids and growth conditions 
 
2.2.2. S. cerevisiae plasmids 
 
A list of plasmids used in this study is provided below (Table 1). 
 
 
Table 1. Plasmids used in this study. 
Name Backbone Source 
I-HmuI Target Site (Lagging) pRS416 GeneCust Europe Laboratories 
I-HmuI Target Site (Leading) pRS416 This study 
Gal1-I-HmuI-NLS-3Myc pRS402 GeneCust Europe Laboratories 
8His-Smt3-KallR-RGG pRS415 GeneCust Europe Laboratories 
8His-Smt3-KallR-RAG pRS415 GeneCust Europe Laboratories 
8His-Smt3-KallR-RAGG pRS415 GeneCust Europe Laboratories 
8His-Smt3-KallR-RIGG pRS415 GeneCust Europe Laboratories 
8His-Smt3-KallR-REQIGG pRS415 This study 
Smt3-KallR-RGG pRS415 This study 
Dep1-5HA_KtoR_1mut. pRS415 GeneCust Europe Laboratories 
Dep1-5HA_WT pRS415 GeneCust Europe Laboratories 
Ntg1-5HA_KtoR_2mut. pRS415 GeneCust Europe Laboratories 
Ntg1-5HA_WT pRS415 GeneCust Europe Laboratories 
Rpc53-5HA_KtoR_4mut. pRS415 GeneCust Europe Laboratories 
Rpc53-5HA_WT pRS415 GeneCust Europe Laboratories 
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2.2.1. S. cerevisiae strains 
 
A list of the strains used in this study is provided below (Table 2). 
 
Table 2. Yeast strains used in this study. 
ID Genotype Source 
H-HmuI    
CCG4072 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2,   ars608D::HIS3 ars609D::TRP1 Cell Cycle group 
CCG8181 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 dSPOITS(lagging)HYG This study 
CCG8186 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA This study 
CCG8210 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 dSPOITS(lagging)HYG SpoINLS (ADE) This study 
CCG8217 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA SpoINLS(ADE) This study 
CCG8256 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 SPO1ts(HYG URA3)plasmid SpoI NLS Gal ADE This study 
CCG8262 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA SpoINLS(ADE) bar-::LEU This study 
CCG8341 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 dSPOITS(lagging)HYG rad14::KAN This study 
CCG8352 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 bar1-::LEU This study 
CCG8397 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA bar-::LEU This study 
CCG8400 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 bar1-::LEU PlasmidSPOI(leadding) HYG URA This study 
CCG8516 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2,  ars608D::HIS3 ars609D::TRP1 bar1-::LEU PlasmidSPOI(leadding) HYG URA  SpoINLS (LEU) This study 
CCG8689 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 dSPOITS(lagging)HYG rad52::NAT This study 
CCG8691 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 dSPOITS(lagging)HYG SpoINLS (ADE) rad52::NAT This study 
CCG8716 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA SpoINLS(ADE) bar-::LEU SpoI-GFP (KAN) This study 
CCG8345 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA SpoINLS(ADE) bar-::LEU rad14::KAN This study 
CCG8576 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA SpoINLS(ADE) bar-::LEU rad14::KAN RAD4::NAT This study 
CCG8577 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(lagging)HYG URA SpoINLS(ADE) bar-::LEU rad14::KAN RAD16::NAT This study 
CCG8676 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(leading)HYG URA SpoINLS(ADE) bar-::LEU This study 
CCG8710 W303-1 mata ura3-1 his3-11,15  trp1-1 leu2-3,112 can1-100 ade2, ars608D::HIS3 ars609D::TRP1 plasmidSPOITS(leading)HYG URA SpoINLS(ADE) bar-::LEU rad14::KAN This study 
SUMO    
CCG5271 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Johnson et al., 1997 
CCG5272 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + p316-HF-SMT3 (SMT3 promoter) Johnson et al., 1997 
CCG9105 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + p316-HF-SMT3 (SMT3 promoter) Scc1-7HIS 1MYC (KAN) This study 
CCG9107 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS  Scc1-7HIS 1MYC (KAN) + pRS415 Smt3 KallR RGG LEU This study 
CCG9302 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 Smt3 KallR RGG LEU (SMT3 promoter) This study 
CCG9362 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 Smt3 KallR RGG LEU (SMT3 promoter) TBP 7HIS-1Myc (KAN) This study 
CCG9363 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 Smt3 KallR RGG LEU (SMT3 promoter) Gcn5 7HIS-1Myc (KAN) This study 
CCG9474 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 8HIS-Smt3 KallR RGG LEU (SMT3 promoter) This study 
	   58	  
CCG9483 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 8HIS-Smt3 KallR RAGG LEU (SMT3 promoter) This study 
CCG9484 BBY48 matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 8HIS-Smt3 KallR RAG LEU (SMT3 promoter) This study 
CCG4620  BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Zhou et al. 2004 
CCG7813 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 This study 
CCG9303 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Clb2-9Myc HYG This study 
CCG9304 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Gcn5-9Myc HYG This study 
CCG9368 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6;  Tfg1-9Myc HYG This study 
CCG9369 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6;  Rad16-9Myc HYG This study 
CCG9313 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Rpc4-9Myc HYG This study 
CCG9315 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 TBP-3HA HYG This study 
CCG9306 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Gcn5-9Myc HYG This study 
CCG9307 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Tfg1-9Myc HYG This study 
CCG9309 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Clb2-9Myc HYG This study 
CCG9311 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Rad16-9Myc HYG This study 
CCG9314 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Rpc53-9Myc HYG This study 
CCG9317 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 TBP-3HA HYG This study 
CCG9510 BBY48 Matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 8HIS-Smt3 KallR IGG LEU (SMT3 promoter) This study 
CCG10022 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 pRS415 DEP1-5HA-KtoR This study 
CCG10024 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 pRS415 DEP1-5HA This study 
CCG10030 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 pRS415 NTG1-5HA This study 
CCG10032 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 pRS415 NTG1-5HA-KtoR This study 
CCG10034 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 pRS415 RPC53-5HA This study 
CCG10036 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 pRS415 RPC53-5HA-KtoR This study 
CCG10044 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 pRS415 DEP1-5HA This study 
CCG10050 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 pRS415 NTG1-5HA This study 
CCG10054 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 pRS415 RPC53-5HA This study 
CCG10066 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Rps1a-9Myc hyg This study 
CCG10067 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Rps1a-KtoR-9Myc hyg This study 
CCG10071 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Rps1a-9Myc hyg This study 
CCG9668 BBY48 Matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 8HIS-Smt3 KallR RGG LEU (SMT3 promoter) lys1::hyg This study 
CCG10068 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6 Cdc48-9Myc hyg This study 
CCG10076 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 Cdc48-9Myc hyg This study 
CCG10080 BBY48 Matalpha, trp1-1, ura3-52, his2∆200, leu2-3, 112, lys2-801 Smt3∆HIS + pRS415 8HIS-Smt3 KallR RGG LEU (SMT3 promoter) Nse2CD::hyg This study 
CCG3730 SK1 Matalpha ho::LYS2 lys2 leu2::hisG arg4-nsp ura3 his4x trp1::hisG NSE2C∆hygB Cell Cycle group 
CCG912 BY4733 MATa his3D200 leu2D0 met15D0 trpD63 ura3D0 NET1-9myc(TRP)  Cell Cycle group 
CCG5601 BY4741 MATa his3 1 leu2 0 met15 0 ura3 0 6HisFLAG-smt3::kanMX6; Net1-9myc NAT Cell Cycle group 
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2.2.3. Growth conditions 
 
  Yeast extract peptone dextrose (YPD) and synthetic drop out media lacking 
amino acids have been made according with “Methods in yeast genetics 1997”. Solid 
media was prepared by addition of 2% agar power. Media was mixed with different 
carbon sources than glucose if needed (galactose or raffinose), all at 2% final 
concentration.   
 
 Yeasts were also grown on media containing 200 μg/ml geneticin, 300 μg/ml 
hygromycin B, 100 μg/ml nourseothricin or phleomycin at 0.3 mg/ml to select strains 
carrying KAN, HPH, NAT or ZEO markers respectively. Yeast were also grown on 5-
FOA plates made of synthetic media supplemented with 1 g/l 5-FOA and 3% uracil. 
 
Cells growing in solid media plates were incubated at the indicated temperature 
in a Memmert 500 oven. Cultures growing in liquid media were incubated at the 
indicated temperature in flasks, shaken at 160-180 r.p.m. in a SM1003 shaking 
incubator (Kuhner). Yeast strains were long-term stored at -80°C in water with 16% 
glycerol. 
 
Cells growing for SILAC-based mass spectrometry analysis were incubated in 
Kaiser synthetic drop out media without lysine, with the addition of 2% glucose and 
either; 20 mg/l L-Lysine (Formedium) or 20 mg/l L-Lysine (13C6/15N2) (Cambridge 
Isotope Laboratories). 
 
 
2.2.4. Cell cycle arrest 
 
 Cell cycle arrest in G1 was performed in strains with the BAR1 gene deleted. α-
Mating factor (Sigma) was added to the culture (O.D. 0.3-0.4) at a final concentration 
of 1.5x10-8 M. After 2 hours, more than 90% of the cells were stop at G1 (checked by 
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microscopy). Half of the initial dose of α-Factor was added every 2 h in order to keep 
the arrest (up to 8 h). 
  
 
2.2.5. DNA damage and oxidative stress induction 
 
 Oxidative stress induction was performed by addition of 10 mM of H2O2 to 
cells at O.D. 0.8 during 1h prior to harvest. DNA damage induction was performed by 
addition of 0.05% MMS to cells at O.D. 0.8 for 90 minutes prior to harvest. 
 
 
2.2.6. Competent cells 
 
Yeast was cultured in YPD (50ml) or synthetic drop out media and harvested at 
0.5<OD595<0.8. Yeast pellet was washed twice in distilled water and once in SORB 
(100mM lithium acetate, 10mM Tris pH8, 1mM EDTA pH8, 1M Sorbitol, adjusted to 
pH8 with acid acetic) and were resuspended in 360μl of SORB. Denatured salmon 
sperm DNA was added to a final concentration of 1mg/ml. Sample was kept in 50μl 
aliquots and frozen at -80°C. 
 
 
2.2.7. Transformations 
 
Transformation DNA and 360 μl PEG (100 mM lithium acetate, 10 mM Tris 
pH 8, 40% PEG 3350) was added to aliquots, and the transformation was incubated at 
room temperature (RT) for 30 minutes. A heat sock (42°C) was then performed for 15 
minutes with prior addition of 46 μl DMSO. After heat shock cell were resuspended 
either in distilled water, and plated on prototroph selective media, or in YP (with the 
addition of glucose or galactose) and incubated shaking at RT for at least 4 hours before 
being plated on antibiotic resistant selective media.  
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 Gene knockout transformants, plasmids and cassette integrations were 
confirmed by colony PCR (polymerase chain reaction).  Colonies were suspended in 
10μl of distilled water in a PCR tube to which 15 μl of GoTaq® Flexi DNA polymerase 
(Promega) PCR reaction mix was added. PCR standard conditions were used (see PCR 
methods). When possible, transformants were also confirmed by phenotype. 
 
 Knockout of BAR1 was confirmed by growth of drops of isolate colonies 
dissolved in 20 μl of distilled water in a YPD plate containing αFactor 3 μM final 
concentration. No growth confirmed the BAR1 knockout. Transformants of epitope-
tagged proteins were verified by colony PCR and by western blotting. 
 
 
2.2.8. Genomic integration by homologous recombination 
 
 Gene deletion, modification or insertion of epitope tags were performed by a 
PCR strategy (Goldstein and McCusker 1999; Knop, Siegers et al. 1999; Janke, 
Magiera et al. 2004). Cassettes containing the selectable markers and the epitope tags 
were amplified with primers with ends that drive integration by homologous 
recombination at a specific site. 
 
 
2.2.9. Drops/phenotype analysis by growth test 
 
 10-fold dilutions of exponential growing cells were made in PBS. Cells were 
spotted (6 μl drops) onto agar media, incubated at the appropriated conditions for 3-5 
days and then photographed. 
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2.3. Bacteria methods 
 
Plasmid DNA was added to aliquots of E. coli One Shot® TOP10 chemically-
competent cells (Invitrogen) and incubated on ice for 30 minutes. Heat shock for 30 
seconds at 42°C was followed by 2 minutes of cooling on ice. 250 μl of SOC media was 
then added and cells were incubated shaking at 37°C for 1 hour. The cells were plated 
on LB with either 50 μg/ml ampicillin or 0.1 mg/ml kanamycin (Blunt II-TOPO® 
vector) for overnight incubation at 37°C. 
 
 Plasmid extraction for yeast transformation or cloning techniques, E. coli 
carrying the relevant plasmid was cultured in either 2 ml or 50 ml LB with the 
pertinent antibiotic (as described above). The QIAprep® Spin Miniprep kit (Qiagen) or 
the Plasmid Midi kit (Qiagen), for 2 ml or 50 ml respectively, were used to harvest the 
plasmid DNA.  
 
 
2.4. Molecular biology and biochemical methods 
 
2.4.1. Isolation of genomic DNA from S. cerevisiae 
 
 10ml of culture at O.D. 0.5 were harvested, washed in PBS and resuspended in 
500 μl of DNA extraction buffer (1% SDS, 100 mM NaCl, 50 mM Tris-HCl pH 8.0, 10 
mM EDTA), with 4 μl β-mercaptoethanol and 40 units of lyticase (Sigma). The sample 
was incubated at 37°C for 10 minutes. 500 μl of phenol/chloroform/iso-amylalcohol 
(25:24:1) was added to each sample and mix with the pipette. The phenol emulsion was 
transferred to prepared phase lock gel tubes (5prime) and spun down at 12.000 r.p.m. 
for 5 minutes. Aqueous phase was transferred to a fresh eppendorf and 2 vol of pre-
chilled EtOH were added. Samples were spun at 14.000 r.p.m. and 4°C for 30 minutes, 
washed with 70% EtOH, and spun again at 14.000 r.p.m. for 10min. Ethanol was 
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removed and samples air-dried for 20 minutes. Dry DNA was resuspended in 100 μl TE 
Buffer with 1 mg/ml RNase. 
 
 
2.4.2. Molecular cloning  
 
For cloning procedures, DNA cloning standard methods were followed (see 
Methods for Molecular Biology). 
 
Sequence-specific digestion of DNA was done with restriction enzyme 
following the specifications given by the manufacturer (NewEngland Biolabs). 10 units 
of enzyme were used for the digestion of 1 μg of DNA. 
 
Separation of DNA fragments by gel electrophoresis was done in 0.8% gels 
containing 0.5 μg/ml ethidium bromide, at 90 V in 1x TAE buffer. DNA was visualized 
using a UV transilluminator. 
 
Purification of DNA fragments from agarose gels was done using the QIAquick 
Gel Extraction Kit (Qiagen) after DNA had been excised from the gel using a scalpel.  
 
Ligation of DNA fragments was performed using the Rapid DNA ligation kit 
(Roche) following the manufacturer’s protocol. 
 
DNA sequencing reactions were performed by the MRC Genomic Core 
Facility, CSC, Hammersmith Hospital, London. 
 
 
2.4.3. PCR methods 
 
 Colony PCR was performed using GoTaq® Flexi DNA polymerase (Promega) 
system, and PCR for HR integration or cloning was performed with the Expand High 
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Fidelity System (Roche). Primers at 0.15 μM and dNTP mix at 300 μM was used. 
Standard PCR conditions were used (annealing temperature of 55°C and 40 cycles). 
Extension times were estimated supposing an extension rate of 0.8 Kb per minute.  
 
   
2.4.4. Fluorescence microscopy 
 
Cells were fixed in paraformaldehyde solution (4% w/v paraformaldehyde, 3.4% 
w/v sucrose), shacken for 15 minutes at RT, washed once in potassium 
phosphate/sorbitol (0.1 M potassium phosphate pH 7.5, 1.2 M Sorbitol) and 
resuspended in a small volume of the same buffer. Cell were store up to one week at 
4°C. Before observation, cells were sonicated at low power 4 seconds in a Vibracell 
sonicator. 1% Triton was added and DNA was stained by DAPI/Antifade (Eugene) at 
25 ng/ml final concentration. Images were collected on a Leica IRB using a 
Hamamatsu D742-95 digital camera and OpenLab™ software (Improvision). A tunable 
light source or an ultraviolet mercury lamp (Leica) was used. For detection of GFP 
signal, different z-axis planes were flattened into a two-dimensional projection and 
processed in OpenLab.   
 
 
2.4.5. Chromatin Immunoprecipitation and RT-PCR 
 
Chromatin Immunoprecipitation (ChIP) was performed as described in Nelson 
et al. (2006) (Nelson, Denisenko et al. 2006), and the following modifications applied. 
2 μg α-Myc antibody (Roche) was used. Pre-equilibrated beads were a 50:50 slurry of 
protein A and Protein G (Roche).  
 
 Real-time PCR reactions were performed using the Sensimix NoRef Kit 
(Quantance) and carried out following manufacture’s instructions. 3 μl input DNA and 
oligonucleotide primer pairs at 1.5 μM were used in a final volume of 20 μl. 
Amplification was done in a DNA Engine Opticon2 thermal cycle together with the 
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Bio-Rad CFX96 Real-Time-system and analyzed by CFX manager (Bio-Rad). The 
melting curve of each primer pair was analyzed to confirm the absence of contaminant 
PCR products. The relative occupancy of the immunoprecipitated at the locus was 
calculated as follows: 2(CtIP-CtImput). Ct-IP and Ct-input are mean threshold of PCR done 
in duplicate on input and IP DNA samples.  
 
 
2.4.6. Southern blotting 
 
DNA extraction 
 
 10ml of yeast culture at O.D. 0.4 was harvested, washed with PBS, stored in dry 
ice for few minutes and kept at -80°C. 400 μl of DNA extraction buffer (1% SDS, 100 
mM NaCl, 50 mM Tris-HCl pH 8.0, 10 mM EDTA), 4 μl β-Mercaptoethanol and 2 μl 
of RNase were added to each sample, together with 40 units of Lyticase (Sigma). 
Samples were then incubated at 37°C for 10 minutes. 450 μl of phenol/chloroform/iso-
amylalcohol (25:24:1) was added to each sample and mix with the pipette and samples 
were kept rotating for 30 minutes. The phenol emulsion was transferred to prepared 
phase lock gel tubes (5prime) and spun down at 12.000 r.p.m. for 5 minutes. Aqueous 
phase was transferred to a fresh eppendorf and 2 vol of pre-chilled EtOH were added. 
Samples were spun at 14.000 r.p.m. and 4°C for 30 minutes, washed with 70% EtOH, 
and spun again at 14.000 r.p.m. for 10min. Ethanol was removed and samples air-dried 
for 20 minutes. Dry DNA was resuspended in 150 μl TE Buffer. DNA concentration 
was measured in a NanoDrop ND-1000 spectrophotometer (Labtech) and confirmed 
by running 5 μl of the sample in mini-agarose gels (0.8% agarose) containing ethidium 
bromide (5 μg/ml final concentration).  
 
Gel electrophoresis 
  
 DNA was separated in a gel of 0.8% High Gel strength agarose in 1xTBE. Gel 
was run at RT at 25 V during 24 hours using 1xTBE running buffer in a MAX HORIZ 
SUB (Amersham Bioscience) running system. Gel was washed 5 minutes in water, 
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followed by 10 minutes in depurination buffer (0.125 M HCl), followed by ten 
minutes in water. Gel was then placed in denaturing buffer (0.4 M NaOH, 1 M NaCl) 
for 30 minutes, washed in water for 5 minutes and placed in neutralizing buffer (1.5 M 
NaCl, 0.5 M Tris HCl, pH 7.5) for 30 minutes.  
 
Blotting 
 
 The gel was blotted in a Vacumgene XL (Amersham Bioscience) into a nylon 
transfer membrane (GE healthcare). The membrane was equilibrated by washing it in 
water for 5 minutes and in 20xSSC during 15 minutes. DNA was transferred from the 
gel to the membrane in 20xSSC buffer during 1 hour. After blotting DNA was 
crosslinked to the membrane in a UV Stratalinker 2400 (Startagene). Membrane was 
then washed in 5xSSC during 4 h so salt excess was eliminated, and either proceed to 
hybridation or store in a sealed bag at RT. 
 
Probing 
  
 The probe was made from 75 ng of DNA from purified PCR product. Probe was 
made by random prime labeling with fluorescein nucleotides (Roche) following 
manufacture’s protocol. Membrane was blocked during 1 hour at 65°C (hybridizer 
oven, Techne) with blocking solution (5xSSC, 0.1% SDS, Dextran Sulfate 0.05 g/ml, 
10% Rapid-hyb buffer, GE Healthcare) in a hybridisation tube FHB12 (Techne) . Probe 
was then added to the blocking solution and hybridisation was carried out overnight. 
Membrane was washed with twice with Buffer1 (1xSSC, 0.1% SDS) during 15 minutes 
and then twice with Buffer 2 (0.5% SSC, 0.1% SDS) during 10 minutes. 60°C are kept 
during the washes. 
     
Signal amplification 
 
 Membrane was blocked in 150ml AB buffer (100 mM Tris-HCl, 150 mM NaCl, 
pH 7.5) with 1% skimmed milk powder for 1 hour at RT. Membrane was the incubated 
with 100 ml of AB buffer with 0.5% skimmed milk powder and 1:250000 alkaline 
phosphatase conjugated anti-fluorescein F(ab)2 (Roche) for 1 hour. Then, three washes 
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of 10 minutes each were done with AB buffer with 0.2% Tween®-20. The blot was 
covered with 10 ml CDP Star (GE Healthcare) and the signal detected with a high 
performance chemiluminescence film (Amersham Hyperfilm™ ECL, GE Healthcare).   
  
 
2.4.7. RIPA protein extraction 
 
50 ml of culture was normally harvested after overnight growth at 
0.6<OD595<0.8, washed with PBS and transfer to a eppendorf tube. About 500 μl glass 
beads were added together with 50 μl of RIPA (10 mM sodium phosphate, 150 mM 
NaCl, 10 mM EDTA, 0.1% SDS, 1% NP40). Cells were broken using 3 cycles of 20 
seconds each in a fastprep machine (MP Biomedicals) at 4°C. The base of each 
eppendorf was pierced twice using a hot 21-gauge needle. Eppendorf were then placed 
on the top of new ones and centrifuged at 2.000 r.p.m. for 1 minute at 4°C. Sample in 
the new eppendorf were then further centrifuged at 14.000 r.p.m. for 10 minutes at 
4°C. Supernatant was transferred to a fresh tube. Protein concentration was measured 
using Pierce® BCA Protein assay (Thermo scientific). 
 
 
2.4.8. Urea protein extraction 
 
This extraction method was used for detection of conjugated Smt3 and 
sumoylated proteins. 100 ml - 200 ml was normally harvested, cells washed in PBS with 
10mM NEM, and placed in dry ice. 500μl of Extraction Buffer A (8 M urea, 100 mM 
NaH2PO4, 10 mM Tris-HCl, 10 mM N-Ethylmaleimide, 0.05% Tween®-20, adjusted to 
pH 8 with NaOH) was added and the eppendorf was topped up with glass beads. Cells 
were broken using 4 cycles of 30 seconds in a fastprep machine (MP Biomedicals). The 
base of each eppendorf was pierced twice using a hot 21-gauge needle. Eppendorf were 
then placed on the top of new ones and centrifuged at 2.000 r.p.m. for 1 minute at 
4°C. Sample in the new eppendorf were then further centrifuged at 14.000 r.p.m. for 
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10 minutes at 4°C. Supernatant was transferred to a fresh tube. Protein concentration 
was measured using Pierce® BCA Protein assay (Thermo scientific). 
 
 
2.4.9. NaOH/TCA protein extraction 
 
 This method was used for Smt3 purification and purification of sumo-substrates 
to be analyzed by MS. 9l of culture were harvest at O.D.0.9 using 1 l centrifuge bottles 
in a F8S-6x1000y rotor in a centrifuge. Cells were washed in chilled PBS with 20mM 
NEM. Cells were resuspended in 250 ml of lysis buffer (1.85 N NaOH, 1.85% β-
Mercaptoethanol) and incubated in ice for 30 minutes. TCA was added to a final 
concentration of 25% and keep in ice for 30 more minutes. Sample was spun at 15.000 
r.p.m. for 10 minutes in acetone-resistant tubes. The pellet was washed with 250 ml 
acetone and spun again at 15.000 r.p.m. for 10 minutes. The pellet was air-dried for 10 
minutes and resuspended in 100 ml of Binding buffer (6 M Guanidine hydrochloride, 
100 mM NaH2PO4, 10 mM Tris-HCL, 20 mM NEM, pH 8) by vortexing for 10 
minutes at RT. Resuspended proteins were recover after a spun at 15.000 r.p.m. for 10 
minutes. All spins were performed at 4°C.  
 
 
2.4.10. HIS tag purification 
 
For Smt3 purification, purification of sumoylated proteins for western blot 
analysis and purification of sumoylated proteins for MS analysis. Prior to the 
purification, 40 mM imidazol was added to the Binding buffer for Smt3 purification 
from YP grown cells, 20 mM imidazol was added for Smt3 purification from SM 
grown cells, for purification of sumoylated proteins for MS analysis, and for Smt3 pull 
down assays for detection of sumoylated proteins by western blotting.    
 
Protein extraction was adjusted to pH 8 and mix with equilibrated Ni-NTA 
agarose (800 μl Ni-NTA slurry per liter of original culture). Ni-NTA agarose (Qiagen) 
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was equilibrated by 2 washes in 15 ml of Extraction Buffer A or Binding buffer. 
Samples were incubated in rotation at 4°C for 2 h.  
 
The temperature was kept at 4°C for the rest of the process. For big volume 
purification, after incubation, agarose beads were centrifuged at 2.000 r.p.m. for 2 
minute and wash twice with urea wash buffer (8 M urea, 100 mM NaH2PO4, 10 mM 
Tris-HCl, 20 mM N-Ethylmaleimide, 40 mM Imidazol, adjusted to pH 6.5). Agarose 
beads were resuspended in urea wash buffer (10 ml per column to be used). Sample was 
placed in Poly-Prep® chromatography columns (Bio-Rad) (1 column each 2 ml original 
agarose beads). 15 ml of urea wash buffer was added to each column and protein was 
eluted by adding 6 ml Elution buffer per column (8 M urea, 100 mM NaH2PO4, 10 
mM Tris-HCl, 500 mM Imidazol, adjusted to pH 4.5 with HCl). 
 
For small volume purification, after incubation, agarose beads were washed 
twice with 1 ml of Buffer A and twice with 1ml of Buffer B (8 M urea, 100 mM 
NaH2PO4, 10 mM Tris-HCl, 10 mM N-Ethylmaleimide, 0.05% Tween®-20, 20 mM 
imidazol, adjusted to pH 6.5 with NaOH) with 10 minutes of incubation in rotation in 
between each wash. All supernatant was removed and 8 μl of LDS sample buffer 4x 
(Invitrogen), 2 μl of β-Mercaptoethanol and 3 μl of imidazol were added to the beads. 
Samples were incubated at 95°C for 5min. 
 
 
2.4.11. SDS-PAGE gels and western blotting 
 
The Bio-Rad SDS-PAGE system was generally used with 10% acrylamide gels. 
Resolving casting solution: 33.4% ProtoGel® Acrylamide solution, 26% ProtoGel® 
resolving buffer, 0.2% ammonium sulphate, 0.2% TEMED. Stacking casting solution: 
13% ProtoGel® acrylamide solution, 25% ProtoGel® Stacking buffer, 0.2% APS, 0.2% 
TEMED. Gels were run at 120 V during 30 minutes and then at 140 V, using Tris-
glycine-SDS running buffer (All reagents are from National Diagnostics). 
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4-12% Tris-Bis and 3-8% Tris-Acetate NuPAGE® gel (invitrogen) were used for 
detection of sumoylated proteins, following manufacturer instructions. 
    
Gels were transferred to PVDF transfer membrane (GE Healthcare) in the Bio-
Rad blotting system in Tris-glycine transfer buffer (National Diagnostics) containing 
20% methanol for 1 hour at 280 mA. Membranes were blocked in 5% skimmed milk 
powder in PBS with 0.1% Tween®-20 (PBSt) for at least 50 minutes. Membranes were 
then incubated in blocking buffer with the primary antibody at 4°C overnight, using 
either; mouse monoclonal anti-c-myc IgG1κ antibody (Roche) or anti-HA IgG1 
antibody 12CA5 (Roche), or anti-Flag IgG2 antibody M2 (Sigma) at 1/2000 dilution; 
or polyclonal rabbit anti-Smt3 Ab (abcam) at 1:500 or 1:5000 dilution (from 1mg/ml 
stock) to detect conjugated Smt3 and free Smt3 respectively. 
 
After a wash in PBSt, the membrane was incubated in blocking buffer with 
sheep anti-mouse IgG Horseradish-Peroxidase-linked antibody (GE healthcare) at 
1/10.000 dilution (if previously used a mouse antibody) or goat anti-rabbit IgG-HRP 
conjugated antibody (SantaCruz) at 1:10.000 dilution (if previously used a rabbit 
antibody). After a further wash with PBSt, the ECL Plus Western Blotting detection 
system (GE healthcare) was used, and the signal coming from the secondary antibody 
was detected using a luminescent image analyzer (ImageQuant LAS4000 mini, GE 
healthcare) or a high performance chemiluminescence film (Amersham Hyperfilm™ 
ECL, GE Healthcare).  
 
 
2.4.12. Sample preparation for mass spectrometry 
 
 Protein extraction after elution from agarose beads was adjusted to pH 7 and 
filtered through a 50 kDa MWCO protein filter (Vivaspin 20, GE Healthcare) up to 1 
ml (one filter was used for every 12 ml of elution sample). Buffer A (w/o Tween®-20) 
was added in a proportion 10:1 and the sample filter again up to 1 ml. Sample was place 
in a 10 kDa MWCO protein filter (Vivaspin 2, GE Healthcare), and filtered up to a 
volume 1/100000 of the original volume of the culture (i.e. 90 μl from a 9 l culture). 
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Protein sample was then digested with Lys-C endonuclease (Roche) at final 
concentration of 0.02 μg/μl. The reaction was incubated at 37°C for 12 hours.  
 
A standard 4% β-mercaptoethanol / 2% SDS loading buffer was added to the 
sample, left on the bench for 15 minutes and loaded into a 12% Tris-Bis NuPAGE® gel 
(invitrogen). Gel was run using Invitrogen system with NuPAGE® MOPS SDS running 
buffer (invitrogen) for 2 h at 140 V. After the running, the gel was stained using 
SimplyBlue™ SafeStain (invitrogen) following manufacturer’s protocol. The band of 
interest was cut from the gel. 
 
 
2.4.13. Mass spectrometry (performed by Dr. Bram Snijders, head of Portein 
Analysis and Proteomics, Clare Hall Laboratories, Cancer Research UK)  
 
Peptides were in-gel digested using trypsin. First, gel bands were distained using 
40% acetonitrile, 200 mM ammonium bicarbonate. Gel pieces were shrunk with 
acetonitrile and enough trypsin solution (10 ng/μl trypsin in 10% acetonitrile in 50 
mM ammonium bicarbonate) was added to cover the gel pieces. Gel pieces were 
incubated overnight at 37°C. Peptides were extracted with 5% Formic acid in 
acetonitrile. The extract were dried to completeness in a vacuum concentrator and 
resuspended in 10 μl of 0.1% trifluoric acetic acid (TFA). 
 
 Peptide mixtures were loaded onto a 75 μm i.d. c18 column (pepmap, dionex) 
and eluted with acetonitrile over a 60 minute gradient stretching from 3% acetonitrile 
to 50% acetonitrile (both in 0.1% formic acid) at 300 nl/minute using an RSLC 
Ultimate (dionex) onto a LTQ-Orbitrap-Velos (Thermofisher). Profile spectra were 
acquired in the orbitrap (30,000 resolution) and the 6 most intense +2 or +3 charge 
ions were selected for fragmentation in the linear ion trap (LTQ).  Peak lists were 
created by proteome discover (thermo fisher). 
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2.4.14. Mass spectrometry data analysis 
 
Peak lists were submitted to Mascot© (Perkins, Pappin et al. 1999) or search 
with Andromeda (Cox, Neuhauser et al. 2011) in the MaxQuant platform. Data was 
searched against a Saccharomyces cerevisiae database (to which the recombinant Smt3 
was manually added) following a standard protocol (Cox, Matic et al. 2009). Mass 
tolerances for Ms and MS/MS data were 10 part per million (ppm) and 0.5 Da 
respectively. Methionine oxidation and glygly modification of lysine were allowed as 
variable modification. The false discovery rates at the peptide, protein and site level 
were 0.005, 0.01 and 0.01 respectively.	  
 
 
2.4.15. Bioinformatic analysis 
 
 Statistical analysis and charts were created using the SPSS software 
environment. Graphic representation of the local context of the sumo-acceptor lysines 
was created using iceLogo (Colaert, Helsens et al. 2009). Sumo motifs were assigned to 
sumo-acceptor lysines using the 3of5 web application for pattern matching (Seiler, 
Mehrle et al. 2006). Subcellular distribution and function of sumoylated proteins was 
obtained from the Gene Ontology (GO) slim mapper part of The Saccharomyces 
Genome Database (SGD, http://www.yeastgenome.org).   
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C h a p t e r  3 .   
R E S U L T S :  R E P A I R  B Y  S I S T E R  
C H R O M A T I N  R E C O M B I N A T I O N  
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3.0. Objectives 
 
The objective of this section of the project was to develop a strategy to study 
Sister Chromatid Recombination (SCR) by the generation of a site-specific double 
strand break (DSB) in one of the sister chromatids. A site-specific single strand break 
(SSB) will be induced at the chromosome VI whilst cells are arrested in G1. This nick is 
expected to become a DSB upon fork arrival, such that it triggers SCR repair (explained 
in introduction). The study of the molecular mechanism involved in SCR requires that 
a high percentage of the cell population synchronously activates SCR. The goal is to 
induce the nick in at least 70% of the cell population. 
Figure 11. Strategy for the study of SCR. A site-specific nick is created in cells arrested in 
G1. After release to the cell cycle SCR is synchronously activated. The DNA structures and 
the proteins involved in the SCR pathway can be studied, i.e. by 2-dimensional gel 
electrophoresis and Chromatin Immuno-Precipitation respectively. 
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3.1. Strain design 
 
The site-specific SSB will be created by the I-HmuI nickase expressed in yeast 
under the control of the Gal1 promoter. The I-HMUI gene is part of a group I intron 
located in the DNA polymerase gene of the bacteriophage SPOI. I-HmuI in this 
context is needed for the initiation of intron homing by which, the intron is copied 
and inserted in a cognate intronless allele. I-HmuI is able to make a single-strand break 
that promotes the insertion of the intron through recombination. I-HmuI has a great 
DNA-binding specificity due to its long target site sequence, 20 bp (Goodrich-Blair and 
Shub 1996). Its target site is not present in the budding yeast genome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. I-HmuI target site. (A) I-HmuI target site and nick site as described in (Shen, 
Landthaler et al. 2004). (B) DNA sequence synthesized by Genecust© containing the I-HmuI 
target site, the hygromycin B resistant gene and homologous sequences of the genes PES4 and 
LSB3 at the Chr.VI. 
	   76	  
The plasmid TS-pRS416, containing the I-HmuI target site, was synthesized by 
Genecust© (6 Rue Dominique Lang, L3505 Dudelange, Luxembourg). The hygromycin 
B resistant gene was added close to the target site, and homologous sequences for the 
PES2 and LSB3 genes (Chr.VI) were placed at each side. This construct was flanked by 
StuI cut sites, and placed in the pRS416 backbone plasmid (Figure 12). 
 
The TS-pRS416 plasmid was cut with StuI and the fragment containing the 
target site was integrated between the genes PES2 and LBS3 (Chr.VI) in the strain 
CCG4072. An important feature of the CCG4072 background is that the replication 
origins ARS608 and ARS609 (Chr.VI) have been deleted. The insertion of the I-HmuI 
target site was on a distal region to ARS607 replication origin. Hence, replication is 
unidirectional through the cleavage site, easing the analysis of any repair event during 
replication. I-HmuI cleaves only one DNA strand, therefore, its target-site can be 
placed either at the leading or at the lagging strand, allowing the independent study of 
these two constructs. (Figure 13).  
 
 
 
Figure 13. I-HmuI target site cloning. I-HmuI target site was placed after ARS607 at 
Chr.VI. The replication origins ARS608 and ARS609 have been deleted.  
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The I-HMUI gene sequence preceded by the Gal1 promoter, and with a NLS 
sequence and a 3-Myc tag at the C-terminus was synthesized by Genecust© into the 
pRS402 backbone plasmid. This plasmid was linearized with the enzyme StuI and 
integrated at the ADE2 locus. Positive colonies were grown in galactose and the 
expression of I-HmuI checked by immunoblotting (Figure 14B).    
 
In order to verify that I-HmuI was transported to the nucleus, its C-terminus 3-
Myc tag was substituted for an EGFP tag using the pYM tagging system (Janke, 
Magiera et al. 2004). The expression of I-HmuI-GFP was induced with galactose during 
4 hours. The GFP signal coming from the I-HmuI-GFP co-localize with the nucleus 
(Figure 14A). 
 
 
 
 
Chromatin immunoprecipitation (ChIP) was performed with the strain 
CCG8262. This strain contains the I-HmuI target site not at the Chr.VI but at the 
lagging strand of the centromeric plasmid TSlagging-pRS416. The ChIP confirms the 
specific binding of I-HmuI to its binding site. There is more than 14 fold increase 
(asynchronous cells) and more than 35 fold increase (G1-arrested cells) in the PCR 
product with the closest primers to the target site, only after expression of I-HmuI 
Figure 14. I-HmuI expression and nuclear localization. (A) fluorescent microscopy is used to 
verify that I-HmuI (tagged with EGFP) is transported to the nucleus. (B) Immuno blot to 
verify the expression of I-HmuI (tagged with 3Myc) after galactose induction. 
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(Figure 15). No detectable increase of any PCR product is detected in cells prior to 
expression of I-HmuI (raffinose) or when glucose is added to the media (inhibitor of 
the expression of I-HmuI). Unspecific binding is only detected in asynchronous cells. 
There is a 6 and 10-fold increase of the PCR product within the -1350 and +4200 pairs 
of primers, respectively.  
 
 
 
 
Figure 15. (A) ChIP analysis of H-
HmuI binding to its target site. 6 
different pairs of primer within the 
plasmid and one at the chromosome 
VI (control) were used. The target 
site of I-HmuI is mark in red. (B) 
asynchronous culture; (C) G1 
arrested culture. Graphic 
representation of the increased on 
PCR product from ChIP samples in 
relation with their input samples.  
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3.2. Quantification of I-HmuI cleavage efficiency 
 
 
The potential of I-HmuI for creating a stable SSB at the Chr.VI was assessed in 
the rad52 mutant. A nick induced during G1 will be converted into a DSB upon fork 
arrival. This DSB will be preferably repaired by SCR, for which the Rad52 protein is 
needed. The viability of rad52 mutants was measured on galactose plates, where I-
HmuI is constantly induced (Figure 16). No differences are observed in the viability of 
rad52 mutants in which I-HmuI is expressed, indicating a very low activation if any of 
SCR due to the activity of I-HmuI.  
 
 
 
 
 
 
 
 
 
 
 
 
Alternatively, the strain CCG8262 was used to quantify the efficiency of the I-
HmuI cleavage at the target site. This strain expresses the I-HmuI nickase under the 
Gal1 promoter and contains the I-HmuI target site in the centromeric plasmid 
TSlagging-pRS416. Having the target site in a plasmid rather than integrated in the 
genome should ease the quantification of I-HmuI cleavage efficiency. Un-nicked 
plasmids retain supercoiling, whilst nicked plasmids lose all supercoiling and become 
relaxed. When a SSB is transformed into a DSB, plasmids become linear. These 
conformational changes are measurable by southern blot due to a markedly different 
mobility of these DNA molecules in agarose gel. 
 
Figure 16. Effect of I-HmuI expression 
in the rad52 mutant. A wild type 
strain containing I-HmuI under Gal1 
promoter and a rad52 mutant 
(without I-HmuI) are used as a 
control. 
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The gel electrophoresis conditions used in this experiment (see materials and 
methods) separates DNA molecules so supercoiled plasmids run faster then linear, and 
these faster than relaxed. The TSlagging-pRS416 plasmid expressed in E. coli was used 
as a control (Figure 17). Equal amounts of purified plasmid were kept at 4°C, or 
digested at 37°C with either Nb.BsmI (nickase with a single recognition site present in 
the TS-pRS416) or with HindIII (restriction enzyme which creates a single double 
strand break in the TSlagging-pRS416). 
 
 
 
  
 
 
 
 
 
Although equal amounts of DNA were loaded, after southern blotting, the 
signal corresponding to supercoiled plasmid is considerably weaker than that from 
nicked plasmid, and this one weaker than the one corresponding to linear plasmid. 
Hence, signal corresponding to different topological forms cannot be compared. 
However, the quantification of nicked plasmid in vivo should be still possible. DNA 
samples digested with the nickase Nb.BsmI are used as a control of the total amount of 
nicked plasmid.  
 
Figure 17. Plasmid conformation 
measured by southern blotting. 
Undigested plasmids retain supercoiling 
(uncut), whilst nicked plasmids loss all 
supercoiling and become relaxed 
(Nb.BsmI). When a DSB is created or nick 
becomes a DSB, plasmids become linear 
(HindIII). The probe used recognizes the 
Hygromycin B gene sequence. 
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In addition, a little fraction of the plasmid in the undigested sample appears 
linear and relaxed, suggesting that nicks and DSBs might be created during the 
technique proir to the gel electrophoresis.  
 
The I-HmuI cleavage efficiency in vivo was quantified by southern blotting 
following the same conditions previously described for the control experiment. Cells 
were arrested in G1 (CCG8262 strain) and the expression of I-HmuI induced by the 
addition of galactose to the media. Glucose was added to the control culture so that the 
GAL promoter of the I-HMUI gene is strongly inhibited. Cells were kept arrested in 
G1 up to 6 h after induction. Equal amounts of each DNA sample were digested with 
Nb.BsmI and run in the same gel. 
 
 
 
 
 
 
Figure 18. Nick efficiency. Cells were 
grown in raffinose for 48 h, then arrested 
in G1 (time 0). Either 2% glucose (no I-
HmuI expression) or 2% galactose (I-
HmuI expression) were added and cultures 
were kept arrested in G1. Samples were 
taken at 2, 4 and 6 hours after 
galactose/glucose addition. (B) 
Percentages were calculated in relation to 
the Nb.BsmI-digested samples. (An 
approximate error of +/-5% is assumed in 
the quantification).  
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The amount of nicked plasmid in G1-arrested cells increases from 5% to 26% 
after induction of I-HmuI (Figure 18). The amount of nicked plasmid in cells with no 
expression of I-HmuI also increases from 5% to 17% after 6h. This artifact nicked 
plasmid could be due to either the growing conditions (G1-arrest), the extraction 
technique or both. However, artifact nicked plasmid should not prevent an accurate 
quantification of the plasmid cleaved by I-HmuI. 
 
The presence of nicked plasmid (TSlagging-pRS416) after induction of I-HmuI 
was quantified in mutants of the NER pathway. The rad14 mutant accumulated a 
higher quantity of nicked plasmid after 6h of expression of I-HmuI than the wild type. 
After 6h of I-HmuI induction, nicked plasmid accounts for almost 40% in the wild 
type and almost 50% in the rad14 mutant. Considering that artifact nicked plasmid 
explain a 17% of the total, the net amount of nicked plasmid due to the cleavage of I-
HmuI is 20% and 30% in the wild type and rad14 mutant respectively (Figure 19).  
 
 
 
Figure 19. Nick efficiency in WT and rad14 
mutant. Samples were collected as 
previously described. (B) Nicked plasmid 
was quantified in two independent 
experiments. Percentages were calculated 
in relation to the Nb.BsmI-digested 
samples. (An approximate error of +/-5% 
is assumed in the quantification). 
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Further NER pathway mutants were also tested: the single mutant rad4, and the 
double mutants rad14rad16 and rad14rad4 (data not shown). The amount of nicked 
plasmid observed in these mutants due to the cleavage of I-HmuI was similar to the one 
observed in the rad14 single mutant.    
 
The experiment described in Figure 19 was also done with a wt and rad14 
mutant strain containing the TSleading-pRS416 plasmid, which contains the I-HmuI 
recognition site at the leading strand. This plasmid was made by inverting the I-HmuI 
recognition site flanked by the NotI sites (≈1 kb fragment) at the TSlagging-pRS416 
plasmid. The results obtained with the TSleadding-pRS416 plasmid in both wt and 
rad14 mutant are similar to those at Figure 19. 
 
The results obtain in mutants of the NER pathway indicates that NER is 
responsible for the repair of nicks created by I-HmuI during G1 arrested cells. However, 
the accumulation of single strand breaks in wild type or NER-defective strains due to 
the expression of I-HmuI is by all means insufficient for the study of SCR as it was 
designed in the original objectives of this study. The small accumulation of nicked 
plasmid after induction of I-HmuI agrees with the lack of activation of SCR observed 
in the rad52 mutant when I-HmuI is expressed. These experiments indicate that either 
I-HmuI has a poor nickase activity in S. cerevisiae or that DNA damage repair 
mechanisms active during G1 (other than NER) repair the nick created by I-HmuI and 
hence prevent its accumulation.  
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C h a p t e r  4 .   
R E S U L T S :  S U M O Y L A T I O N  S I T E S  M A P P I N G  
A N D  Q U A N T I T A T I V E  M A S S  
S P E C T R O M E T R Y  
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4.0. Objectives 
 
The development of a proteome-wide approach for the in vivo identification of 
sumoylation-sites by mass spectrometry. Description of a SILAC-based mass 
spectrometry assay for the quantification of site-specific sumoylation.     
 
 
4.1. Construction of the Smt3 variant  
 
 The successful identification of sumo-acceptor lysines by mass spectrometry is 
substantially dependent on the amino acid sequence of Smt3 itself (explained in the 
introduction: 1.10. Mass spectrometry of post-translational protein modifications). 
 
The modification of the amino acid sequence of Smt3 helps the purification of 
sumoylated proteins, and their detection by mass spectrometry. There are a number of 
successful studies where the sequence of Smt3 was modified for this purpose (Zhou, 
Ryan et al. 2004; Denison, Rudner et al. 2005). The protocol for the purification of 
sumoylated proteins developed here is based on the substitution of the wild type Smt3 
for a Smt3 variant in which all lysines have been substituted for arginines, named 
Smt3-KallR. This allows a Lys-C digestion step, which cleans the sample from peptides 
other than those covalently attached to Smt3. In addition, eight histidines have been 
added to the N-terminus of Smt3 (Figure 20). The use of HIS affinity-purification 
allows working under denaturing conditions. Denaturing conditions prevent the 
action of proteases, among them of sumo-proteases. 
 
 Figure 20. Smt3 aa sequence of WT and KallR. Lysines changed to arginines 
are in red color. 8 histidines have been added at the N-terminus. The I96 at 
the C-terminus has been changed to R. 
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In addition, the used Smt3 variant has an I96R modification at its C-terminus. 
The I96 residue has been substituted for arginine, creating the RGG sequence at the C-
terminus. SUMO-acceptor lysines modified with Smt3 RGG will keep, after trypsin 
digestion, a small 2Gly tag of 114 Da. This reduces considerably the complexity of the 
tandem MS spectrum (Wohlschlegel, Johnson et al. 2006). 
 
The construct was introduced in a centromeric plasmid (8His-SMT3-KallR-
RGG-pRS415, created by Genecust©) which contains the gene constantly expressing 
the Smt3 variant under its endogenous promoter. This plasmid was introduced into the 
CCG5272 strain (Johnson, Schwienhorst et al. 1997). In this strain the endogenous 
SMT3 gene has been knocked out and a copy of HF-Smt3 WT (6xHIS-FLAG-tagged) 
is present in a p316-URA plasmid. Once the CCG5272 strain was transformed with the 
8His-SMT3-KallR-RGG-pRS415(LEU) construct, cells were selected against the 
presence of the p316-URA plasmid by passage in 5-FOA agar plates. 5-FOA media only 
allows the growth of cells which lack the URA gene. The resultant strain only contains 
the Smt3 variant (CCG9474). This strain exhibits normal growth in YPD with and 
without MMS (Figure 21).   
 
 
Figure 21. Viability of the strain containing the Smt3 variant. The strain containing the Smt3-
KallR-RGG variant shows viability similar to the WT strain on YPD and on YPD in the 
presence of MMS. 
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4.1.1 Smt3 variant C-terminus analysis 
 
Three different modifications of the Smt3 C-terminus were tested. The Smt3 C-
terminus variants RAG, RAGG and RIGG could, in theory, generate simpler spectra 
than RGG. In addition, the risk of indentifying any possible contaminant peptide 
modified by ubiquitin or Nedd8 (both with RGG C-terminus) would be reduced. 
However, there is no previous information in the literature about the viability of these 
Smt3 variants.  
 
 
 
 
The pRS415 plasmids containing the three SMT3 variant genes (C-terminus 
RAG, RAGG and RIGG) were created using the 8HIS-Smt3-KallR-RGG pRS415 
plasmid as a template (PCR and cloning methods described in Material and Methods). 
The strain CCG5272 was transformed with the 8HIS-Smt3-KallR-RAG-pRS415, 8HIS-
Smt3-KallR-RAGG-pRS415 and 8HIS-Smt3-KallR-RIGG-pRS415 constructs and the 
p316-URA plasmid selected against in 5-FOA plates. 
 
No colonies transformed with the plasmid 8HIS-Smt3-KallR-RIGG-pRS415 
survived in the 5-FOA plates, indicating that this Smt3 variant does not complement 
the deletion of the endogenous Smt3. Colonies transformed with the plasmids 8HIS-
Smt3-KallR-RAG-pRS415 and 8HIS-Smt3-KallR-RAGG-pRS415 and growing on 5-
FOA plates were checked by Smt3 immunoblotting.  
Figure 22. Smt3 aa sequence of WT, KallR RGG, KallR RAG, KallR RAGG and KallR RIGG. The 
HIS tag is masked in bold letters at the N-terminus. The lysines substituted for arginines are 
marked in red. The FLAG tag is marked in orange. 
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Interestingly, FLAG-tagged Smt3 is still found in the RAG and RAGG strains 
(Figure 23). This indicates that the endogenous HF-Smt3 is still expressed. The strain 
transformed with the 8HIS-Smt3-KallR-RAGG-pRS415 plasmid seems to have retained 
the Smt3 variant together with the WT. The difference in the presence of sumoylated 
proteins between the HF-Smt3 WT strain and the 8HIS-Smt3-KallR RGG strain is 
probably due to a better purification of the 8HIS tag than the 6HIS tag. 
Figure 23. Smt3 immunoblotting of 
Smt3 WT and Smt3 variants RGG, 
RAG and  RAGG (contained in a 
pRS415 plasmid). After Smt3-HIS pull 
down samples were separated by SDS-
PAGE gel. An immuno blot anti-Smt3 
was done for the upper part and anti-
FLAG at the lower part. 
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5.2. Smt3 purification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Summary of the Smt3 
extraction and purification assay 
developed in this study. Cells are lysed in 
NaOH and TCA. Smt3 is then purified 
with Ni-NTA beads. Purified proteins are 
then digested with Lys-C enzyme and 
separated by SDS-PAGE gel. The region 
that corresponds to peptides between 15 
and 25 kDa is recovered from the gel and 
digested with Trypsin previous to mass 
spectrometry analysis. The purification 
method is explained in detail in Material 
and Methods).  
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The Smt3 purification protocol here developed (Figure 24) aims to facilitate the 
detection of sumo-acceptor lysines by MS. This can be achieved by maximizing the 
concentration of Smt3-conjugated peptides present at the sample analyzed by MS. 
Abundant non-sumoylated peptides can saturate the mass spectrometer and hide the 
mass spectra of sumoylated peptides present in low concentrations.   
 
The strain CCG9474, containing the Smt3-KallR-RGG variant was used to test 
and improve a Smt3 purification method previously described (Wohlschlegel 2009). 
 
 Four different steps of the protocol were tested; cell lysis, Smt3-affinity 
purification, protein filtration and Lys-C digestion. Three different methods of cell lysis 
were compared. NaOH/TCA (Trichloroacetic acid) extraction (Riezman, Hase et al. 
1983), and two different mechanical methods; glass beads extraction (Conzelmann, 
Riezman et al. 1988) and cell cryo-lysis in a coffee grinder as described in a protocol 
from Dr. Bruce Goode’s laboratory (the Goode’s lab web site, 
http://www.bio.brandeis.edu/goodelab/links.html).   
 
 Despite the fact that a similar protein concentration is obtained from the 
NaOH/TCA and the glass beads lysis methods (Figure 25), further analysis by MS 
indicated that NaOH/TCA lysis helps Smt3 to remain conjugated to its substrate 
throughout the purification protocol. Any further experiment here explained is based 
on NaOH/TCA cell lysis. 
 
  
 
 
Figure 25. The total amount of protein 
extracted from 4.5 l of culture growing in 
YPD, harvested at O.D.0.8. Protein was 
measured after cell lysis. Smt3 purification 
and mass spectrometry analysis was 
performed with the NaOH lysis and Glass 
Beads lysis samples.    
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The optimum conditions for Ni-NTA affinity purification of Smt3 8His tagged 
were found by quantifying the amount of conjugated Smt3 bound to Ni-NTA beads. 
The time of incubation and the concentration of imidazol dissolved in the media were 
the two variables tested. The histidine side-chain binds the nickel ions retained by the 
NTA groups on the matrix. The imidazol ring shares the same structure of the histidine 
side-chain (Figure 26). The presence of a low imidazol concentration is enough to 
prevent the binding of background proteins with low binding affinity to Ni-NTA 
groups.  
 
 
 
 
 
 
 
 
 
Total cell extract protein sample was incubated with Ni-NTA beads during 1h, 2 
h or 4 h. The imidazol concentration used in this experiment was 20 mM as 
recommended by the manufacturer (QIAGEN). Protein was then eluted from the NTA 
matrix and separated by SDS-PAGE gel. Immunoblotting against Smt3 shows that the 
highest amount of conjugated-Smt3 is recovered after 2 h of incubation (Figure 27a). 
After 4 h of incubation, the amount of conjugated-Smt3 is drastically reduced. The 
amount of free Smt3 doubles from 2 h to 4 h of incubation.  
 
 
Figure 26. Ni-NTA beads and imidazol 
molecular structure. (Picture obtained 
from Ni-NTA purification handbook, 
QIAGEN).  
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Total cell extract protein sample was incubated for 2 h with Ni-NTA beads in a 
media containing increasing concentrations of imidazol; none, 20 mM, 40 mM and 
80 mM. Protein was then eluted from the NTA matrix and separated by SDS-PAGE 
gel. Total protein concentration was equalized for all samples, therefore differences in 
the quantity of conjugated-Smt3 detected by immunoblotting represent differences in 
the ratio sumoylated::background proteins. Maximum concentration of conjugated-
Smt3 is detected when 40 mM imidazol is added to the sample (Figure 27b). 
 
 After the incubation step, Ni-NTA beads are washed to remove background 
proteins. Proteins are then eluted from the Ni-NTA beads by the addition of a low pH 
buffer with a high concentration of imidazol (500 mM). The volume of the sample 
after elution (10-20 ml) must be reduced to allow digestion with the Lys-C protease and 
loading of the sample into a SDS-PAGE gel. Reduction of the volume of the sample is 
performed using Vivaspin® centrifugal concentrators. These protein filters come in a 
range of different pore sizes (from 10 kDa to 100 kDa).  
 
Centrifugal concentrators of three different pore sizes were tested, 30 kDa, 50 
kDa and 100 kDa. The desirable result is to retain sumoylated proteins (>25 kDa) while 
free Smt3 (15 kDa) and other small peptides go through the filter and are eliminated 
from the sample. 50 kDa seems to be the maximum pore size in which all-possible 
Figure 27. Smt3 binding to 
Ni-NTA beads. Immuno blot 
was performed against anti-
Smt3 antibody. The signal at 
15 kDa correspond with free 
Smt3. Signal at higher 
molecular weight corresponds 
with conjugated Smt3. 
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sumoylated proteins are retained (Figure 28). The filtration through the 30 kDa filter 
(data not shown) was considerably slower than through the 50 kDa. Longer filtration 
time could, in theory, increase the chances for Smt3 to deconjugate from its substrate. 
The 100 kDa pore size allows some possible sumoylated proteins to go through. 
 
 
 
  
 
 
 
 After reducing the volume of the sample (up to ≤200 μl), proteins are digested 
with Lys-C. Lys-C is a serine endopeptidase that hydrolyzes peptide bonds specifically at 
the carboxyl side of Lysines. Proteins digested with Lys-C create a pool of peptides that 
are rarely grater than 5 kDa, if full digested. The Smt3 KallR RGG variant expressed in 
the CCG9474 strain has no lysines in its sequence. Hence Smt3 cannot be cleaved by 
Lys-C, and its molecular weight remains of 15 kDa. Any other protein, sumoylated or 
non sumoylated, that contains lysines in its sequence will be digested to small peptides. 
However, lysines covalently attached to Smt3 cannot be cleaved by Lys-C. Hence, Lys-
C-fragmented peptides covalently attached to Smt3 (product of Lys-C digestion of 
sumoylated proteins) will keep an overall molecular weight greater than 15 kDa. After 
Lys-C digestion, non sumoylated peptides (<10 kDa), free-Smt3 (15 kDa) and 
conjugated-Smt3 (≥15 kDa) can be separated according to their size in a SDS-PAGE 
gel. 
Figure 28. 50 kDa and 100 kDa centrifugal concentrators 
test. Smt3 protein purification contained in 8 M Urea buffer 
(denaturing conditions) was filtered through centrifugal 
concentrators of pore size 50 kDa and 100 kDa. The protein 
retained by the filter was loaded (S) together with the 
discarded sample that went through the filter (F). The 
discarded samples were concentrated in a centrifugal 
concentrator of pore size 10 kDa prior to loading. 
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The efficiency of Lys-C digestion was tested with protein samples contained in 
three different buffers; 4M urea, 8 M urea and 1 M urea/10% acetonitrile. Urea and 
acetonitrile are both denaturing agents. Lys-C shows the highest cleavage efficiency in 
the protein sample contained in 8 M urea (Figure 29). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Denaturing conditions and low temperature throughout the Smt3 purification 
process reduced the deconjugation of Smt3 from target proteins by inhibiting the 
action of SUMO-proteases. This inhibition is also helped by addition of protease 
inhibitors. For instance, N-ethylmaleimide (NEM), a strong inhibitor of cystein-based 
proteases, such as SUMO-proteases, has been widely used in SUMO-purification assays 
(Johnson 2004; Dadke, Cotteret et al. 2007).  
 
Smt3 was purified in the presence of 10 mM or 20 mM NEM, or in the 
presence of a protease inhibitor cocktail (Roche). The highest quantity of sumoylated 
proteins is purified in the presence of 20mM NEM (Figure 30).  
 
Figure 29. Lys-C digestion efficiency in the presence of denaturing agents. Total 
cell protein extract was digested with Lys-C at 37°C. The amount of enzyme used 
is 1/40 of the protein by weight and 1/5 in volume. Equal samples were taken at 2 
h, 5 h and 17 h after addition of Lys-C. The control sample (No enzyme) was kept 
in 8M Urea at 37°C with no Lys-C.  
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Figure 30. Consequences of the addition of proteases 
inhibitors during protein extraction and Smt3 
purification. Protein extracted, purified, and run in a 
SDS-PAGE gel. Immuno blot performed anti-Smt3 
antibody. The signal corresponds with conjugated 
Smt3. A strain with the untagged Smt3 is used as a 
control. 
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4.3. Qualitative MS analysis (SUMO sites mapping) 
 
 
 Smt3 purification for mass spectrometry analysis was performed using 9l of 
culture (CCG9474) growing in YPD, and harvested at O.D. 0.9. The Smt3 purification 
was performed as described in Material and Methods. Lys-C digested peptides were 
separated by size in a SDS-PAGE gel. The area that corresponds to peptides between 15 
and 25 kDa (containing peptides conjugated to Smt3) was cut from the gel, 
fragmented in smaller horizontal bands and digested with trypsin (Figure 31). These 
fractions were digested and loaded in the mass spectrometer separately, so the 
complexity of the peptide mixture was reduced.  
 
 
 
 
 
 
Orbitrap and linear Ion trap was combined for the mass spectrometry analysis. 
After peptides were ionized, their size was determined with the Orbitrap, and the most 
intense ions were then fragmented in a linear Ion trap (see Material and Methods). The 
peak lists created by the mass spectrometer were submitted to Andromeda (Cox, 
Neuhauser et al. 2011), a free peptide search engine integrated into the MaxQuant 
Figure 31. Sumoylated peptides separated 
by size in a SDS-PAGE gel. 5 μl out of 100 
μl of the protein sample was kept 
undigested. The rest of the protein sample 
was digested with Lys-C for 14 h. Protein 
samples were separarted by SDS-PAGE gel 
12% acrilamide. The conditions used allow 
a good separation of proteins, in 
particular, between no-conjugated Smt3 
(15 kDa) and peptides conjugated to Smt3 
(15-25 kDa).   
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platform, and to Mascot (Perkins, Pappin et al. 1999), a peptide search engine only 
available under subscription. 
 
As a result, 257 sumo-acceptor lysines were database-matched (Table 3). 182 
sites have a high probability score (Andromeda peptide score >90, or Mascot peptide 
score >30). 128 sites were detected by both search engines, Mascot and Andromeda. 
Modified lysines at the C-terminus of peptides were not taken into account.  
 
Table 3. Sumo-acceptor lysines detected under no DNA damage conditions, database-matched with 
Andromeda and Mascot. The GENE column displays the Standard Name of the gene encoding the 
protein to which the sumoylated peptide belongs. The MODIFIED SEQUENCE column displays the 
sequence of the sumoylated peptide. The sumo-acceptor lysine is denoted with “(gl)”.  
GENE Andromeda Score 
Mascot 
Score Modified Sequence 
ABF1 110.6 45 QQGVTIK(gl)NDTEDDSINK 
ABF1 114.7 20 NEDDK(gl)LPHEVAEQLR 
ABF1 123.6  VSNDSK(gl)LDFVTDDLEYHLANTHPDDTNDK 
ADE1  81 SITK(gl)TELDGILPLVAR 
AIM44  46 LNMEK(gl)DIK 
ALY2 149.2 36 FAPLDK(gl)VTLHR 
AOS1 156.8 41 VEK(gl)LSEDEIALYDR 
APL3  27 LNK(gl)DFR 
ARO8  21 LTEGLK(gl)R 
ARP7  24 LAPLIK(gl)EENDMENMADEQK 
ARP8  24 LTK(gl)EIKDLEGHYVNAPDK 
BDP1 160.5 46 KGSGGIMTNDLK(gl)VYR 
BDP1  26 DK(gl)LLNADIPESDRK 
BDP1  41 K(gl)AHTAIQLK 
BIR1 138.0 41 VIK(gl)PEFEPVPSVAR 
BNI1  23 K(gl)LDEINR 
BOP3 261.2 86 IGASAVAALNDNISIK(gl)EEDVAR 
BRX1  28 AEAAVERK(gl)IK 
BUB1  22 K(gl)LDVLVER 
BUD27 103.8  LEDFK(gl)EYNK 
BUD3 87.4  TGNEDVGNNNPSNSIPK(gl)IEKPPAFK 
BUD3 121.1 34 NK(gl)QENINSSSNLFPEGK 
BUD3 185.8 41 FFEIEEELK(gl)EELK 
BUD4 121.0 26 TGLGIGMLK(gl)TPVK 
BUR2  27 AK(gl)DPIR 
CBF5 136.7 43 EDFVIK(gl)PEAAGASTDTSEWPLLLK 
CBF5  47 VNENTPEQWK(gl)K 
CDC11  23 EAKIK(gl)QEE 
CDC11  33 VQQELLLK(gl)R 
CDC12 93.6 28 YK(gl)EEENALK 
CDC12 130.6 33 K(gl)YFTDQVK 
CDC3 172.1 80 KLQK(gl)SETELFAR 
CDC3 208.3 81 FEAAESDVK(gl)VEPGLGMGITSSQSEK 
CDC3 312.1 74 SLKEEQVSIK(gl)QDPEQEER 
CDC3  43 SLK(gl)EEQVSIK 
CDC48 237.5 54 EVK(gl)VEGEDVEMTDEGAK 
CIN5 156.0 68 MTDTAFVPSPPVGFIK(gl)EENK 
CIT1  23 AEEIK(gl)K 
CMR1 169.0 43 LSDLIK(gl)DEDESALLEK 
CMR1 195.0 54 IFLFTDDSGTIK(gl)QEE 
CRZ1 108.5  PK(gl)IESGIVNIK 
CRZ1 352.1 95 IESGIVNIK(gl)NELDDTSK 
CYC8  29 QPTHAIPTQAPATGITNAEPQVK(gl)K 
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GENE Andromeda Score 
Mascot 
Score Modified Sequence 
DEP1 251.8 58 LSSLVK(gl)QETLTESLK 
DNF1  24 TSK(gl)DIARTK 
EAF7 113.2  EVK(gl)FEDEEK 
ECM17  25 ENK(gl)LTLLTR 
ECM22  25 VSK(gl)TSTGKR 
ENP1  25 ILLDK(gl)K 
ESL2  23 DKK(gl)ER 
FLP1 85.4 25 EMIALK(gl)DETNPIEEWQHIEQLK 
FTR1  26 QELTEEQK(gl)R 
GCN2 101.4  LMIDSPHLK(gl)K 
GCN4 150.0 38 FIK(gl)TEEDPIIK 
GCN5 167.1 75 VK(gl)LENNVEEIQPEQAETNK 
GZF3  24 AISNVK(gl)TETTPPHFIPFLQSSK 
HAP1  28 VK(gl)QESSDELKKDDFMK 
HDA1  41 MDSVMVK(gl)K 
HMO1 110.9 43 TTDPSVK(gl)LK 
HMO1 124.4 30 DAIIAAPVK(gl)AVR 
HPC2 235.4  MQTQTDTNAEVLNTDNSIK(gl)K 
HTA1  36 ATK(gl)ASQEL 
HTB1  42 AVTK(gl)YSSSTQA 
HTB2 145.3  AVTK(gl)YSSSTQA 
IES4 162.7 32 EPADEDPEVK(gl)QLEK 
ILV2  22 K(gl)QEELDAKLK 
IRA1  23 GIIQMSK(gl)MFR 
ISW1 109.7 21 DIISPLLLNPTK(gl)R 
ISW1 121.1 51 AK(gl)IEDTSNVGTEQLVAEK 
ISW1  20 LK(gl)EEGSR 
JIP5  25 K(gl)DLYEHGIKK 
KAP123 105.7 25 TSLLQTAFSEPK(gl)ENVR 
KRR1 105.0 28 DFIAPEEEAYK(gl)PNQN 
LHS1  25 K(gl)LEQEKSR 
LRE1  27 NLIDNMK(gl)GR 
MCD1 119.4 20 ELSEEK(gl)EVIFTDVLK 
MGA2 97.2 27 ALK(gl)EEEEDEHENK 
MLP2 155.5 42 RVK(gl)EEYDIWQSR 
MRP8 115.7 30 EFK(gl)DIPDLK 
MRPL11  43 IK(gl)QTGGKLTK 
MSC1  27 TAK(gl)ENFNK(gl)ISK 
MSN5  23 SELTK(gl)R 
NBA1  21 YEEGLK(gl)R 
NCB2 175.7 56 LHHNSVSDPVK(gl)SEDSS 
NET1 104.3 37 SDLFK(gl)MIEGDDTDLPQWFK 
NET1 109.8 25 VADLK(gl)SANIGGEDLNK 
NET1 149.2 21 IK(gl)SSIVEEDIVSR 
NFI1 157.2 34 NENQGTVK(gl)QEQDYDSR 
NOP12 126.5 49 LLNEEAEAEDDK(gl)PTVTK 
NOP12  29 SSAIDNLFGNIDEK(gl)KIESSVDK 
NOP56 113.2  LEFYNTGK(gl)PTLKNELAIQEAMELYNK 
NOP56 182.6  PTLK(gl)NELAIQEAMELYNK 
NOP7 122.1 35 LDPTEIEEDVK(gl)VESLDASTLK 
NOP7  16 K(gl)EEQAENLKKKK 
NOT5  18 LESDLK(gl)REIK 
NSR1 91.5  LSWSIDDEWLK(gl)K 
NTG1 146.2 42 LENDISVK(gl)VED 
NUM1  18 ESLSDK(gl)IEELTNQKK 
PAA1 230.7 32 ELIK(gl)EEYDN 
PGI1 177.8 33 TLSVK(gl)QEFQK 
PGK1 123.8 25 VK(gl)ASKEDVQK 
PMS1  27 HYTSK(gl)IAK 
POB3 95.2 41 KEESSNEVVPK(gl)KEDGAEGEDVQMAVEEK 
POL30 139.5  LMDIDADFLK(gl)IEELQYDSTLSLPSSEFSK 
POL30 254.6 63 DLSQLSDSINIMITK(gl)ETIK 
PPR1  23 TDLSK(gl)R 
PRE2 95.4 47 VK(gl)EEEGSFNNVIG 
PRP3  30 K(gl)LKQEEDEK 
PRP45 143.0 42 DVSEK(gl)IILGAAK 
PRP45 157.5 81 LDEAVNVK(gl)SEGASGSHGPIQFTK 
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GENE Andromeda Score 
Mascot 
Score Modified Sequence 
PRR1  19 LKQVAVK(gl)R 
PSF2   20 ELDRK(gl)IQYEK 
PUS1 108.4  K(gl)ADFDDEK(gl)DKK 
RAD16 127.4 36 NDNDEIIEIK(gl)EER 
RAD23  20 VPLDLEPSNTILETK(gl)TK 
RAD52 167.1 44 NLVK(gl)IENTVSR 
RAD9  27 RYK(gl)DELSK 
RAP1 170.1 79 DSIRPK(gl)TEIISTNTNGATEDSTSEK 
REB1 250.5 54 ELVDYFSSNISMK(gl)TEN 
REP2 113.9 23 NLTVK(gl)AR 
REP2 184.3 43 GAYK(gl)LQNTITEGPK 
REP2  70 MDDIETAK(gl)NLTVK 
RMR1  25 K(gl)FMGNR 
RNR2 123.0 31 STK(gl)QEAGAFTFNEDF 
RPC37 222.4  SEEVK(gl)AEDDTGEEEEDDPVIEEFPLK 
RPC37  44 SIDNK(gl)LFVTEEDEEDRTQDR 
RPC53 108.5 54 EPTPSVK(gl)TEPVGTGLQSYLEER 
RPC53 121.1 37 VK(gl)LEEESK 
RPC53 180.7 33 PAVK(gl)EEKEDMETQASDPSK 
RPC53 211.5 77 GFIK(gl)SEGSGSSLVQK 
RPC53  62 MAK(gl)YLNNTHVISSGPLAAGNFVSEK 
RPC82 167.3 63 LK(gl)TEDGFVIPALPAAVSK 
RPD3 121.8 31 DAEDLGDVEEDSAEAK(gl)DTK 
RPL13 134.8 46 GFTLAEVK(gl)AAGLTAAYAR 
RPL18A 138.1 39 VVLK(gl)ALFLSK 
RPL20A   26 IK(gl)SSIVEEDIVSR 
RPL25 122.7 20 AVK(gl)ELYEVDVLK 
RPL25 174.9 69 LDSYK(gl)VIEQPITSETAMK 
RPL28 111.5 33 FVSK(gl)LAEEK 
RPL28 123.8 46 IPNVPVIVK(gl)AR 
RPL34A 111.6 49 AFLIEEQK(gl)IVK 
RPL34B 147.7   AFLIEEQK(gl)IVK 
RPL4A 148.3 53 LNPYAK(gl)VFAAEK 
RPL4B 181.7   LNPYAK(gl)VFAAEK 
RPL5 133.1 37 VAAK(gl)IAALAGQQ 
RPL8A 96.1 42 NFGIGQAVQPK(gl)R 
RPO21 119.3   VDLLNTDHTLDPSLLESGSEILGDLK(gl)LQVLLDEEYK 
RPP1B 153.8 36 ALEGK(gl)DLK 
RPS0A 106.6 48 TWEK(gl)LVLAAR 
RPS0A   28 AVLK(gl)FAAHTGATPIAGR 
RPS1 127.8 32 VSGFK(gl)DEVLETV 
RPS10A 100.7 21 HEEIDTK(gl)NLYVIK 
RPS13 118.0 33 K(gl)GLTPSQIGVLLR 
RPS17A 98.9 21 GISFK(gl)LQEEER 
RPS17A 130.6 41 YYPK(gl)LTLDFQTNK 
RPS21A 115.3 35 ADDHASVQINVAK(gl)VDEEGR 
RPS24A   28 K(gl)QFVVDVLHPNR 
RPS3 140.3 61 ALPDAVTIIEPK(gl)EEEPILAPSVK 
RPS31 188.6   LIFAGK(gl)QLEDGR 
RPS6A 88.5 24 K(gl)GEQELEGLTDTTVPK 
RPS8A 135.9 27 NVK(gl)EEETVAK 
RPS8B 117.7   NVK(gl)EEETVAK 
RPS9B 130.2   K(gl)AEASGEAAEEAEDEE 
RRF1   26 QK(gl)MNEIK(gl)QGNFNPK 
RRP9   79 TIDEYNNFDAGDLDK(gl)DIIASR 
RSC4 109.1   LIAKPETVQSEVK(gl)NER 
RSC58 235.4 72 VK(gl)QEELLNTNEEGINR 
RTT107   27 K(gl)FK(gl)VAK 
RVB1 159.5 64 K(gl)EIVVNDVNEAK 
SAT4   20 DLK(gl)PENLLLTHDGVLK 
SCC2   24 K(gl)SEIVSRPEAK 
SCM4 110.8 23 TLK(gl)PESER 
SDC1 110.8 32 SVTNQNVK(gl)IEESSSTNSVIEESSEPK 
SEC26   24 FVMPSK(gl)NKELK 
SEF1 108.0 31 DSK(gl)VSVQTYLSR 
SET1   23 LQENLK(gl)K 
SGS1   23 QLENDIK(gl)LEVIR 
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GENE Andromeda Score 
Mascot 
Score Modified Sequence 
SHS1 129.4 29 SIK(gl)TESSPK 
SHS1 232.9 43 EIK(gl)QENENLIR 
SIR2 111.1 34 IK(gl)VAQPDSLR 
SIR3  27 IK(gl)IEPSADDDVNNGNIPSQR 
SIR4 146.6 34 APFIK(gl)SESKPFSSDALSK 
SIZ1 88.6  VIPEYLGNSSSYIGK(gl)QLPNILGK 
SIZ1 153.7 53 NFLQNALVVGK(gl)SDPYR 
SKI3  22 SDIK(gl)QLLK 
SKO1 116.1 50 DTNVVK(gl)SENAGYPSVNSRPIILDK 
SKO1  50 DTNVVK(gl)SENAGYPSVNSRPIILDK 
SLD3  25 K(gl)DINETIR 
SLI15  22 NNVYMNTLK(gl)YEDK 
SMC5  20 LDDIVSK(gl)ISAR 
SNF2 84.5  DIGAELK(gl)R 
SOD1 174.8 45 K(gl)THGAPTDEVR 
SPP41 90.6 50 RPQIK(gl)PEVSVINLVQNLVNTK 
SPP41 106.9  GVTTPIK(gl)IEDSDANVPPVSIAVSTIEPSQDK 
SPP41 124.4  VK(gl)QQLDK 
SPP41 131.1  PK(gl)SEDHEWPLSDSSASQNYDAHLK 
SPP41  26 LIDVSLKPLNEAK(gl)PK 
SPT15 187.2 33 DGTKPATTFQSEEDIK(gl)R 
SPT15  57 DGTK(gl)PATTFQSEEDIK 
STB3 81.6  EVSPPQAISVK(gl)SEASSSIFSK 
STH1 134.3 26 LIQLDELPK(gl)VFR 
STH1 187.0  EDIEEHFK(gl)K 
STH1  37 EDIEEHFK(gl)K 
SUM1 79.3 19 YFVEPSTK(gl)QESLLLSAPSSSR 
SUM1 84.9 28 K(gl)TPGDEETTTFVPLENSQPSDTIR 
SUM1 100.5  VNVEENK(gl)TEK 
SUM1 140.6 41 LPSGPK(gl)DDVDTLALTSAQNQANSLR 
SUM1 145.4 68 IITIK(gl)SSSENSGNNTTNNNNTDNVIK 
SUM1 211.5 66 IK(gl)NEIPINSLLPSSK 
SUM1  27 ALPSITDIPVSDDSDIK(gl)R 
SWC3 186.7 41 TTAESTQVDVK(gl)K 
SWR1 139.7  YDHIAK(gl)VEEPSEAFTIK 
SWR1 140.8 43 LLAQAEDEDDVK(gl)AANLAMR 
SWR1  33 AGGEQDLADLK(gl)FR 
TAF14 214.5 63 TGSASTVK(gl)GSVDLEK 
TAF5  25 IVLEYLNK(gl)K 
TAH11  34 EK(gl)MPDSQANLMDRLR 
TDH2  28 TASGNIIPSSTGAAK(gl)AVGK 
TEC1  20 K(gl)IENFIK 
TEF1  35 LPLQDVYK(gl)IGGIGTVPVGR 
TFG1 122.9 45 GSLVK(gl)KDDPEYAEEREK 
TFG1 124.8  AVDSSNNASNTVPSPIK(gl)QEEGLNSTVAER 
TFG1 198.6 42 K(gl)DDPEYAEEREK 
TFG1 213.7 74 VK(gl)DEDPNEYNEFPLR 
TFP1  17 AIK(gl)EESQSIYIPR 
TOF2 137.6 52 LHQSQGK(gl)EALFR 
TOP1 98.7 29 IK(gl)TEPVQSSSLPSPPAK 
TOP2 174.2 18 TEEEENAPSSTSSSSIFDIK(gl)KEDK 
TRI1 156.0 35 EIK(gl)LENESLPNLSG 
TUP1 169.0 49 ETTTLPSVK(gl)APESTLK 
TUP1 183.0 48 DYDFK(gl)MNQQLAEMQQIR 
TUP1 202.2 54 LQNQK(gl)DYDFK 
TYE7 103.8  SSETTLIK(gl)PESEFDNWLSDENDGASHINVNK 
TYE7 107.7 24 LQQIIPWVASEQTAFEVGDSVK(gl)K 
UBA2 133.2 33 LLAIENLWK(gl)TR 
UBA2 144.1 32 IK(gl)QETNELYELQK 
UBC9 204.5 56 VLLQAK(gl)QYSK 
UBI1  34 TLSDYNIQK(gl)ESTLHLVLR 
UBI1  74 LIFAGK(gl)QLEDGR 
UBI4 128.7  TLSDYNIQK(gl)ESTLHLVLR 
UBI4 158.1  LIFAGK(gl)QLEDGR 
UME6  22 DREITDPNVK(gl)LDENESK 
UPC2 95.6  ADGSVESDSSVDLPPTIK(gl)K 
UTP7 105.2 28 TNSDIPDVK(gl)PDVK 
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GENE Andromeda Score 
Mascot 
Score Modified Sequence 
VHR1 258.5  NLFNIINK(gl)NK 
VHR2 107.7 48 LQK(gl)FDIEDQPLESEQEYDFIAK 
VMA1 93.3  AIK(gl)EESQSIYIPR 
VPS24  23 MK(gl)IDEAIR 
VPS72 119.8 47 VNSDELK(gl)PTALPDVTLDAIANK 
WRS1  28 QIQK(gl)K 
YAP5 116.1  QK(gl)LETLTLK 
YDR089W  29 FK(gl)QLMK 
YJR129C 105.5  IK(gl)IEETPNLISAASTTGFR 
YLR455W 206.1  NSISIK(gl)EDPEDNQK 
YRR1  26 NK(gl)LIKSCGFCRR 
YSH1 165.6 72 IEPIK(gl)EENEDNLDSQAEK 
ZEO1 195.5 30 NEATPEAEQVK(gl)K 
 
 
More sumo-acceptor lysines were indentified by Mascot (217) than by 
Andromeda (168). However, 40% of the Mascot matches have a score lower than 30. 
54% of the sumo-acceptor lysines mapped only by Andromeda and 48% of those 
mapped by both, Mascot and Andromeda, are within a sumo-consensus sequence. 
However, only 28% of the sumo-acceptor lysines mapped only by Mascot are within a 
sumo-consensus sequence. This is due to a big number of low score matches (Mascot 
score <30) with no sumo-consensus sequence (Figure 32). High score matches from 
Mascot and Andromeda are similar. 
 
 
   
  
 Figure 32. Differences between Mascot and Andromeda search engines. Database-
search results obtained by Mascot and Andromeda are compared in function of the 
peptide score and the presence of a sumo consensus site around the sumo-acceptor 
lysine mapped.  
 
 
	   103	  
4.4. Mass Spectrometry data verification 
 
 
4.4.1 Spectra and mass error 
 
Manual verification of peptide identifications was performed for sumoylated 
peptides of proteins of interest and for Andromeda matched peptides with score lower 
than 90. Analyzed peptides were filtered by the criteria of a reasonable coverage of b- 
and/or y-ion leader, in particular, covering the SUMO-acceptor lysine and the 
surrounding amino acids (Figure 33).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Tandem MS spectrum of peptide GFIK(gl)SEGSGSSLVQK from 
Rpc53. Amino acids covered by the b-y ion leader are in red.  
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The mass error of a given peptide represents the difference between the 
experimental mass of the peptide and the theoretical mass according with the database. 
A low mass error (i.e. 2>ΔM>-2) is an indication of an accurate mass detection and 
therefore a reliable database match. The mass error (ΔM) of the Andromeda matches is 
within +/- 2 ppm (Figure 34). 
 
 
 
 
 
 
 
 
 
Figure 34. Mass error from the 168 
peptides database matched by 
Andromeda (no damage conditions).  
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4.4.2 SUMO sites in the literature 
 
Sumo-acceptor lysines detected in the mass spectrometry analysis were 
compared with sumo-acceptor lysines described in previous studies done in S. cerevisiae 
(Figure 35). Previously studies were based on either MS or site-directed 
mutagenesis/immunoblotting, or a combination of both. Most of the SUMO-acceptor 
lysines previously found were also detected in this study (✔). Only App2, Rhr2, Srs2, 
Kap114, Cdc13 and Ecm11 were not detected in this study. SUMO-acceptor lysines 
were detected in all other proteins, although not all published sites were mapped. 
Previously described SUMO-acceptor lysines K1128 of Sir4 and K35 of Aos1 do not 
match the results obtained here.  
 
 
 
 
 
 
 
 
Figure 35. Previously published SUMO-acceptor lysines. (Johnson and Blobel 1999; 
Hoege, Pfander et al. 2002; Zhou, Ryan et al. 2004; Denison, Rudner et al. 2005; Sterner, 
Nathan et al. 2005; Nathan, Ingvarsdottir et al. 2006; Sacher, Pfander et al. 2006; Chen, 
Silver et al. 2007; Zavec, Comino et al. 2008; Hang, Liu et al. 2011; Silver, Nissley et al. 
2011; Kolesar, Sarangi et al. 2012; Rothenbusch, Sawatzki et al.). 
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4.4.3 Confirmation of sumoylation by immunoblotting 
 
The sumoylation of an individual protein can be detected by immunoblotting 
(Johnson and Blobel 1999). Detecting protein sumoylation by immunoblotting offers 
a very direct confirmation of the Smt3 attachment to the target protein.  
 
Detection of sumoylated forms of proteins from a whole cell extract protein 
sample is, in most cases, difficult. The signal from the sumoylated forms of the protein 
is often too weak to be detected. Smt3 pull down prior to immunoblotting is used to 
increase the concentration of the sumoylated forms of the protein. In this experiment, 
the proteins of interest were Myc- or HA-tagged in strains where Smt3 contains a 
6HIS/Flag tag (HF-Smt3) at its N-terminus (Johnson, Schwienhorst et al. 1997). Cells 
were lysed under denaturing conditions and Smt3 was purified using Ni-NTA beads. 
Once the proteins have been separated by SDS-PAGE gel, sumoylated and non 
sumoylated forms of the proteins are detected by immunoblotting against Myc or HA 
(Figure 36). 
 
 
As a confirmation of the results obtained in the mass spectrometry analysis, 
several proteins for which sumo-acceptor lysines have been detected were studied by 
this method. These include; Rpc53, TBP, Tfg1 and Rad16 (not known to be 
sumoylated at the time the experiment was done), the known sumoylated target Gcn5 
(Sterner, Nathan et al. 2005), and Clb2 (thought to be a false positive match after the 
manual verification of the mass spectrometry data). 
Figure 36. Detection of sumoylated proteins by immunoblotting. The control strain contains 
the Myc/HA-tagged protein but Smt3 is untagged, hence sumoylated  proteins are not purified.  
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The proteins Rpc53, Rad16, Gcn5 and Clb2 were tagged with 9xMyc, and TBP 
with 3xHA at the C-terminus. HIS pull down and immunoblotting against the epitopes 
Myc and HA were performed as described in Materials and Methods.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In accordance with the results obtained from the mass spectrometry analysis, 
Rpc53, Rad16, Gcn5 and TBP are sumoylated in vivo, and Clb2 is not (Figure 37). 
Rpc53, Tfg1, Rad16 and TBP show a ladder of sumoylated forms. Gcn5 shows a single 
sumoylated form.   
 
Figure 37. Detection of sumoylated forms of the 
proteins by immunoblotting after Smt3 purification. 
The non sumoylated form of the protein is often 
detected in both HF-Smt3 and control samples due to 
unspecific binding of the protein to the Ni-NTA beads. 
Fob1, a known sumo target (Prof. Luis Aragon’s lab, 
unpublished data) is used as a positive control.     
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4.4.4 SUMO substrate purification 
 
The same approach developed for the Smt3 purification and mass spectrometry 
analysis of sumo-acceptor lysines was applied to the identification and mapping of 
sumo sites belonging to a unique protein. A substrate-specific purification should 
decrease the complexity of the MS spectra and ease its interpretation. In addition, the 
mass spectrometer will have more time to look at peptides which are close to the 
background signal, increasing the sensitivity of the analysis.  
 
 
 
 
 
An un-tagged Smt3 variant was synthesized. The 8xHis (contained in the 8His-
SMT3-KallR-RGG-pRS415 plasmid) was deleted by PCR (see Methods for Molecular 
Biology, PCR cloning protocols). The new plasmid created, SMT3-KallR-RGG-pRS415, 
was introduced into the CCG5272 strain as previously described. In the resulting strain, 
Gcn5, TBP or Scc1 were 7xHIS tagged using the pYM tagging system. These sumo-
target proteins were purified under denaturing conditions using a slightly modified 
protocol from the one for Smt3 purification (see Material and Methods). Purified 
protein samples were digested with Lys-C. After the digestion, sumoylated peptides 
remain with a size ≥15 kDa since Smt3, albeit untagged, is KallR (Figure 38).  
 
Figure 38. Purification of a unique sumoylated protein by HIS pull down. Smt3 contains no tag while 
the substrate protein to be studied is tagged with 7HIS. His-pull down is performed and the purified 
protein is digested with Lys-C. 
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The purified samples of Gcn5, TBP and Scc1 were separated by SDS-PAGE gel 
before and after Lys-C digestion. All three proteins were detected by mass spectrometry 
before Lys-C digestion with a high coverage (>80%), suggesting a good purification. 
Mass spectrometry analysis of the samples after Lys-C digestion detected one 
sumoylated peptide from Gcn5 (K25), two from TBP (K47, K97) and none from Scc1. 
In addition, the no sumoylated form of Gcn5 K25 was detected in the sample before 
Lys-C digestion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Gcn5, TBP and Scc1 purification 
before Lys-C digestion. The expected location 
of the purified protein is indicated with a red 
box. In all three purifications unspecific 
proteins remain in the  
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4.4.5 Smt3 bona fide C-terminus analysis 
 
Diglycine-modified lysines detected by mass spectrometry after Smt3 
purification could be due to modification by ubiquitin or Nedd8. Both these modifiers 
would leave a diglycine tag after trypsin digestion identical to that from Smt3-KallR-
RGG. Affinity purification of Smt3 followed by Lys-C digestion should eliminate 
peptide modified by any UBL other than Smt3. However, the complete exclusion of 
ubiquitinated or neddylated contaminants cannot be guaranteed.  
 
The following experiment was performed to estimate the possible presence of 
ubiquitinated and neddylated contaminants in the Smt3 purification previously done. 
 
The centromeric plasmid 8His-SMT3-KallR-REQIGG-pRS415 (created by 
Genecust©) contains the gene expressing the Smt3 variant used previously for the Smt3 
purification protocol with the difference that the RGG conjugating terminus has been 
replace for the native RIEQGG C-terminus (Figure 40). This plasmid was introduced 
into the CCG5272 strain as previously described. 
 
 
 
 
Sumo-acceptor lysines modified by the 8His-Smt3-KallR-REQIGG keep a side 
chain of 5 aa after trypsin digestion (EQIGG). Therefore, any diglycine-modified 
lysines detected by mass spectrometry under these conditions can only be due to either 
false positive hits, or to ubiquitinated or neddylated contaminants.  
 
Figure 40. Smt3 aa sequence of WT, KallR RGG and KallR REQIGG. Lysines changed to 
arginines are in red. The flag sequence at the HF-Smt3 in is orange.  
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A large culture of 9 l of the strain expressing the 8His-SMT3-KallR-REQIGG 
variant was grown in YPD and harvested at O.D. 0.9. Smt3 purification and mass 
spectrometry analysis was performed as described in Material and Methods.  
 
Only 23 diglycine-modified lysines were detected by mass spectrometry (Table 
4). No peptide scored more than 80 (Andromeda) or 30 (Mascot). And none of these 
diglycine-modified lysines are placed within a sumo consensus sequence. This indicates 
that sumo-acceptor lysines identified after purification of Smt3-RGG (Table 3) are 
indeed due to sumoylation. 
 
 
 
Table 4. Diglycine-modified lysines detected in the Smt3-REQIGG experiment, database-matched 
with Andromeda and Mascot. The sumo-acceptor lysine is denoted with “(gl)”. 
 
 
 
 
 
 
 
 
 
 
Gene Andromeda Score Modified Sequence 
ATG14 14 RNK(gl)MK(gl)CR 
BUD27 80 LEDFK(gl)EYNK 
INP2 17 K(gl)K(gl)NSPGLK(gl)R 
IOC4 21 TK(gl)AK(gl)K(gl)EK 
MOD5 49 MLKGPLKGCLNMSK(gl)K 
NMD2 18 NK(gl)IK(gl)K(gl)IVLK 
RIT1 47 K(gl)ENK(gl)SVR 
SNU56 7 YSEGNK(gl)PGFMTQDEIK(gl)QHCIGTIK 
Gene Mascot Score Modified Sequence 
BNI1 15 K(gl)LDEINR 
CCT8 12 GLMK(gl)PSGGK 
HSP104 12 YFAIPDIK(gl)K 
IFH1 20 LYK(gl)KTQK(gl)PSTR 
IFH1 17 LYK(gl)K(gl)TQKPSTR 
MLP2 16 SLKNVTEK(gl)NR 
NET1 11 EK(gl)TSKSNEK 
NUM1 11 RGLQIALTTK(gl)EDKK 
RIF1 11 NLK(gl)GPLK 
RPC53 13 DTK(gl)DALSTR 
SKI2 26 K(gl)HKEILNGESAKGAPSK 
SKI2 20 KHK(gl)EILNGESAKGAPSK 
SNI2 20 QGFIPSTVIHAK(gl)K 
SWA2 28 YLEILK(gl)SK 
AIM44 14 LNMEK(gl)DIK 
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4.4.6 SUMO-acceptor lysines mutation 
 
The specific mutation of sumo-acceptor lysines, although laborious, has been 
widely used in the past not only to verify mass spectrometry data but also for de novo 
detection of sumoylated proteins.    
 
 Sumo-acceptor lysines in the proteins Dep1, Reb1, Rpc53, Rps1a, and Ntg1 
were substituted for arginines (KtoR). Arginines, albeit chemically similar to lysines, 
cannot become sumoylated. This is the most reliable way of verifying that the sumo-
acceptor lysines indentified by MS are indeed correct. In addition, the study of these 
sumo-mutant proteins could give a useful inside into the functional significance of 
sumoylation in these target proteins.  
 
The WT and KtoR sequences of the genes DEP1, RPC53 and NTG1 were 
created by Genecust©. They were expressed under their endogenous promoter and 
contained a 5HA tag at the C-terminus of the protein.  
 
Rps1a and Reb1 were tagged with 9myc, and the sumo-acceptor lysine was 
substituted for an arginine by PCR (see Methods for Molecular Biology, PCR cloning 
protocols). Smt3 pull down followed by immunoblotting against the epitopes Myc and 
HA was performed as described in section 4.4.2. to test whether these lysines were 
sumo-sites. 
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The sumo-site mutant proteins Dep1, Rps1a, Rpc53 and Ntg1 lose all 
sumoylation compared with WT proteins. This indicates that all sumo-acceptor lysines 
present in these proteins were successfully mapped using the mass spectrometry 
strategy. On the other hand, the KtoR substitution in Reb1 had a moderate affect in 
preventing sumoylation in unchallenged cells but a big effect (loss of sumoylation) 
under DNA damage conditions (Figure 41). 
 
Figure 41. Smt3 pull down of sumo-mutant proteins. The control sample comes from a 
strain that contains the Myc/HA-tagged WT protein but an untagged Smt3. Sumoylated 
protein is indicated with a red dot. MMS treatment is 0.05%MMS during 1h. 
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4.4.7. Data verification summary 
 
The data obtained by mass spectrometry has been verified by a number of 
independent methods. This confirms that our mass spectrometry analysis of 
sumoylated proteins is a reliable method to map in vivo sumo-acceptor lysines.   
 
Mass spectrometry and immunoblotting for the study of sumoylation are not 
excluding methods, but complementary. Each of them has advantages over the other. 
In this study, mass spectrometry analysis had a clear quantitative advantage. A limited 
number of proteins can be normally studied by immunoblotting while hundreds of 
sumo-acceptor lysines were identified by mass spectrometry. There is also an important 
qualitative advantage in the use of mass spectrometry. Researchers have to choose 
before hand the proteins that will be studied by immunoblotting. This step introduces a 
bias to the experiment that was not present in our proteome-wide mass spectrometry 
analysis. As a consequence, mass spectrometry analysis is more likely to discover 
unexpected sumo-target proteins and to open new lines of investigation.  
 
 However, mass spectrometry results of sumoylation should always be validated 
by immunoblotting and site-specific mutagenesis of acceptor lysines. These techniques 
can directly prove site-specific sumoylation of a target protein. In addition, sumo-
mutant proteins can be used to study the biological role of sumoylation.      
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4.5. Quantitative mass spectrometry (SILAC) 
 
 
4.5.1 Technique set up 
 
The strategy developed here for the identification of sumo-acceptor lysines 
could be transform into a quantitative method by using SILAC-based mass 
spectrometry.  For this purpose, heavy labelled lysine (12C  13C, 14N  15N) will be 
incorporated to the culture media. Due to the big volume of culture needed for the 
experiment only one labelled amino acid can be used if the assay is to be kept at a 
reasonable cost. Lysine is the only acceptor residue of Smt3; therefore, labeling lysine 
ensures that heavy isotopes will be present at all sumoylated peptides. This should make 
possible the quantification of any sumoylated peptide detected by mass spectrometry.   
 
Cells were grown in synthetic media (Kaiser), where normal lysine can be 
substituted for heavy isotope labelled lysine. In order for proteins to be labelled, cells 
need to incorporate lysine from the media. For this reason, the gene LYS2 was knocked 
out in the strain previously used for the Smt3 purification (CCG9474). The resulting 
strain (CCG9668) was grown in media containing normal lysine, heavy labelled lysine 
and no lysine at all (Figure 42). The lack of growth in media without lysine indicates 
that the CCG9668 do not have the capacity of producing lysine, and all of it is 
incorporated from the media. There is no difference in growth in media containing 
normal or heavy labelled lysine.         
 
Figure 42. Growth of the 
CCG9668 strain in synthetic 
media without lysine, with 
normal lysine and with heavy 
labeled lysine. 
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SILAC-based mass spectrometry was first used for the quantification of 
sumoylation in response to oxidative stress. The study of Mms21-dependent 
sumoylation under DNA damage involves working with the slow growing Mms21 C-
terminus knock out (mms21CD) and with considerably big quantities of a DNA 
damage inducing agent. Thus optimization of the Smt3 purification for SILAC-based 
mass spectrometry can be more easily done by the study of the oxidative stress 
response. This assay is done with wild type strains and involves the manipulation of 
hydrogen peroxide (H2O2), a strong oxidizer of no risk for the health of the researcher.  
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4.5.2 SILAC analysis under oxidative stress 
 
A large culture of 9 l (CCG9668) growing in synthetic media with normal 
lysine was treated with 1mM H2O2 at OD 0.85 during 1h before harvest. A culture of 9 
l growing in synthetic media with heavy labelled lysine, up to OD 0.9, is used as a 
control sample. Both samples were mixed prior to protein extraction to avoid 
variability during the extraction and purification. The Smt3 purification and mass 
spectrometry analysis were done as described in Material and Methods. The peak lists 
created by the mass spectrometer were submitted to Andromeda. 
 
As a result, only 14 sumoylated peptides were successfully database-matched, of 
which 12 were quantified (Figure 43). The number matches is extremely low 
considering the big volume of sample used (18 l) and that the same protocol for protein 
extraction and mass spectrometry analysis has been proved successful in the past.  
 
 
 
Gene Score Modified Sequence Log2 
Ratio H/L BAF1 62.4 QQGVTIK(gl)NDTEDDSINK -1.59 
BIR1 131.2 VIK(gl)PEFEPVPSVAR -0.36 
BIR1 85.3 ELSGLK(gl)K -0.37 
HMO1 120.2 TTDPSVK(gl)LK  
NTG1 107.3 RPLVK(gl)TETGPESELLPEK  
POL30 102.3 IVRDLSQLSDSINIMITK(gl)ETIK -3.79 
REB1 85.9 ELVDYFSSNISMK(gl)TEN 0.03 
RPC53 76.2 VK(gl)LEEESK 0.12 
RPC53 153.0 GFIK(gl)SEGSGSSLVQK -0.48 
SIR4 110.6 APFIK(gl)SESKPFSSDALSK -0.98 
SPP41 119.2 RPQIK(gl)PEVSVINLVQNLVNTK -0.35 
SUM1 88.1 IK(gl)NEIPINSLLPSSK -1.41 
TOP2 100.7 KIK(gl)LEDK -4.02 
UBC9 192.1 VLLQAK(gl)QYSK -0.15 
 
 
 
Figure 43. Sumo-acceptor lysines under oxidative stress quantified by SILAC. The sumo-acceptor 
lysine is denoted with “(gl)”. The fourth column displays the Log2 of the ratio heavy-labeled 
peptide :: light-labeled peptide for the peptides quantified by the mass spectrometer. The scatter 
plot presents sumoylated peptides in terms of ratio heavy :: light labeled peptides and the intensity 
of the peptide peak in the mass spectrum.    
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One possibility is that the use of different culture media explains this result. The 
Smt3 purification for detection of sumo-acceptor lysines developed in this study was 
based on growth in YP media. However, SILAC-based mass spectrometry requires the 
use of synthetic media (SM) where normal lysine can be substituted for heavy labelled 
lysine.  
 
In order to assess whether the new growing conditions might be affecting the 
Smt3 purification, 4.5 l of culture (CCG9668) were grown in YP and 9 l in SM. Both 
cultures were treated with 1 mM H2O2 at OD 0.85 during 1 h previous to harvest. The 
Smt3 purification was done as described in Material and Methods. Half of the sample 
from SM grown cells was purified under low concentrations of imidazol. 2 mM 
imidazol was added during the Ni-NTA binding and 20 mM during the Ni-NTA beads 
wash prior to elution. A lower concentration of imidazol should increase the binding of 
Smt3 to Ni-NTA beads, and hence more sumoylated proteins might be purified.    
 
After Lys-C digestion, the three samples were separated by SDS-PAGE gel. The 
gel was stained with SimplyBlue™ SafeStain (Invitrogen) so peptides could be visually 
identified (Figure 44). There was a clear increase in the amount of peptides purified 
when the concentration of imidazol is reduced. Purified Smt3 (15 kDa) is almost 
undetectable in the SM-40 mM imidazol sample compared with the YP or SM-low 
imidazol samples.  
 
 
 
Figure 44. SDS-PAGE gel of protein 
samples after Lys-C digestion. SM and 
YP samples have been purified with 
40mM imidazol. SM low imidazol 
sample has been purified with 2-20 
mM imidazol.  
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  The SM-low imidazol sample was analyzed by mass spectrometry as described 
in section 4.3. 60 sumo-acceptor lysines were database-matched with Andromeda (data 
not shown). The quality of the spectra and matches was comparable to those from 
experiments done in YP under no damage conditions. All protein samples for any 
further SILAC-based experiments were purified under low imidazol conditions. 
 
A 9 l of culture (CCG9668) growing in synthetic media with normal lysine was 
treated with 1 mM H2O2 at OD 0.85 during 1h before harvest. A 9 l of culture 
growing in synthetic media with heavy labelled lysine, up to OD 0.9, was used as a 
control sample. For a more robust quantitative analysis, a reverse experiment was also 
performed, where heavy labelled lysine was incorporated in the H2O2 treated culture 
and normal lysine in the control culture.  
 
The Smt3 purification and sample preparation for mass spectrometry was 
performed as described in Material and Methods. Lys-C digested peptides were 
separated by size in a SDS-PAGE gel and the region that corresponds to peptides 
between 15 a 25 kDa (containing the Smt3-comjugated peptides) was cut from the gel 
and used for MS analysis. Orbitrap and linear Ion trap was combined for the mass 
spectrometry analysis (see Material and Methods). The peak lists created by the mass 
spectrometer were submitted to Andromeda. 
 
As a result, 143 sumo-acceptor lysines were database-matched with a high 
probability score (Andromeda peptide score ≥90), of which 126 were quantified in at 
least one of the experiments and 51 were quantified in both, forward and reverse 
experiment. Modified lysines at the C-terminus of peptides were not taken into 
account. Among the peptides found to be sumoylated, many had already been detected 
in the previous qualitative mass spectrometry analysis in section 4.3.  
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Table 5. Sumoylated peptides detected by SILAC-based mass spectrometry under oxidative stress. 
The sumo-acceptor lysine is denoted with “(gl)”. The fourth and fifth columns display the ratio 
heavy-labelled :: light-labelled of each peptide. This value is expressed as Log2 of the ratio; therefore, 
value 0 corresponds to equal amount of heavy and light peptide. Positive values represent higher 
quantity of heavy than light peptide. Negative values represent higher quantity of light than heavy 
peptide.   
 
Gene Score Modified Sequence Ratio H/L forward 
Ratio H/L 
reverse 
Intensity 
for/rev 
ABF1 155.2 VSNDSK(gl)LDFVTDDLEYHLANTHPDDTNDK -0.112 -0.501 7.2/7.5 
ABF1 160.5 QQGVTIK(gl)NDTEDDSINK -0.963 0.213 7.2/8.4 
ABF1 162.7 MDK(gl)IVVNYYEYK -0.400  6.3/ 
APC5 109.1 K(gl)K(gl)TDELLESLSVEEDR   /6.8 
ARP7 79.3 LAPLIK(gl)EENDMENMADEQK -1.298  6.1/ 
ASG1 160.59 LLSNIK(gl)TER   5.4/ 
BDP1 99.5 KGSGGIMTNDIK(gl)VYR -1.593  6.2/ 
BDP1 153.3 NTAK(gl)EEDQTAQR  0.069 4.9/6.5 
BDP1 186.1 K(gl)TEVVLGTIDDLK -1.540  6.6/ 
BFR2 93.5 SIADQISDIAIK(gl)PVNK 0.348  6.4/ 
BIR1 123.9 ILEDVSVK(gl)NETPNNEMLLFETGTPIASQENK -0.798 0.035 7.2/7.8 
BIR1 140.1 VIK(gl)PEFEPVPSVAR -0.796 -0.036 7.0/7.9 
BIR1 176.8 EISGIK(gl)KETDDGK   5.1/ 
BMH2 162.5 IVSSIEQK(gl)EESKEK  0.250 /6.4 
BOP3 274.1 IGASAVAALNDNISIK(gl)EEDVAR -0.219 -0.439 7.2/8.6 
BSP1 145.3 NIK(gl)KEEEDSIPEAIK  -0.597 6.1/7.0 
BUD4 109.4 AGNK(gl)QENNEINIKAEEEIEPMTQQETDGLK  0.112  
BUD4 149.3 QENNEINIK(gl)AEEEIEPMTQQETDGIK -1.581  6.1/ 
CBF2 102.7 DNQPIK(gl)KEENIVNEDGPNTSR  0.047 /6.1 
CDC19 105.4 IIVK(gl)IENQQGVNNFDEILK  -0.319 /6.3 
CDC3 136.6 SIKEEQVSIK(gl)QDPEQEER -2.251  6.1/ 
CDC48 256.8 EVK(gl)VEGEDVEMTDEGAK -1.651 0.901 6.8/7.6 
CET1 88.1 IAGNAVGSVVK(gl)KEEEANAAVDNIFEEK -0.977 -0.180 6.8/0 
CMD1 113.9 SSNITEEQIAEFK(gl)EAFAIFDK   5.7/ 
CMR1 177.9 LSDLIK(gl)DEDESALLEK -2.839 1.269 6.3/7.3 
CMR1 235.3 IFLFTDDSGTIK(gl)QEE -1.353 1.383 6.9/7.4 
CRZ1 334.8 IESGIVNIK(gl)NELDDTSK -1.571 2.435 6.3/8.1 
DEP1 295.9 LSSLVK(gl)QETLTESLK 0.283 -0.380 7.5/8.0 
EBP2 211.9 SQELK(gl)KEEPTIVTASNLK -2.019 1.006 6.1/6.6 
FBA1 113.4 DYIMSPVGNPEGPEK(gl)PNK -0.989  5.9/ 
FLP1 113.3 EMIALK(gl)DETNPIEEWQHIEQLK -0.584 0.020 6.9/7.3 
GCN4 98.2 FIK(gl)TEEDPIIKQDTPSNLDFDFALPQTATAPDAK  -3.271 /7.5 
GCN4 124.4 TEEDPIIK(gl)QDTPSNLDFDFALPQTATAPDAK  -3.185 6.5/7.4 
GCN5 201.0 VK(gl)LENNVEEIQPEQAETNKQEGTDK -1.410 0.045 6.1/8.0 
GZF3 126.3 AISNVK(gl)TETTPPHFIPFLQSSK  1.250 /6.5 
HAP1 133.0 VK(gl)QESSDELKKDDFMK -2.718  6.0/6.5 
HMO1 174.2 TTDPSVK(gl)IK -1.031 1.185 7.5/7.1 
HPC2 274.6 MQTQTDTNAEVINTDNSIK(gl)K -0.866 0.303  
HSC82 252.1 KPK(gl)IEEVDEEEEEK -1.687 1.166 6.5/6.4 
HTA1 133.6 ATK(gl)ASQEL  0.123 /6.4 
HTB2 183.7 AVTK(gl)YSSSTQA 1.265 -0.935 6.9/7.0 
IES4 214.2 GSEFTASDVK(gl)GSDDK  -1.068 5.4/7.0 
INO80 124.6 SIAVIINKEDK(gl)DISDFSK -1.691  6.0/ 
ISW1 111.6 AK(gl)IEDTSNVGTEQIVAEK -0.597  6.2/ 
ISW1 160.2 DIISPLLLNPTK(gl)R  0.749 /6.9 
LIF1 146.8 ISNQSVIK(gl)MEDDDFDDFQFFGISK -1.479  5.8/ 
MCM1 58.4 QQPQQQQPQQQQQVINAHANSIGHINQDQVPAGAIK(gl)QEVK   6.2/ 
MET28 223.1 VAATTAVVVK(gl)EEEAPVSTSNEIDK -0.128  6.2/ 
MRP8 156.5 EFK(gl)DIPDLK 0.074 0.011 7.9/8.2 
NCB2 125.5 IHHNSVSDPVK(gl)SEDSS   5.1/ 
NET1 121.0 SQAEPSGIVEPK(gl)R   /5.8 
NET1 182.4 EKEDTNDK(gl)LLEK  -2.511 /5.7 
NET1 218.1 SDIFK(gl)MIEGDDTDIPQWFK -1.070 -1.101 6.1/6.9 
NFI1 143.9 NENQGTVK(gl)QEQDYDSR -1.419  6.0/ 
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Gene Score Modified Sequence Ratio H/L forward 
Ratio H/L 
reverse 
Intensity 
for/rev 
NHP10 132.1 VADSK(gl)GGEDGSIVSSN   5.3/ 
NHP10 213.5 KISNIDADDDKEENEQK(gl)IK -1.702  6.4/ 
NOP12 92.1 LLNEEAEAEDDK(gl)PTVTKTDETSVPLTSAAK 0.291 -0.625 6.5/7.1 
NOP12 162.6 SSAIDNIFGNIDEK(gl)KIESSVDK -0.351  6.1/ 
NOP7 163.6 QEDSLLKLDPTEIEEDVK(gl)VESLDASTLK  1.508 /7.6 
NTG1 97.8 IK(gl)QEEVVPQPVDIDWVK   6.5/ 
NTG1 166.3 RPLVK(gl)TETGPESELLPEK   7.0/ 
PAA1 221.9 ELIK(gl)EEYDN -3.833 2.461 6.2/6.7 
PDC1 142.1 ITQDK(gl)SFNDNSK -0.968  5.5/ 
PGK1 159.7 VK(gl)ASKEDVQK -1.327  6.5/ 
POB3 126.9 KEESSNEVVPK(gl)KEDGAEGEDVQMAVEEK -0.943  7.1/ 
POL30 184.3 LMDIDADFLK(gl)IEELQYDSTLSLPSSEFSK -2.460 3.527 7.6/8.1 
POL30 250.3 IVRDISQISDSINIMITK(gl)ETIK -4.003 3.708 9.0/8.6 
PRP45 117.7 LDEAVNVK(gl)SEGASGSHGPIQFTK  -0.858 /6.8 
RBA50 132.8 DVHFIK(gl)EESQNEINIEKIDINDPNFNDK   5.9/ 
REB1 257.0 EIVDYFSSNISMK(gl)TEN 0.050 0.018 7.0/6.5 
REP2 213.6 MDDIETAK(gl)NITVK 1.470  6.7/ 
RHR2 116.5 TYDAIAK(gl)FAPDFADEEYVNKIEGEIPEK -0.551  6.9/ 
RNR2 253.8 STK(gl)QEAGAFTFNEDF -0.090 -0.176 7.0/7.0 
RPB4 154.0 HIK(gl)HENANDETTAVEDEDDDIDEDDVNADDDDFMHSETREK -0.872  6.9/ 
RPC37 220.9 SEEVK(gl)AEDDTGEEEEDDPVIEEFPIK -1.755  6.7/ 
RPC53 123.4 EPTPSVK(gl)TEPVGTGLQSYLEER  0.988 6.1/7.4 
RPC53 136.9 LPAFERPAVK(gl)EEKEDMETQASDPSK -1.557 1.358 6.5/6.8 
RPC53 157.7 VK(gl)LEEESKRGNDK 0.795 -0.450 7.4/8.0 
RPC53 172.8 LPAFERPAVKEEK(gl)EDMETQASDPSK  1.358 /6.8 
RPC53 234.9 GFIK(gl)SEGSGSSIVQK 0.443 -0.227 8.1/8.9 
RPC82 101.4 LK(gl)TEDGFVIPALPAAVSK -0.840 0.437 7.1/7.2 
RPL18B 123.9 ALK(gl)QEGAANK  -0.119 /5.8 
RPL25 121.5 APK(gl)YASK 0.318  6.3/ 
RPL25 140.3 LDSYK(gl)VIEQPITSETAMK  -0.561 /6.7 
RPL34A 126.0 AFLIEEQK(gl)IVK 0.178 -0.460 7.1/7.2 
RPL35B 103.9 EQIASQIVDIK(gl)K 0.272  6.6/ 
RPL4B 150.5 LNPYAK(gl)VFAAEK 0.066 0.005 7.4/7.7 
RPL8B 229.5 NFGIGQAVQPK(gl)R  -0.120 /7.3 
RPS0B 110.4 TWEK(gl)LVLAAR  0.864 /7.2 
RPS10A 122.3 HEEIDTK(gl)NLYVIK 0.124 -0.437 6.5/7.0 
RPS17B 142.1 YYPK(gl)ITIDFQTNK 0.491 -0.351 7.1/6.9 
RPS1A 136.0 VTGFK(gl)DEVLETV -1.189 1.590 6.3/6.5 
RPS20 161.2 SDFQK(gl)EK(gl)VEEQEQQQQQIIK    
RPS3 165.7 AIPDAVTIIEPK(gl)EEEPIIAPSVK -0.205 0.056 7.5/8.4 
RPS8B 165.0 NVK(gl)EEETVAK  1.296 /7.5 
RPT6 111.6 YGEPQK(gl)VVLK  -0.177 /9.0 
RRP15 142.1 IFNAIIATQVK(gl)TEK 0.416  6.7/ 
RSC2 113.6 TSVK(gl)RESEPGTDTNNDEDYEATDMDIDNPK -4.131  6.2/ 
RSC58 153.8 KVK(gl)QEEIINTNEEGINRK    
SDC1 188.9 SVTNQNVK(gl)IEESSSTNSVIEESSEPK -0.459  6.2/ 
SHS1 185.3 EIK(gl)QENENLIR 0.412 -0.170 7.1/8.3 
SIC1 94.2 LTDEEK(gl)R    
SIR3 140.3 KIK(gl)IEPSADDDVNNGNIPSQR    
SIR4 139.9 APFIK(gl)SESKPFSSDAISK -0.494  6.4/ 
SIZ1 101.2 STNTDILTEK(gl)GSSAPSR   5.8/ 
SIZ1 125.5 NFLQNALVVGK(gl)SDPYR  1.306 /6.8 
SIZ1 167.1 TLDPK(gl)SYNIVASETTTPVTNR  1.623 /6.9 
SKO1 182.3 DTNVVK(gl)SENAGYPSVNSRPIILDK 0.208 -0.922 6.0/7.4 
SLI15 101.4 EVK(gl)NYYQSPVR   /6.5 
SLI15 226.7 NNVYMNTLK(gl)YEDK  -0.399 /7.3 
SPA2 88.9 TIK(gl)REEEDEDFDRVNHNIQITGAYTK  0.801 /7.2 
SPP41 94.2 IPEIK(gl)NESVDLGSNITDILSSTITNILPEITATDVK -1.296 -0.879 5.7/7.6 
SPP41 110.0 GVTTPIK(gl)IEDSDANVPPVSIAVSTIEPSQDKLELTK -0.909 0.291 7.2/8.3 
SPT15 138.0 DGTKPATTFQSEEDIK(gl)R  0.395 /7.5 
SPT7 56.4 NGFGTVIK(gl)QEDDDQIQFHNDHSINGNEAFEK   5.8/ 
STB3 94.9 EVSPPQAISVK(gl)SEASSSIFSK -1.637 1.449 7.2/7.8 
STP1 156.5 IK(gl)SEVNAK  0.735 /6.6 
SUM1 135.5 K(gl)TPGDEETTTFVPLENSQPSDTIRK  0.673 /6.6 
SUM1 213.7 IK(gl)NEIPINSLLPSSK -0.759 -0.008 7.8/8.3 
SWC3 188.4 TTAESTQVDVK(gl)KEEEDVK  -0.117 /7.4 
SWI3 107.2 IQKEEEPENNTVIEGVK(gl)EESQPDENTK -2.004  6.0/ 
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Gene Score Modified Sequence Ratio H/L forward 
Ratio H/L 
reverse 
Intensity 
for/rev 
TAF14 220.2 TGSASTVK(gl)GSVDLEK -1.978  6.7/ 
TDH2 105.3 TASGNIIPSSTGAAK(gl)AVGK -0.435 0.520 6.3/6.7 
TFG1 62.5 AVDSSNNASNTVPSPIK(gl)QEEGLNSTVAEREETPAPTITEK  -0.651 /7.3 
TFG1 200.1 VK(gl)DEDPNEYNEFPLR -2.158 1.150 7.0/7.4 
TFG1 235.9 K(gl)DDPEYAEEREK 0.170 -0.097 6.3/7.6 
TFG1 235.9 GSLVK(gl)KDDPEYAEEREK  -0.031 /8.5 
TOP2 120.7 KIK(gl)IEDK -0.976  6.8/ 
TOP2 160.4 TPSVSETKTEEEENAPSSTSSSSIFDIK(gl)KEDK -3.413  6.4/ 
TRI1 105.1 VLLSAPLQK(gl)FLGSEELPR  1.515 6.2/6.8 
TRI1 162.4 EIK(gl)LENESLPNLSG -1.668 1.227 7.0/7.2 
TUP1 90.9 ETTTIPSVK(gl)APESTIK -0.062  6.4/ 
TUP1 97.2 IWNIQNANNK(gl)SDSK -0.393  6.3/ 
TUP1 144.0 DAYEEEIK(gl)HLK  -1.127 /6.2 
TUP1 188.9 LQNQK(gl)DYDFK  -0.410 /7.4 
TYE7 119.5 SSETTLIK(gl)PESEFDNWLSDENDGASHINVNK -2.976 2.965 7.1/8.9 
TYE7 126.9 K(gl)QDEDGAETAATTPIPSAAATSTK   5.9/ 
TYE7 144.8 TNIDAK(gl)ETK   5.6/ 
UBA2 123.6 LLAIENLWK(gl)TR  1.249 /5.9 
UBC9 297.4 VLLQAK(gl)QYSK 0.133 -0.258 7.9/8.9 
UBI4 180.9 LIFAGK(gl)QLEDGR -0.030 0.737 6.9/8.0 
VHR1 193.1 NLFNIINK(gl)NK  0.638 /7.7 
VHR2 165.2 IQK(gl)FDIEDQPIESEQEYDFIAK   5.6/ 
VIP1 166.4 SGIK(gl)KEPIESDEVPQQETK -1.779  5.5/ 
VPS72 158.3 SDIK(gl)RDETTNEDSDDQVR  0.080 /7.0 
YLR455W 124.1 NSISIK(gl)EDPEDNQK 0.542 -0.690 5.6/6.3 
YSH1 159.4 IEPIK(gl)EENEDNLDSQAEK -1.067 0.314 5.9/7.0 
ZEO1 99.9 GQEVK(gl)EQAEASIDNIK -1.125  5.5/ 
ZEO1 137.9 NEATPEAEQVK(gl)KEEQNIADGVEQK -1.278 1.411 6.7/7.2 
 
 
 
 
 
 
 
 The ratio heavy/light isotope was normalized to 0 using as reference the mean 
of the ratio from all peptides containing lysines. This assumes that most of the 
proteome do not undertake a significant quantitative change upon oxidation stress 
(Figure 45 B,D).  
 
SILAC-based mass spectrometry analysis shows that sumoylation is generally 
increased upon oxidation stress. This result is in accordance with the large increase in 
protein sumoylation detected by immunoblotting after treatment with hydrogen 
peroxide (Zhou, Ryan et al. 2004). Some sumoylated peptides however show a 
significant decrease in sumoylation upon oxidative stress, i.e. Net1, Gcn4 and Htb2, or 
no change at all, i.e. Rps3, Reb1, Mrp8, Rnr2 and Ubc9 (Figure 45A,C)  
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Figure 45. Quantification of sumoylation under oxidative stress. (A,B) Forward 
experiment. A negative value for the Log2 of the ratio heavy/light-labeled peptide 
means an increase of sumoylation under oxidative stress. (C,D) Reverse 
experiment. A positive value for the Log2 of the ratio heavy/light-labeled peptide 
means an increase of sumoylation under oxidative stress. (A,C) Sumoylated 
peptides are plotted in function of the ratio heavy/light peptide and the intensity 
of the peptide peak in the mass spectrum. (B,D) Plot showing all lysine-
containing peptides (green) and sumoylated peptides (red) quantified by the mass 
spectrometer. All ratios H/L have been normalized to value 0. Forward 
experiment; 3105 K-containing peptides and 77 sumoylated peptides. Reverse 
experiment; 3881 K-containing peptides and 87 sumoylated peptides. 
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 There is a strong overall correlation between the quantification from the 
forward and reverse experiment (R=0.68) (Figure 46). The only two significant 
exceptions are Net1 (SDIFKglMIEGD…) and Spp41(IPEIKglNESVD…).    
 
 
 
Figure 46. Sumoylated peptides quantified in both experiments, forward and reverse. 
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4.5.3 SILAC control data 
 
The accuracy of the quantitative results mainly depends on the resolution of the 
mass spectrometer and the signal intensity of the measured molecules. The accuracy of 
the quantification of individual proteins was estimated, when possible, by calculating 
the standard deviation from the ratios of all peptides that quantify the same protein. 
Protein extractions before Smt3 purification, from forward and reverse experiments, 
were analyzed by SILAC-based mass spectrometry (data not shown). These results are 
used to calculate standard deviations for individual proteins and to quantify variations 
in the total amount of protein upon oxidative stress.  
 
In addition, relative quantification was also done between two identical samples 
(both treated with H2O2) in order to detect any possible artifact variation introduced 
during the extraction and purification of the proteins or during the mass spectrometry 
analysis of the peptides. 
 
A culture of 18 l (CCG9668) growing in synthetic media, of which 9 l were 
grown with normal lysine and 9 l with heavy-labelled lysine, were treated with 1mM 
H2O2 at OD 0.85 during 1h before harvest. The Smt3 purification and the SILAC-
based mass spectrometry analysis were performed as described in the previous forward 
and reverse experiments. The peak lists created by the mass spectrometer were 
submitted to Andromeda. 
 
As a result, 106 sumo-acceptor lysines were database-matched, 93 of which with 
a high probability score (Andromeda peptide score ≥90). 82 of these lysines had been 
previously mapped in the forward/reverse experiment. Modified lysines at the C-
terminus of peptides were not taken into account.  
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Table 6. Sumoylated peptides detected under oxidative stress in the control experiment. The GENE 
column displays the Standard Name of the gene encoding the protein to which the sumoylated 
peptide belongs. The SCORE is an estimation of the quality of the peptide spectra and identification. 
The MODIFIED SEQUENCE column displays the sequence of the sumoylated peptide. The SUMO-
acceptor Lysine is denoted with “(gl)”. The fourth column displays the ratio heavy-labelled :: light-
labelled of each peptide. This value is expressed as Log2 of the ratio.  
 
Gene Score Modified Sequence Log2 Ratio 
H/L ABF1 131.35 QQGVTIK(gl)NDTEDDSINK 0.097 
ABF1 163.91 VSNDSK(gl)LDFVTDDLEYHLANTHPDDTNDKVESR 0.147 
APA1 167.32 ALTFFQDWLNENPELK(gl)K -0.321 
ASG1 111.95 LLSNIK(gl)TER 0.046 
BDP1 93.839 K(gl)TEVVLGTIDDLK -0.027 
BDP1 160.48 KGSGGIMTNDLK(gl)VYR 0.004 
BIR1 83.182 ELSGLK(gl)KETDDGK -0.108 
BIR1 137.86 ILEDVSVK(gl)NETPNNEMLLFETGTPIASQENK -0.011 
BIR1 147.33 VIK(gl)PEFEPVPSVAR 0.066 
BMH2 106.49 IVSSIEQK(gl)EESKEK 0.156 
BOP3 282.19 IGASAVAALNDNISIK(gl)EEDVAR -0.026 
CDC48 244.44 EVK(gl)VEGEDVEMTDEGAKAEQEPEVDPVPYITK -0.212 
CET1 85.805 IAGNAVGSVVK(gl)KEEEANAAVDNIFEEK 0.055 
CMR1 173.44 LSDLIK(gl)DEDESALLEK -0.224 
CMR1 265.22 IFLFTDDSGTIK(gl)QEE -0.067 
CRZ1 118.52 IESGIVNIK(gl)NELDDTSK -1.158 
DEP1 308.74 LSSLVK(gl)QETLTESLK 0.316 
EBP2 190.82 SQELK(gl)KEEPTIVTASNLK -0.397 
ESC1 68.309 VNEGEEPEHQAVDIPVKVEVK(gl)EEQEEMPSK -0.180 
FHL1 147.54 HPQNTTTDIENEVENPVTDDNGNLK(gl)LELPDNLDNADFSK -0.475 
GCN4 155.46 FIK(gl)TEEDPIIKQDTPSNLDFDFALPQTATAPDAK -0.202 
GCN4 155.46 TEEDPIIK(gl)QDTPSNLDFDFALPQTATAPDAK -0.099 
GCN5 137.73 RVK(gl)LENNVEEIQPEQAETNKQEGTDK -0.153 
HAA1 128.67 IGSQENSVK(gl)QENYSK -0.387 
HMO1 186.76 TTDPSVK(gl)LK 0.215 
HMS1 153.36 DSSLLSAASIVK(gl)KEQLSGFENFLPLSK -0.050 
HPC2 286.14 MQTQTDTNAEVLNTDNSIK(gl)KETGSDSEDLFNK -0.595 
HSC82 170.66 KPK(gl)LEEVDEEEEEK -0.388 
HTA1 127.12 ATK(gl)ASQEL 0.349 
HTA2 101.99 TAK(gl)ASQEL 0.349 
IES4 117.09 K(gl)KEPADEDPEVK 0.147 
IES4 93.011 GSEFTASDVK(gl)GSDDK 0.285 
ISW1 137.79 AK(gl)IEDTSNVGTEQLVAEK 0.018 
MRP8 162.97 EFK(gl)DIPDLK 0.447 
NET1 203.87 VADLK(gl)SANIGGEDLNK 0.220 
NOP12 74.123 LLNEEAEAEDDKPTVTK(gl)TDETSVPLTSAAK -0.067 
NOP7 151.39 LDPTEIEEDVK(gl)VESLDASTLK -0.797 
NTG1 122.39 ELNVEAEINVK(gl)HEEK -0.740 
NTG1 193.77 RPLVK(gl)TETGPESELLPEK -0.666 
NTG1 94.532 IK(gl)QEEVVPQPVDIDWVK -0.523 
PAA1 146.36 WIDMERELIK(gl)EEYDN -0.232 
PGK1 150.35 VK(gl)ASKEDVQK -0.130 
POL30 295.12 IVRDLSQLSDSINIMITK(gl)ETIK -0.548 
POL30 193.96 LMDIDADFLK(gl)IEELQYDSTLSLPSSEFSK -0.251 
PRE2 123.95 VK(gl)EEEGSFNNVIG 0.178 
PRP45 94.856 TNYEKLDEAVNVK(gl)SEGASGSHGPIQFTK 0.395 
RAD52 205.13 NLVK(gl)IENTVSR -0.202 
RAD52 87.647 K(gl)PVFGNHSEDIQTKLDK -0.007 
RAD59 112.58 NEANTNYNLLSATNSKPTFIK(gl)LEDAK 0.196 
RHR2 98.684 TYDAIAK(gl)FAPDFADEEYVNKLEGEIPEK -0.456 
RNR2 77.746 AAADALSDLEIK(gl)DSKSNLNK -0.320 
RNR2 255.16 STK(gl)QEAGAFTFNEDF 0.023 
RPB4 108.72 HLK(gl)HENANDETTAVEDEDDDLDEDDVNADDDDFMHSETREK 0.137 
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Gene Score Modified Sequence Log2 Ratio 
H/L RPC53 253.16 RGFIK(gl)SEGSGSSLVQK -0.041 
RPC53 120.15 VK(gl)LEEESK 0.077 
RPC82 103.61 KLK(gl)TEDGFVIPALPAAVSK -0.558 
RPL4B 161.17 LNPYAK(gl)VFAAEK -0.003 
RPL8B 167.09 NFGIGQAVQPK(gl)RNLSR 0.304 
RPL9B 80.387 YVYAHFPINVNIVEK(gl)DGAK -0.353 
RPS0A 164.97 TWEK(gl)LVLAAR 0.516 
RPS10A 147.26 HEEIDTK(gl)NLYVIK 0.650 
RPS1A 143.24 VTGFK(gl)DEVLETV -0.415 
RPS1B 150.04 VSGFK(gl)DEVLETV -0.316 
RPS3 206.59 ALPDAVTIIEPK(gl)EEEPILAPSVK 0.006 
RPS8B 182.46 NVK(gl)EEETVAK -0.224 
RSC58 204.52 KVK(gl)QEELLNTNEEGINRK -0.344 
RTF1 124.42 NAEHVK(gl)KEDSNNFDSK -0.488 
SHS1 120.99 SIK(gl)TESSPK -0.517 
SHS1 172.88 EIK(gl)QENENLIR -0.206 
SIR4 204.35 APFIK(gl)SESKPFSSDALSK -0.123 
SIZ1 90.379 NFLQNALVVGK(gl)SDPYRVQAVK -0.004 
SIZ1 144.27 STNTDILTEK(gl)GSSAPSR 0.143 
SKO1 161.51 DTNVVK(gl)SENAGYPSVNSRPIILDK 0.396 
SLI15 162.36 NNVYMNTLK(gl)YEDK 0.162 
SPP41 112.75 VK(gl)QQLDK -0.647 
SPP41 104.53 IPEIK(gl)NESVDLGSNITDILSSTITNILPEITATDVK -0.256 
SPP41 110.25 GVTTPIK(gl)IEDSDANVPPVSIAVSTIEPSQDKLELTK -0.210 
SPP41 190.82 RPQIK(gl)PEVSVINLVQNLVNTK -0.033 
SPT15 136.7 PATTFQSEEDIK(gl)R -0.116 
STB3 80.361 EVSPPQAISVK(gl)SEASSSIFSKPISTSSPAGLAAAQR -0.149 
STH1 106.93 VFREDIEEHFK(gl)KEDSEPLGR -0.193 
SUM1 220.97 SDASNRIK(gl)NEIPINSLLPSSK -0.078 
SWC3 118.13 TTAESTQVDVK(gl)KEEEDVK -0.319 
TAF12 111.34 SAIFK(gl)QTEPAIPISENISTK -0.241 
TAF14 244 TGSASTVK(gl)GSVDLEK -0.102 
TDH2 152.34 TASGNIIPSSTGAAK(gl)AVGK -0.201 
TDH2 85.67 VVDLVEHVAK(gl)A -0.138 
TFG1 83.567 AVDSSNNASNTVPSPIK(gl)QEEGLNSTVAEREETPAPTITEK -0.126 
TFG1 266.35 VK(gl)DEDPNEYNEFPLR -0.121 
TFG1 229.23 GSLVK(gl)KDDPEYAEEREK 0.187 
TFG1 229.23 K(gl)DDPEYAEEREK 0.239 
TOP2 140.8 TPSVSETKTEEEENAPSSTSSSSIFDIK(gl)KEDK -0.777 
TRI1 114.69 VLIPK(gl)NDLISRDQELSLR -0.086 
TRI1 185.25 EIK(gl)LENESLPNLSG -0.078 
TRI1 173.06 VLLSAPLQK(gl)FLGSEELPR -0.010 
TUP1 80.688 LQNQK(gl)DYDFK -0.393 
TUP1 172.27 DAYEEEIK(gl)HLK -0.317 
TUP1 79.633 ETTTLPSVK(gl)APESTLK -0.306 
TYE7 138.08 TNLDAK(gl)ETK 0.465 
TYE7 151.84 SSETTLIK(gl)PESEFDNWLSDENDGASHINVNK 0.569 
UBA2 177.42 RIK(gl)QETNELYELQK -0.588 
UBC9 238.73 VLLQAK(gl)QYSK 0.313 
VMA1 151.98 AIK(gl)EESQSIYIPR -0.647 
YLR455W 202.16 NSISIK(gl)EDPEDNQK 0.453 
YSH1 130.72 IEPIK(gl)EENEDNLDSQAEK -0.809 
ZEO1 72.883 NEATPEAEQVKK(gl)EEQNIADGVEQK -0.344 
 
  
The control experiment covered most of the peptides previously quantified in 
the forward and reverse experiment. Quantitative values for the log2 of the ratio H/L in 
the control experiment are within +/-1. There is a statistically significant increase of 
sumoylation in both forward and reverse experiment when the fluctuations in the 
quantification of the control experiment are subtracted (Figure 47 and Figure 48). 
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Figure 48. Wilcoxon signed rank test.  
Forward-control; forward values are significantly 
lower than control, p-value < 6.8e-5. Reverse-
control; reverse values are significantly higher than 
control, p-value < 2.3e-4. Reverse-forward; reverse 
values are significantly higher than forward, p-
value < 2.6e-14.  
Figure 47. Quantitative data 
from the three SILAC 
experiments; control, forward 
and reverse. 
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4.5.4 SILAC data verification 
 
Sumoylation of an individual proteins can be detected by immunoblotting as 
shown in section 4.4.3. This technique can also detect variations in sumoylation in 
response to oxidative stress, and it is used to confirm the results obtained from the 
SILAC-based mass spectrometry experiment. 
 
The sumoylation dynamics in response to oxidative stress was studied in the 
following proteins; Tfg1, Rpc53, Gcn5, Cdc48 and Net1. First, the data obtained in the 
SILAC-based analysis of protein extraction prior to Smt3 purification was examined 
(Table 7). There is no significant variation in the amount of protein upon oxidative 
stress (-0.2 < Log2 Ratio H/L < 0.3). The standard deviation in the Net1 quantification 
is significantly higher than in the rest of proteins. No peptides belonging to Gcn5 were 
detected. 
 
 
 
Table 7. Quantitative data prior to Smt3 purification. 
Protein Experiment N° peptides Average ratioH/L SD ratioH/L Log2 ratioH/L 
Cdc48 forward 42 0.89 0.09 -0.16 
  reverse 30 0.87 0.06 -0.19 
Net1 forward 28 0.93 0.18 -0.09 
  reverse 4 1.14 0.52 0.19 
Rpc53 forward 3 0.93 0.06 -0.11 
  reverse 0 - - - 
Tfg1 forward 4 0.94 0.08 -0.09 
  reverse 1 1.22 0 0.29 
 
 
 
 
   The proteins Rpc53, Tfg1, Gcn5, Cdc48 and Net1 were tagged with 9xMyc at 
the C-terminus. Affinity-purification and immunoblotting were performed as 
described in Materials and Methods.  
 
In accordance with the results obtained by SILAC-based mass spectrometry 
analysis, sumoylation upon oxidative stress increased in the proteins Rpc53, Gcn5 and 
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Cdc48, and decreased in the protein Net1. The sumoylation pattern of Tfg1 also 
changed upon oxidative stress. Tfg1 sumoylated forms increased under oxidative stress 
with the exception of the band at 170 kDa (Figure 49).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Changes in 
sumoylation upon 
oxidative stress on 
proteins Rpc53, Gcn5, 
Tfg1, Net1 and Cdc48. 
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4.5.5 Quantitative analysis of Mms21-dependent sumoylation 
 
The SP-RING domain at the C-terminus of Mms21 (mms21CD) was deleted in 
the strain CCG9668 as described in study of Dr. Zhao (Zhao and Blobel 2005). 
mms21CD mutants were knockout for the sumoligase activity of Mms21. The resulting 
strain also contains the Smt3-KallR-RGG and is deficient for the LYS2 gene. The 
deletion of the Mms21 C-terminus was verified by the lost of viability in MMS. The 
mms21CD in the background CCG9668 shows a reduction in viability in permissive 
conditions compared with the CCG9668 or the mms21CD in a wild type background 
(Figure 50). 
 
 
 
 
 
 
 
 
  
A culture of 9 l of the mms21CD (in the CCG9668 background) growing in 
synthetic media with normal lysine was treated with 0.05% MMS at OD 0.8 during 90 
min before harvest. The control sample was a 9 l of culture (CCG9668) growing in 
synthetic media with heavy labelled lysine, treated with 0.05% MMS at OD 0.8 during 
90 min before harvest.  
 
Although the mms21CD showed an initial growing rate slower than the control 
sample, both cultures had a similar growth rate at the time of harvest. Before the 
addition of MMS prior to harvest, an aliquot of each culture was plated in YP agar and 
YP agar containing 0.005% MMS. mms21CD and control cells showed a similar 
growth in both conditions (Figure 51). These observations suggest that the mms21CD 
sample might have been contaminated with a wild type strain. 
 
Figure 50. Viability of the mms21CD  in the Smt3-KallR-RGG background. 
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Simultaneously, the Smt3 purification and the SILAC-based mass spectrometry 
analysis were performed as described in Material and Methods. The peak lists created by 
the mass spectrometer were submitted to Andromeda. 
 
As a result, 217 sumo-acceptor lysines were database-matched, 198 with a high 
probability score (Andromeda peptide score ≥90). Modified lysines at the C-terminus 
of peptides were not taken into account (Supplementary Data, Table 9). Relative 
quantification showed no significant difference between the mms21CD and control 
samples. This result is in accordance with the growth rate observed in YP agar, and 
supports the theory that the sumoligase mutation in the mms21CD might have been 
reverted. 
 
The mms21CD used in this experiment and kept in stock at -80°C was plated 
for five days in YPD broth and YPD broth containing 0.005% MMS. The mms21CD 
has a reduced viability in both conditions. Interestingly, some individual colonies of 
the mms21CD mutant growing in YPD show higher growth. This could be explained 
by the presence of few wild type cells in the stock. 
 
 
 
Figure 51. Viability of 
mms21CD and control 
culture at the time of 
harvest. Drops were 
plated on YPD and YPD 
containing MMS.  
Figure 52. Viability of the mms21CD  after 5 days in YP agar. Drops were 
plated on YPD and YPD containing MMS. 
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4.5.6 Quantitative mass spectrometry summary 
 
The data obtained suggest that relative quantification of sumoylation can be 
reliably performed by SILAC-based mass spectrometry. The methodology here 
developed allows a proteome-wide site-specific mapping of sumo-acceptor lysines and 
the relative quantification of sumoylation at these sites.  
 
A statistically significant increase in sumoylation was observed under oxidative 
stress when taken in consideration background fluctuation in the quantification and 
quantitative changes in the proteome. This result was validated by the study of changes 
in sumoylation upon oxidative stress using immuno blotting. All the proteins studied 
by this method showed the sumoylation pattern predicted by mass spectrometry.    
 
The data also suggested that changes in sumoylation are not equal in sumo-
acceptor lysines belonging to the same protein. Different sumo-sites within a protein 
might behave differently in response to oxidative stress. An example of this are Tfg1, 
Rpc53 and Tup1.  
 
 Despite the successful analysis of sumoyaltion under oxidative stress, SILAC-
based mass spectrometry could not be used for the study of Mms21-dependent 
sumoylation. The presence of two point mutations at the SP-RING domain at the C-
terminus of Mms21 (mms21CD) knockout the sumoligase activity of this enzyme 
(Andrews, Palecek et al. 2005). The mms21CD has been successfully used to study the 
role of Mms21 sumoligase activity in genome stability (Zhao and Blobel 2005; Hwang, 
Smith et al. 2008). However, the mms21CD has a slower growth rate than the wild type 
strain and a severe sensitivity to genotoxins. In addition, the presence of Smt3-KallR-
RGG further decreases the viability during unchallenged growth of the mms21CD 
mutant. Under these growth conditions quantitative mass spectrometry cannot be 
performed.  
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C H A P T E R  5 .   
R E S U L T S :  S U M O  T A R G E T  S I T E S  A N D  
S U M O Y L A T E D  P R O T E I N S  A N A L Y S I S  
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5.0. Objectives 
 
 Analysis of the local sequence around the sumo-acceptor lysines mapped by 
mass spectrometry. Analysis of the subcellular distribution and function of sumoylated 
proteins.  The sumo-sites and sumoylated proteins analyzed in this section belong to 
three different analysis; of sumoylation in unchallenged grown cell, in cells under 
oxidative stress and in cells under MMS-induced DNA damage (summary of sumo-
acceptor lysines can be found at Supplementary Data, Table 3). 
 
 
5.1. Analysis of sumo-sites 
 
  A total of 364 sumo-acceptor lysines were mapped. For the purpose of this 
study, the sumo-site consensus motif are grouped in four different categories, namely; 
the core consensus motif ([VILP]KxE) (Rodriguez, Dargemont et al. 2001), the 
phosphorylation-dependent motif ([VILP]Kx[ED]x[S or xS]) (Yang and Gregoire 
2006), the negatively charged/acidic consensus motif ([VILP]Kx[ED][ED][ED]) 
(Yang, Galanis et al. 2006) and the inverse consensus motif ([ED]xK[VILP]) (Matic, 
Schimmel et al. 2010).  
 
Only 45% of all the sumo-acceptor lysines were within a sumo consensus motif. 
However, almost 70% of the sumo-acceptor lysines repeatedly detected under the three 
conditions (unchallenged growth, oxidation stress and MMS treatment) are within a 
sumo consensus motif. Similar proportion of sumo consensus motif is found among 
the sumo-acceptor lysines that experienced a significant change in sumoylation upon 
oxidative stress (SILAC oxidation experiment). Interestingly, 70% of the sumo-
acceptor lysines only detected after MMS treatment were within a non-consensus 
sumo motif (Figure 53). 
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Figure 53. Graphic representation 
of the local context of the sumo-
acceptor lysines mapped by mass 
spectrometry. “3 exp.” are sumo-
acceptor lysines repeatedly 
detected under the 3 conditions. 
“Only MMS” are those detected 
only under MMS treatment. 
“SILAC oxidation” are those for 
which SILAC-based MS detected a 
quantitative difference upon 
oxidation.  
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Figure 54. Graphical representation of the 
local context of the sumo-acceptor lysines 
grouped by sumo consensus motifs. 
 
The core sumo consensus motif is predominant among sumo consensus motifs. 
This is followed by the inverse consensus motif and the phosphorylation-dependent 
motif. However, actual phosphorylation at the serine contained in the phosphorylation-
dependent motifs was not confirmed. Hence the number of phosphorylation-
dependent motifs assigned is likely to be an over estimation, as some of these motif 
might be sumoylated independently of the possible phosphorylation of the serine 
residues.  
 
Valine and isoleucine are the residues predominately found preceding the sumo-
acceptor lysines at sumo consensus motifs. 50% of the inverse consensus motifs 
contain an aspartic acid and no a glutamic acid at the position -2. This is in contrast to 
the fact that an aspartic acid at the position +2 is present in only a 6% of the rest of 
sumo consensus motifs. No alternative motif could be theorized from the sequences 
not included in previously described sumo consensus motifs. However, acidic residues 
(preferably glutamic acid) are preferred around the sumo-acceptor lysine at these sites 
(Figure 54). 
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5.2. Subcellular distribution and function of sumo-target proteins  
 
Sumo-acceptor lysines mapped belong to 245 different proteins. Go term 
annotations from the S. cerevisiae database shows that these sumoylated proteins are 
found in all major cellular compartments. However, the presence of sumoylated 
proteins is significantly lower in the RE, Golgi’s apparatus, mitochondrion, membrane 
and cytoplasm when proportionally compared with the whole proteome. On the other 
hand, the amount of sumoylated proteins is proportionally higher in ribosomes and 
much higher in the nucleus. A closer look at nuclear proteins shows that a high 
proportion of sumoylated proteins are found in association with chromatin (i.e. 
transcription factors) (Figure 55). 
 
 
  
 
The subcellular distribution of the proteins detected by the same mass 
spectrometry protocol from a protein extraction prior to Smt3 purification was also 
analyzed. This control data is compared with the subcellular distribution of the whole 
yeast proteome, revealing that cytoplasmatic and mitochondrial proteins were more 
easily detected in the analysis. 
Figure 55. Subcellular distribution of the sumoylated proteins detected by mass spectrometry. 
Subcellular distribution of sumoylated proteins was obtained from the Gene Ontology (GO) slim 
mapper at the SGD website. 
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Considering the control data, the presence of sumoylated proteins in the 
cytoplasm and mitochondrion is lower than the data from sumoylated proteins first 
suggested. No significant differences were found between the subcellular distribution of 
sumoylated proteins found under different conditions.   
 
Functionally, the sumoylated proteins detected by mass spectrometry are 
involved in wide range of biological processes. There is a large number of sumoylated 
proteins involved in nuclear processes such chromatin organization, transcription and 
DNA damage response. When proportionally compared with the whole proteome, a 
significant higher proportion of sumoylated proteins are involved in ribosomal 
biogenesis, chromatin organization, transcription, DNA damage response, DNA 
replication and transcription. 
 
Interestingly, proteins only detected as sumoylated after MMS treatment are 
considerably less likely to be involved in transcription than sumoylated proteins 
detected under the three conditions (unchallenged growth, oxidation stress and MMS 
treatment). Moreover, those proteins that undertake changes in sumoylation upon 
oxidative stress are less likely to be involved in translation than proteins detected in 
any other experiment. 
 
Figure 56. Function of sumoylated proteins detected by mass spectrometry. Protein 
function was obtained from the Gene Ontology (GO) slim mapper at the SGD website. 
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 A large number of sumo-acceptors were found on proteins related to 
transcription. These proteins include subunits of the RNA polymerase I, II and III, as 
well as several transcription activators and repressors. Sumo-acceptor lysines were also 
found on the four core histones and on several proteins involved in the regulation of 
histone metabolism (i.e. acetylation, methylation and histone exchange).  
 
Moreover, some of the sumoylated proteins detected belong to chromatin 
remodeling complexes such as the SWI/SNF, RSC, and ino80 complexes. Others 
belong to pathways vital to DNA stability such as telomere maintenance, DNA repair, 
DNA topology maintenance, chromatid cohesion and the kinetochore (Figure 57).  
 
 
  
 
Figure 57. Sumoylation of proteins related with transcription and chromatin organization. Sumo-
acceptor lysines were found in a wide range of transcription factors, histone modifiers and chromatin 
remodeling proteins.  
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 Sumo-acceptor lysines were mapped on several components of the small (40s) 
and large (60s) ribosomal subunits, on translation initiation and elongation factors and 
on several nuclear proteins involved in ribosome biogenesis (Figure 58A). 
 
Only few sumo-acceptor lysines were found on proteins from the 
ubiquitination and protein degradation pathway (Figure 58B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
Figure 58. Sumoylation of (A) translation related proteins part of the ribosome 
biogenesis pathway and ribosome subunits. Sumoylation of (B) proteins involved in 
other pathways such as the protein post-translational modification pathway and 
cytokinesis. 
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C h a p t e r  6 .   
D I S C U S S I O N  
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6.1. Study of Sister Chromatin Recombination 
 
 
6.1.1. Strain design 
 
The I-HMUI gene from the bacteriophage SPOI was successfully cloned into 
the Saccharomyces cerevisiae genome under the control of the Gal1 promoter.  
 
 Fluorescent microscopy confirmed that I-HmuI is transported into the nucleus 
(Figure 14). This suggests that the NLS sequence at the C-terminus of I-HmuI is 
recognized by the nucleus transport machinery.  
 
 In addition, RT-PCR confirmed that I-HmuI specifically binds its DNA target 
site (Figure 15). Specific DNA binding was enhanced in G1-arrested cells over 
asynchronous. This proves that I-HmuI expressed in yeast retains the functionality of 
its DNA binding domain. Hence, the DNA cleavage domain of I-HmuI could also be 
functional. I also observed that I-HmuI interaction with its target site increases during 
G1. This suggests that the DNA metabolism during the cell cycle (i.e. replication, 
segregation) might make difficult the binding of I-HmuI to DNA. This result is quite 
encouraging since the assay designed to study SCR involves the generation of a nick 
during G1. 
 
 
6.1.2. Quantification of I-HmuI cleavage efficiency 
 
 SCR is not activated in response to the expression of I-HmuI in cycling cells. 
The rad52 mutant is unable to repair by SCR. However, I observed no difference in the 
viability of rad52Δ mutant when the I-HmuI nickase was expressed (Figure 16). This 
suggests that the DNA lesion inflicted by I-HmuI can be repaired by a Rad52-
independent pathway. This excludes the action of SCR, but also of any other repair 
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pathway involving strand exchange. It remains to be assessed whether I-HmuI 
expressed in S. cerevisiae retains its cleavage activity, and whether a nick created by I-
HmuI during G1 is transformed into a DSB during replication such that it triggers 
SCR. 
 
 The presence of a single strand nick in a plasmid is detectable by gel 
electrophoresis. I used this characteristic for the quantification of the cleavage efficiency 
of I-HmuI. However, the signal detected by southern blotting from the supercoiled and 
relax plasmids cannot be compared for quantification purposes. The probe affinity for 
these two topological forms seems to be intrinsically different. Therefore, the cleavage 
efficiency of I-HmuI was quantified relative to a control sample where 100% of the 
plasmid was nicked in vitro. 
 
I observed that G1-arrested cells expressing I-HmuI accumulate nicked plasmid 
in higher quantities than G1-arrested cells with no expression of I-HmuI (Figure 18). 
This difference, albeit reproducible, is remarkably small. In addition, the amount of 
nicked plasmid independent of the expression of I-HmuI increases when cells are kept 
arrested in G1. This suggests that the G1 arrest (unnaturally long for yeast) has 
metabolic effects on DNA.  
 
The small accumulation of nicked plasmid after induction of I-HmuI agrees 
with the lack of activation of SCR observed in the rad52 mutant when I-HmuI is 
expressed. Hence, I conclude that either I-HmuI has a poor nickase activity in S. 
cerevisiae or that DNA damage repair mechanisms active during G1 repair the nick 
created by I-HmuI and hence prevent its accumulation.  
 
The presence of nicks in the DNA strand is one of the most common threats to 
DNA stability and there are a number of DNA repair mechanisms active during G1 
able to repair them before replication. Nucleotide excision repair (NER) is one of the 
mechanisms which might be involved in the repair of a nick created during G1. The 
Rad14, Rad16 and Rad4 proteins recognize and bind damaged DNA during NER. 
These proteins trigger the recruitment of the DNA repair machinery to the damaged 
site and are needed for the correct activation of NER (Prakash and Prakash 2000). 
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Accordingly, the G1-arrested rad14 mutant expressing I-HmuI accumulated a 
higher quantity of nicked plasmid than wild type cells (Figure 19). This result is 
reproducible in other mutants of the NER pathway and indicates that NER is 
responsible for the repair of nicks created by I-HmuI. However, I cannot rule out the 
possibility that other DNA repair mechanisms active during G1 are also preventing the 
accumulation of I-HmuI-nicked plasmid.  
 
The accumulation of single strand breaks in wild type or NER-defective strains 
due to the expression of I-HmuI is by all means insufficient for the study of SCR as it 
was designed in the original objectives of this study. However, the I-HmuI assay 
generates up to 30% of inducible nick in the population, and this could be used to 
verify the results obtained by Dr. Cortes-Ledesma (Cortes-Ledesma and Aguilera 2006). 
Dr. Cortes-Ledesma studied the cleavage of the HO-endonuclease at a suboptimal 
recognition site. They concluded that DSB arise by replication through nicks left 
unrepaired. This observation could be reinforced should the same result be obtained 
with the I-HmuI assay. 
 
It would also be interesting to further study whether a DNA repair pathway 
other than NER is involved in repairing the single strand break created by I-HmuI. On 
one hand, this could be used to study the repair mechanisms themselves. On the other 
hand, mutants of alternative repair pathways (i.e. BER) might show a higher 
accumulation of I-HmuI induced single strand breaks. In turn, this might make 
possible the study of SCR by the I-HmuI system in the future.    
 
 Alternatively, other site-specific nickases could be tested. An example of this is 
the study done by Dr. Nielsen and colleagues (Nielsen, Bentsen et al. 2009). They 
developed the “Flp-nick system”, the creation of a site-specific nick by the cleavage of a 
mutant form of the Flp1 recombinase. Flp1 is a site-specific recombinase encoded in 
the 2-micron plasmid. This plasmid is found in most strains of S. cerevisiae, but it is 
not present in the S. cerevisiae strains used for research purposes. The Flp1-nick system 
is based on the integration of a unique Flp target site in the genome, and of a copy of 
the gene encoding the FlpH305L, a mutant version of Flp. FlpH305L retains the ability 
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to cleave DNA but cannot perform the religation of the DNA strands. As a 
consequence, FlpH305L forms a lasting DNA-protein interaction after cleavage of 
DNA that makes difficult the action of any repair mechanism. The FlpH305L DNA-
protein interaction seems to be removed during S-phase by the action of the replisome. 
 
 Expression of FlpH305L reduces the viability of rad51 mutants, suggesting that 
the single strand break created by FlpH305L might be transform into a DSB that 
triggers SCR. However promising the Flp-nick system looks, the FlpH305L cleavage 
efficiency in vivo claimed by the authors (up to 65% in G1-arrested cells) was not 
clearly established. Furthermore, the Flp-nick system has yet to be used in a functional 
biological study.  
 
 An alternative approach for the study of SCR by the generation of a site-specific 
nick is to engineer a site-specific nickase with similar characteristics to FlpH305L but 
with higher cleavage efficiency. An example of engineered nucleases, although for the 
generation of DSB, is found in the site-specific zinc-finger nucleases (Urnov, Miller et 
al. 2005).   
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6.2. Smt3 purification  
 
 
6.2.1. Construction of Smt3 mutants 
 
The Smt3 protein with the modification KallR and the RGG C-terminus, 
expressed under its own promoter, fully complemented the lack of endogenous Smt3 
under normal conditions and DNA damage (0.01% MMS) (Figure 21). This suggests 
that the conjugation of Smt3 to its target proteins is not impeded or modified despite 
the I93R mutation at its C-terminus or the substitution of lysines for arginines (KallR). 
However, our analysis cannot fully rule out the possibility that these Smt3 variant 
might have a effect on the metabolism of the cell in away that could not be detected in 
this study. 
 
The mutations RAG, RAGG and RIGG at the Smt3 C-terminus do not 
complement the lack of endogenous Smt3. The mutation RIGG made cells unviable, 
and the mutations RAG or Smt3 RAGG were only tolerated as long as the endogenous 
Smt3 remained functional. Only the Smt3 RAGG showed evidence of being attached 
to target proteins, although less efficiently than Smt3 RGG (Figure 23). These results 
show that attachment of Smt3 to target proteins is highly dependent on the diglycine 
motif and the aa sequence previous to it. These results are in accordance with the 
findings of Dr. Wohlschlegel and colleagues (Wohlschlegel, Johnson et al. 2006), who 
tested different modifications at the Smt3 C-terminus and found that the Smt3 
containing the I96R mutation is capable to be incorporated to Smt3 target proteins.    
 
I conclude that the KallR and I96R modifications in the sequence of Smt3 do 
not interfere with the attachment of Smt3 to target proteins in a detectable way, and 
that the 8xHIS tag greatly improved the purification of SUMO-target proteins. The 
8His-Smt3-KallR-RGG was therefore ideally suited for the study of sumoylation by 
mass spectrometry. 
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6.2.2. Purification protocol; Lysis 
 
The NaOH/TCA extraction method, first described by Dr. Riezman (Riezman, 
Hase et al. 1983), helps preserving the attachment of Smt3 to the substrate proteins. 
Mechanical cell lysis extracted an amount of protein comparable to the NaOH/TCA 
method (Figure 25). However, mass spectrometry (MS) analysis showed that more 
Smt3 remained attached to substrate-proteins in the protein sample extracted with the 
NaOH/TCA method. This chemical lysis might help preserving the covalent isopeptide 
bonds that Smt3 forms with its substrate, while preventing protease activity.   
 
 Besides the three methods tested in this study, there are additional extraction 
protocols what could, in theory, be used for the purification of sumoylated proteins. For 
instance, cell lysis with a French press (Denison, Rudner et al. 2005).     
 
 
6.2.3. Purification protocol; Affinity-purification 
 
The incubation time and the concentration of imidazol in the buffer greatly 
influenced the binding of Smt3 to the Ni-NTA affinity-purification beads. Maximum 
binding capacity to the beads was achieved after 2 h (Figure 27). Longer incubation 
seemed to ease the deconjugation of Smt3 from its target protein. This was deduced 
from the decrease on the signal from conjugated Smt3 together with an increase of free 
Smt3 (Smt3 no conjugated to a substrate).     
   
The concentration of sumoylated proteins recovered after Ni-NTA affinity 
purification was the highest when 40 mM imidazol was added to the media (Figure 27). 
The presence of 8 histidines in the Smt3 variant allows the addition of a high 
concentration of imidazol without the lost of Smt3 specific binding. As a consequence, 
unspecific binding was reduced. 
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Unspecific binding to Ni-NTA beads (i.e. of histidine rich proteins) is the major 
factor that contributes to the high complexity of the protein sample analyzed by MS. 
Reduction of unspecific binding increases the concentration of sumoylated protein and 
with it the chances of detection of sumo-acceptor lysines. In previous studies, Ni-NTA 
affinity purification of Smt3 tagged with 6 histidines was done without imidazol or 
under a low concentration of it (Zhou, Ryan et al. 2004; Wohlschlegel 2009). The 
consequence of this was a more complex MS analysis or the need of extra purification 
steps which are likely to reduce the total amount of Smt3 purified. 
 
 
6.2.4. Purification protocol; Protein filters 
 
Centrifugal protein concentrators of 50 kDa size pore allowed the recovery of 
the 100% of proteins ≥15 kDa under denaturing conditions (Figure 28). Filters are 
design to retain proteins equal or bigger to their pore size. This however only applies to 
globular proteins in native conditions, where their 3D shape is preserved. The Smt3 
purification protocol keeps proteins in denaturing condition. Hence the filtering 
specifications provided by the manufacturer are not accurate.  
 
The 100 kDa size pore filter was not able to retain a fraction of the proteins <50 
kDa. In this fraction some sumoylated proteins were lost. However, most sumoylated 
proteins have a molecular weight higher than 50 kDa, and the fraction of proteins <50 
kDa lost through the filter was less than 30% of the total. Considering this, filtering 
through a 100 kDa pore size could eliminate most of the small not-sumoylated peptides 
and not-conjugated Smt3 from the sample hence reducing the complexity of the MS 
analysis. In theory, this gain could make up for the possible lost of few small 
sumoylated proteins and increase the overall chances of identification of sumo-acceptor 
lysines.  
 
The decision to use 50 or 100 kDa size pore might be made on the basis of the 
complexity of the sample. Protein samples with a high content in non sumoylated 
proteins might benefit from filtering through a 100 kDa pore size. Meanwhile, protein 
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samples with a high concentration of sumoylated proteins might be filtered through a 
50 kDa pore size and hence allowing recovery of all possible sumoylated proteins, big 
and small.   
 
 
6.2.5. Purification protocol; Protein digestion 
 
Lys-C digestion is most efficient when the protein sample is contained in a 
strong denaturing buffer (8M urea) (Figure 29). Under denaturing conditions, residues 
are more accessible and therefore lysines are more likely to be cleaved by Lys-C. 
However, denaturing condition could also affect the activity of Lys-C itself. The 
manufacturer suggests that Lys-C enzymatic activity is greatly reduced in the presence 
of urea (86% activity in 4 M urea) and increased in the presence of 10% acetonitrile 
(161% activity). However, the protein digestion test I performed suggests that proteins 
contained in 8 M urea are more easily cleaved by Lys-C than those contained in lower 
concentration of urea or in acetonitrile. This observation is in accordance with the 
protocol for MS sample preparation presented at the Computational Mass 
Spectrometry Based Proteomics Summerschool 2010 by the Dr. Matthias Mann 
laboratory. In addition, keeping the protein sample in 8 M urea buffer during the Lys-
C digestion reduces the length of the protocol and prevents the possible lost of protein 
during buffer exchange. 
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6.2.6. Purification protocol; Denaturing conditions 
 
Protein purification under denaturing conditions (8 M urea), at a low 
temperature (4°C), and the presence of a strong SUMO-protease inhibitor (20 mM 
NEM) increased the amount of sumoylated peptides purified (Figure 30). For this 
reason, most of the published protocols for purification of sumoylated proteins use 
denaturing conditions (Denison, Rudner et al. 2005; Wohlschlegel 2009) and protease 
inhibitors. However, the use of denaturing conditions limits the range of purification 
techniques that can be used. For instance, during antibody-based purification proteins 
are kept in native state. Antibody-based purification has more specificity for the target 
protein and could, in theory, reduce the complexity of the protein sample analyzed by 
MS.  
 
I performed antibody-based purification of Scc1 Myc-tagged under native 
conditions and in the presence of protease inhibitors (data not shown). Scc1 is a 
subunit of the cohesin complex and it is highly sumoylated. However, MS analysis 
detected no sumoylated peptides after Scc1 purification despite obtaining a high 
coverage of Scc1 (<75%). This result suggests that the attachment of Smt3 to its 
substrate is likely to be lost when proteins are kept in native conditions.    
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6.3. Proteome-wide mapping of SUMO-acceptor lysines  
 
 
I mapped 257 sumo-acceptor lysines belonging to 195 different proteins (Table 
3). Among the peptides found to be sumoylated there were many transcription factors 
(i.e. Bdp1, Abf1, Taf14, Crz1, Gcn4, Hpc2, Rap1, Sko1, Sum1, Tfg1, Dep1, Tup1, 
Sef1, Yap5 and Cin5, TBP, etc.), histone modifiers (i.e. Eaf7, Gcn5, Rpd3 and Sdc1) 
and some proteins already known to be sumoylated (i.e. Gcn5, Hmo1, Bir1, Cdc48, 
Sir4, Bop3, Top2, Cdc3, Pol30, Ubc9, Net1, etc.). Further discussion on sumoylated 
proteins and sumo-target sequences can be found in section 6.7. 
 
The probability of a peptide to be a positive identification is represented with a 
score. Andromeda and Mascot peptide scores are calculated based on the probability (P) 
that the match between the experimental data and the protein database is a random 
event. The score is reported as -10 times the logarithm of P, P being calculated 
differently by Mascot (Perkins, Pappin et al. 1999) and Andromeda (Cox, Neuhauser 
et al. 2011). 
 
In this study, a precise calculation of the probability of a positive result is 
particularly challenging. Two levels of uncertainty are present, namely: the random 
match between a sequenced peptide and the database, and the wrong detection of a 
diglycine modification at a lysine.  
 
I considered peptides matched with a score >90 (Andromeda) or >30 (Mascot) 
as positive matches. Andromeda scores are generally 3 times bigger than Mascot scores 
(Cox, Neuhauser et al. 2011), although this does not indicate a larger confidence. 
Peptides with lower score were considered false positives. Of these low score peptides, 
those containing the sumo-acceptor lysine within a sumo consensus sequence are more 
likely to be positive results.  
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6.3.1. Andromeda vs. Mascot 
 
The same data set was submitted to both Andromeda and Mascot database-
search engines. More SUMO-acceptor lysines were indentified by Mascot. However, 
most of the matches only detected by Mascot have a low score (<30) and contain a no-
consensus sumo sequence (Figure 32).  
 
These data suggests that either the Mascot search engine is more likely to match 
false positive results, or that the Mascot search engine is more likely to database-match 
low score peptides containing a real sumo-acceptor lysine within a non-consensus 
sumo motif. The former hypothesis sounds far more reasonable. Hence, I preferably 
used the Andromeda search engine over Mascot in subsequent analysis. Another 
important reason for the preferential use of the Andromeda search engine is that 
Mascot is only available under subscription. Hence access to it is exclusive to 
researchers belonging to the proteomic facility. On the other hand, Andromeda is a free 
access search engine with a simple set up and accessible to any researcher. This makes 
the analysis of the data more flexible and autonomous.      
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6.4. Mass spectrometry data verification  
 
 
6.4.1. Spectra and mass error 
 
The b-y ion leader and the peptide mass error were analyzed as part of the 
manual verification of peptide identifications. This manual verification, albeit 
laborious, are particularly useful for low score peptides. A low mass error and a good 
coverage around the sumo-acceptor lysine by the b-y ion series reduces the possibility 
of a false positive match. Andromeda matched low score peptides that did not show 
these characteristics were filtered out from the result list. 
 
 
6.4.2. SUMO sites in the literature 
 
The experimental data obtained in this study match the results obtained in 
previous studies where sumo-acceptor lysines were detected by MS and by site-directed 
mutagenesis/immunoblotting (Figure 35). Only a few sumo-sites mapped in previous 
studies were not detected in our study. Although most of the sumo-sites described in 
previous studies were detected by mass spectrometry, the protein purification and the 
MS analysis I used are fundamentally different. This explains both the qualitative and 
quantitative differences in the results.  
 
I mapped different sumo-sites from those previously described in the proteins 
Sgs1 (Lu, Tsai et al. ; Zhou, Ryan et al. 2004), Tec1 (Wang, Abu Irqeba et al. 2009), 
Aos1 (Zhou, Ryan et al. 2004) and Sir4 (Denison, Rudner et al. 2005). However, none 
of the published studies ruled out the possibility of additional sumo-acceptor lysines 
within these proteins. In addition, some of the sumo-acceptor lysines published have 
yet to be verified by a MS-independent methods. Until then, the possibility that these 
published sumo-sites are false positive matches cannot be excluded. 
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6.4.3. Confirmation of sumoylation by immunoblotting 
 
Smt3 attachment to sumo-acceptor lysines mapped by mass spectrometry was 
verified by immunoblotting. Rpc53, Rad16 and TBP are sumoylated in vivo (Figure 
37). The mass spectrometry data suggested that Rpc53, and TBP contained more than 
one sumo-acceptor lysine. Accordingly, these proteins showed a ladder of sumoylated 
forms. These results strongly suggest that Rpc53 and TBP are monosumoylated at a 
number of sites (multi-sumoylation). However, the presence of SUMO chains (poly-
sumoylation) cannot be discarded. Poly- and multi-sumoylated forms of a protein 
cannot be differentiated by this immunoblotting assay. In addition, some of the bands 
that form the ladder can be due not to a change in the sumoylation state of the protein 
but to other protein modifications affecting some of the sumoylated forms (i.e. 
ubiquitination and phosphorylation). The possible poly-sumoylation of these proteins 
could be assessed by repeating this assay in a strain where SUMO chain formation is 
blocked.  
 
Rad16 also shows a ladder of sumoylated forms. Although only K103 was 
mapped as sumo-acceptor lysine in our mass spectrometry analysis, a previous study 
reported K93 also as sumo-acceptor lysine (Silver, Nissley et al. 2011). The ladder 
observed in Rad16 could be due to the mono- or poly-sumoylation of both K93 and 
K103 and/or to other modifications affecting the sumoylated forms of Rad16.     
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6.4.4. SUMO substrate purification 
 
Substrate-specific mapping of sumo-acceptor lysines confirmed the results 
obtained from the proteome-wide analysis. However, there is not a major improvement 
in the quality of the ion spectra or in the number of sumo-acceptor lysines detected.  
 
By this technique I detected three diglycine-modified lysines; Gcn5 K25 and 
TBP K47 and K97. Gcn5 K25 and TBP K47 were previously detected in the proteome-
wide analysis, and TBP K97 is the only sumo-acceptor lysine not previously identified. 
This suggests that TBP K97 might be a secondary sumo-site while K47 is the major 
sumo-site at TBP.  
  
The not-sumoylated form of the Gcn5 K25 was detected only before Lys-C 
digestion, suggesting that the analysis of Lys-C digested peptides increases the chances 
of detection of sumo-modified peptides which otherwise could remain hidden in the 
background spectra.  
 
Although sumo-acceptor lysines were identified, mass spectrometry analysis of a 
unique purified protein did not increase the sensitivity of the analysis as it was 
expected. Not having detected sumoylated peptides from the Scc1 purification is 
particularly disappointing since Scc1 is a known sumoylated protein and of great 
interest for our laboratory.    
 
 These results indicate that the complexity of the sample is not a limiting factor 
during the proteome-wide analysis. The extraction technique and the affinity-
purification are more likely to be the limiting factors common to both the substrate-
specific and proteome-wide analysis.  
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6.4.5. Smt3 bona fide C-terminus analysis 
 
 The Smt3 purification protocol successfully eliminates peptides modified by 
ubiquitination or neddylation.  Only a handful of low score diglicine modified peptides 
were detected after purification of 8His-Smt3-KallR-REQIGG (Table 4). These are 
likely to be false positive matches by the search engine. These results also confirm that 
the peptide score is a good indicator of how reliable the peptide matches are. 
 
 
6.4.6. SUMO-acceptor lysines mutation 
 
 Sumo-acceptor lysines mapped by mass spectrometry were mutated and as a 
consequence sumoylation was completely abolished (Figure 41). The proteins studied 
were Dep1, Rps1a, Rpc53, and Ntg1. This result indicates that mass spectrometry 
detected all sumo-acceptor lysines present in these proteins, and that their sumoylation 
is site-specific. 
 
 However, this approach is not without weaknesses. Sumoylation is not always 
site-specific. Some proteins have “backup” sumo-acceptor lysines able to attach Smt3 
when the putative sites are not available. Moreover, sumo-acceptor lysines detected by 
mass spectrometry are not necessarily the only sumoylated lysines within the protein or 
not the most recurrent sites in vivo. 
 
 One example of this is the transcription factor Reb1, for which only one sumo-
acceptor lysine was detected by mass spectrometry (K807). Sumoylation in the 
807KtoR mutant is only eliminated when cell are exposed to DNA damage conditions. 
This suggests that sumoylation of Reb1 is site-specific only under certain conditions, 
and that Reb1 has an alternative sumo-acceptor lysine that was not detected by mass 
spectrometry. 
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6.5. Quantitative mass spectrometry analysis of sumoylation  
  
 
6.5.1. Technique set up 
 
SILAC-based mass spectrometry has been successfully used in the past for the 
study of the S. cerevisiae proteome (de Godoy, Olsen et al. 2008). Stable labelled amino 
acids can be added to the media and be fully incorporated into the proteome of the 
cells. However, this technique has never been used before for the quantification of 
sumoylation in budding yeast.  
 
Cells for quantitative Smt3 purification experiments are grown in Kaiser media, 
a rich synthetic media. Yeast growth rate in this media is comparable to that in YP. I 
observed that the substitution of normal lysines for lysine labelled with heavy isotopes 
in the Kaiser media has no effect in the viability of the cells (Figure 42). I estimated 
that heavy labelled lysine is fully incorporated to the proteome after 5 cell cycles. 
Hence, overnight growth in media containing heavy labelled lysine should be enough 
for full labeling. 
 
Relative quantification of sumoylation by SILAC-based mass spectrometry 
could make possible the detection of MMS21-dependent sumoylation in response to 
DNA damage. This experiment would require knocking out the sumoligase activity of 
MMS21, which considerably decrease the viability of the cells. In addition, the 
sumoylation response to DNA damage is triggered by the addition of MMS to the 
culture. MMS is an alkylating agent, carcinogen, and of yet unknown effect in 
humans. It is all but clear what are the appropriate safety procedures to be follow when 
working with MMS in culture. I therefore decided to set up this technique under more 
favorable conditions. The study of sumoylation under oxidative stress (induced with 
H2O2) can be done with wild type strains and has no harmful effect for the researcher. 
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6.5.2. SILAC analysis under oxidative stress 
 
 I observed that the synthetic media (SM) in which cells were grown has an 
effect in the Smt3 purification. Using the same protocol, the Smt3 purified from SM 
grown cells was a fraction of the Smt3 purified from YP grown cells. In our 
experiment, only 14 sumo-acceptor lysines were detected from a 18 l of SM grown 
culture (Figure 43). Previously I had detected up to 257 sumo-acceptor lysines from 9l 
of YP grown culture. This suggested that cells growing in SM, albeit similarly viable, 
had physiological differences that difficult the purification of Smt3.  
 
The source of the problem in the purification of Smt3 from SM grown cells is 
difficult to define. However, reducing the concentration of imidazol used during the 
affinity-purification increased the amount of Smt3 purified to levels similar to those 
obtained from YP grown cells (Figure 44). The reduction in the concentration of 
imidazol also increased the presence of partially digested peptides after Lys-C digestion. 
The presence of these peptides is likely to increase the complexity of the mass 
spectrometry spectra and hence, decrease the sensitivity of the analysis. Nevertheless, 
mass spectrometry analysis of the sample purified in low imidazol conditions detected a 
number of sumo-acceptor lysines comparable to previous analysis of YP grown cells. 
  
 Sumoylation in response to oxidative stress was analyzed by SILAC-based mass 
spectrometry using the new purification protocol (low imidazol concentration). The 
sumoylation of 126 sumo-acceptor lysines was quantified in two independent 
experiments (forward and reverse) (Table 5). The strong correlation between the results 
obtained in these two experiments suggests that the changes in sumoylation quantified 
under oxidative stress are not random events (Figure 46). 
 
 A significant number of peptides were only identified in one of the 
experiments. Although a correlation cannot be defined from these results, their 
quantification is worth to be taken into consideration. I can find no reason to assume a 
lower accuracy in the quantification of these peptides. The accuracy in the 
quantification is influenced by the intensity of the peptide in the spectra and by the 
	   161	  
resolution of the mass spectrometer. Most of the peptides identified only in one 
experiment have a signal intensity similar to those identified in both, and the 
resolution of the mass spectrometer affects all peptides equally.  
 
 The differences in the results from the forward and reverse experiments were 
most likely due to the human factor during the extraction protocol and MS sample 
preparation, and to the somehow temperamental character of the mass spectrometer. 
    
 Both experiments, forward and reverse, showed that there is a proteome-wide 
increase in sumoylation under oxidative stress (Figure 45). A high increase in 
sumoylation was detected in proteins involved in DNA repair (Cmr1, Pol30, Nhp10, 
Ino80, Lif1), telomere maintenance (Rsc2, Sum1, Sir4) and stress response (Hap1, 
Crz1, Zeo1), in proteins part of the sumoylation machinery (Uba2, Siz1) and proteins 
related to transcription (Bdp1, Rpc37, Taf14, Tye7, Swi3, Gzf3).  
 
Only few proteins showed a significant decrease of sumoylation under oxidative 
stress. Among them there are transcription factors (Rep2, Gcn4, Net1) and a core 
histone protein (Htb2).  
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6.5.3. Control data 
 
 Quantitative differences detected in sumoylated peptides can be due to an 
increase in the sumoylation of a particular sumo-acceptor lysine, or to an increase in 
the total amount of protein. The cellular response to oxidative stress might involve 
quantitative changes in the proteome as well as changes in sumoylation.  
 
Protein extraction prior to Smt3 purification, from the forward and reverse 
experiments, were analyzed by SILAC-based mass spectrometry (data not shown). The 
aim of this analysis was to detect changes in the total amount of protein. I detected and 
quantified peptides for most of the sumo-target proteins previously identified. The 
average ratio between heavy and light forms of all peptides from the same protein was 
used to quantify changes in the total amount of protein upon induction of oxidative 
stress. In addition, the standard deviation (SD) of these ratios was used as a estimation 
of the accuracy in the quantification.  
 
Average ratio and SD was calculated only for proteins of interest. None of these 
proteins showed a significant quantitative change upon induction of oxidative stress.  
 
Moreover, I performed a SILAC-based mass spectrometry analysis comparing 
two samples grown under the same conditions (both under oxidative stress), and 
tagged with normal lysine and heavy labelled lysines respectively. This analysis detected 
minor fluctuations between the two protein samples (Table 6). These fluctuations 
might be due to the labeling, sampling, protein extraction and purification or could be 
introduced by the mass spectrometer itself. These results suggest that quantification of 
two identical samples might have significant fluctuations that should be taken in 
consideration.  
 
In the light of these results, I proved that the results from the forward and 
reverse experiments show a statistically significant increase in sumoylation under 
oxidative stress when taken in consideration background fluctuation in the 
quantification.  
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6.5.4. SILAC data verification by immunoblotting 
 
 The study of sumoylation by immunoblotting clearly verified the quantitative 
results obtained by SILAC-based mass spectrometry for the proteins Gcn5, Net1 and 
Cdc48 (Figure 49). However, our results suggest that the detection of changes in 
sumoylation in multi-sumoylated proteins is particularly challenging.  
 
 Upon oxidative stress, sumoylation is not altered similarly in all sumo-acceptor 
lysines of the same protein. The multi-sumoylated proteins Rpc53 and Tfg1 are an 
example of this. The Rpc53 immunoblot shows no more than a general increase in the 
sumoylation under oxidative stress. However, mass spectrometry data suggests that 
sumoylation in three sumo-acceptor lysines of Rpc53 increases while decreases in the 
other two.  
 
The Tfg1 immunoblot shows a complex sumoylation pattern, with three main 
sumoylated forms of which two increase and one decreases upon oxidative stress. In 
addition, I observed a ladder of sumoylated forms only under oxidative stress. This 
ladder might be the consequence of the poly-sumoylation of the 170kDa sumoylated 
form of Tfg1. This would explain the decrease in the signal from the 170kDa form 
when the ladder is formed. Mass spectrometry data for this same protein suggested that 
sumoylation in the lysines K60 and K61 does not change significantly, while 
sumoylation of K91 increases whilst decreases in K658. In the light of these data I 
suggest that the mono-sumoylated form of Tfg1 increases upon oxidative stress and 
correspond to K91 (120kDa), while the other three sumo-acceptor lysines are involved 
in the ladder observed by immunoblotting.  
 
I reckon that quantification of changes in the sumoylation pattern by 
immunoblotting can be inconclusive. This is particularly obvious when more than one 
sumoylated form of the protein is detected (due to poly/multi-sumoylation or to 
additional modifications upon sumoylation). On the other hand, SILAC-based mass 
spectrometry can accurately quantify changes in sumoylation of individual sumo-
	   164	  
acceptor lysines within a protein with no interference from other modifications 
elsewhere in the protein. 
 
 
6.5.5. Quantitative analysis of MMS21-dependent sumoylation 
 
I observed that the substitution of the endogenous Smt3 for Smt3-KtoR-RRG 
in the mms21CD reduced the viability of the cells (Figure 50). At the beginning of this 
study I observed that the Smt3-KallR-RGG complemented the lack of endogenous 
Smt3 in a wild type strain. This complementation seems to be Mms21-dependent. This 
might also indicate that the sumoligase activity of Siz1, Siz2 or Ubc9 alone is more 
affected by modifications in the sequence of Smt3 than that of Mms21. 
 
The additive effect of the Smt3-KallR-RRG and the mms21CD made 
challenging the study of Mms21-dependent sumoylation by SILAC-based mass 
spectrometry as I initially planned. The double mutant had a low viability during 
unchallenged cell cycles. 
 
In the light of this difficulty, there are two alternative strategies which might 
allow the study of Mms21-dependent sumoylation; the construction of a conditional 
Mms21 mutant, or a combined strategy with MS and immunoblotting.  
 
The Mms21 sumoligase activity is needed during an unchallenged mitotic cell 
cycle. The lack of the sumoligase activity causes slow growing and spontaneous DNA 
damage (Rai, Varma et al. 2011). On the other hand, a conditional Mms21 knockout 
could circumvent the abnormalities observed in the mms21CD while being able to 
quickly remove the sumoligase activity. For instance, a conditional Mms21 knockout 
might be created by the auxin-based degron system. This system enables the rapid 
degradation of a target protein in the presence of auxin, a plant hormone. This system 
does not require changes in temperature that have a wider effect in the cell. The target 
protein is tagged with a sequence that will promote ubiquitin-dependent degradation 
upon the presence of auxin. The auxin-based degron system has been applied to 
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proteins that act in the nucleus as well as cytoplasm (Nishimura, Fukagawa et al. 2009). 
Hitherto, most of the yeast proteins I have tested were successfully degraded by this 
system (Cell Cycle Group unpublished data).  
 
Should the Mms21-degron conditional knockout work, it would allow a more 
accurate quantification of the Mms21-dependent sumoylation that the mms21CD does. 
For the purpose of our experiment, a Mms21-degron conditional knockout would only 
need to be induced for a fraction of a cell cycle. These conditions might introduce less 
variability to the relative quantification than that introduced when the mms21CD is 
compared with a wild type strain. Quantitative changes in sumoylation would be more 
related with the sumoligase function of Mms21, and less with the abnormal growth of 
the mms21CD.       
 
 Alternatively, MS analysis can be focused on the study of sumoylation in cell 
pathways to which Mms21 is related. This study can be done with wild type strains and 
would provide a good understanding of possible Mms21-dependent sumo-targets. 
Following this, immunoblotting analysis can use the mms21CD to study Mms21-
dependent sumoylation. In this strategy, MS provides a proteome-wide viewpoint 
while immunoblotting would show a direct prove of the Mms21 sumoligase activity 
involvement. 
 
 A particularly interesting example of this strategy is the study of Mms21-
dependent sumoylation during homologous recombination (HR) and non-homologous 
end joining (NHEJ). Phenotypical studies on the Mms21 sumoligase activity knockout 
strongly indicate that the sumoligase activity of Mms21 plays a role during HR repair 
yet to be described. Mms21 is a subunit of the Smc5-Smc6 complex, itself involved in 
HR. In addition, a number of proteins intimately involved in HR have been reported 
to be sumoylated. These include the proteins Rad52 and RPA, involved in DNA strand 
exchange, the proteins Sgs1, Sae2, Mre11, Rad50, Xrs2 involved in resection, and the 
resolvase Yen1.  
 
 Little is known about the possible role of the Mms21 sumoligase activity during 
NHEJ repair. The strongest indication of this is the Mms21-dependent sumoylation of 
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Ku70 and that two other members of the NHEJ pathway, Ku80 and Lif1, are also 
sumoylated.   
 
 The SILAC-based analysis of sumoylation I developed could be used for the 
study of these two repair pathways. This study has two challenges not yet faced in 
previous experiments. Relative quantification of sumoylation after activation of HR or 
NHEJ should be done in an arrested cell cycle. Under cell cycle arrest, variability 
between HR/NHEJ-induced sample and control sample is only dependent on the 
pathway activation. Induction of HR or NHEJ pathways in cell cycle arrested cells can 
be achieve by the expression of an inducible endonuclease such as EcoRI, HO or I-SceI.  
 
 Expression of the bacterial gene ECORI in S. cerevisiae has been used for the 
study of DSB repair (Lewis, Westmoreland et al. 1999; Grenon, Magill et al. 2006). 
EcoRI is transported to the nucleus and generates multiple DSBs that retain 
complementary ends. In contrast with DSB with damaged or modified ends, EcoRI-
induced DSBs seems to be repaired by a Rad52-independent pathway, such as NHEJ 
(Lewis, Kirchner et al. 1998). 
 
 The HO and I-SceI endonucleases have long been used for the study of HR 
(Rudin and Haber 1988; Fishman-Lobell, Rudin et al. 1992; Shinohara and Ogawa 
1998; Mimitou and Symington 2008). The HO and I-SceI endonucleases create a site-
specific double-strand break that triggers resection and homologous recombination. For 
the purpose of our study by MS, more than one cleavage site might be placed in the 
yeast genome so the activation of HR is amplified. 
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6.6. Analysis of sumo target sites and sumoylated proteins 
 
 
 87 sumo-acceptor lysines were repeatedly detected across all the experiments. 
These sumo sites were matched with an average Andromeda score of 180. Almost 70% 
of the sumo-acceptor lysines were within a sumo consensus motif. I found no 
differences in the quality of the spectra or of the database matches between sumo-
acceptor lysines within a sumo consensus motif and those contained with in a non-
consensus motif. Hence, I conclude that sumoylation frequently happens on non-
consensus sites. This however does not necessarily indicate the existence of a yet 
unknown sumoligase. Other factors rather than primary site recognition might direct 
sumoylation in some substrates. Some of these factors could be the secondary, tertiary 
and quaternary structure of the protein, or the presence of other sumoylation sites 
within the same protein.  
 
 Of the sumo-acceptor lysines exclusively detected after MMS treatment, only 
30% were within a sumo consensus sequence. These matches have an average protein 
score of 120. These results suggest that sumoylation under this condition is less stable 
or abundant. This could be due to the increase in random-site sumoylation for the 
degradation of proteins. The MMS treatment used in our experiment might have 
activated not only the DNA damage response but also cell death pathways in which 
proteins are a target of proteosome degradation.   
 
 On the other hand, sumo-acceptor lysines that experienced a significant change 
in sumoylation upon oxidative stress were matched with an average protein score of 
165 and 65% were within a sumo consensus motif. In this case, the oxidative stress 
response might be activating a site-specific sumoylation for regulatory purposes. 
Accordingly, some of these sumo-acceptor lysines were found on proteins related with 
the stress response and DNA damage response. 
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Sumoylation is known to play an important role in the metabolism of the 
chromatin and in gene expression. I identified a large number of sumo-acceptor lysines 
on nuclear proteins. Most of these proteins are related to transcription and chromatin 
organization. These are the two largest groups of sumoylated proteins found in our 
study, and together account for 40% of all sumoylated proteins detected.  
 
In accordance to previous studies, I found sumo-acceptor lysines on 
components of the general transcription machinery as well as on components of gene-
specific transcription pathways. I found sumo-acceptor lysines in six subunits of the 
RNA polymerases and on components of the TFIID, TFIIF and TFIIIB, including the 
TATA-binding protein (TBP). Other components of the general transcription found 
sumoylated are the transcription repressors Ncb2, Tup1 and Cyc8.  
 
Sumoylated proteins related to gene-specific transcription include the 
transcription factors Haa1 (of genes encoding membrane stress proteins), Tec1 (of 
filamentation genes), Crz1 and Sko1 (of stress response genes), Gzf3 (of nitrogen 
catabolic genes), and Cin5, Pdr1 and Yrr1 (of drug response genes). 
 
Sumoylation has been previously detected in all four core histones in both 
mammalian cells (Shiio and Eisenman 2003) and yeast (Nathan, Ingvarsdottir et al. 
2006).  In this context, sumoylation seems to have a repressing function by being 
attached to lysines that otherwise could be the target of ubiquitination or acetylation. 
Accordingly, I mapped sumo-acceptor lysines on the four core histones. Control of 
histone function by sumoylation seems to be achieved not only by direct sumoylation 
of histones, but by sumoylation of proteins involved in the modification and exchange 
of histones. I found sumo-acceptor lysines on histone acetylases (i.e. Gcn5, Eaf7, 
HDA1 and the SAGA complex), and on components of the RPD3 complex (involved 
in histone deacetylation), of the Sw1 complex (involved in histone exchange) and of 
the COMPASS complex (involved in histone methylation). 
 
Control of chromatin organization by sumoylation might be also accomplished 
by direct sumoylation of chromatin remodeling complex. I mapped several sumo-
acceptor lysines on components of the SWI/SNF, RSC and ino80 complexes. 
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Sumoylation is also known to control centromeric cohesion. One of the key 
sumo-substrate in this regulatory function is Top2, which controls local chromatin 
structures in the centromeric region (Bachant, Alcasabas et al. 2002). I mapped sumo-
acceptor lysines not only on Top2 but also on kinetochore essential protein Cbf2, and 
on components of the CPC complex, Ndc80 complex and Dam1 complex.  These 
complexes are important players in the regulation of chromosome segregation and 
kinetochore clustering. These results suggest once again that regulation by sumoylation 
is done over a range of substrates and at different levels of the same pathway. The 
functional significance of Top2 sumoylation and of sumoylation of other components 
of the centromeric cohesion and chromosome segregation pathway remains unclear. 
The mapping of sumo-acceptor lysines on these proteins could help the description of 
the control that sumoylation has in the centromeric region.   
 
  Genetic studies in S. cerevisiae have revealed a regulatory function of 
sumoylation on the ribosome biogenesis and the nuclear export of pre-ribosomal 
particles (Panse, Kressler et al. 2006). I found sumo-acceptor lysines on various proteins 
involved in ribosome biogenesis, nuclear export and tRNA processing. I also mapped 
sumo-acceptor lysines on several components of the 40s and 60s ribosomal subunits, 
and on other cytosolic proteins required for translation initiation and elongation. 
Interestingly, out of the 36 sumo-acceptor lysines mapped on the components of the 
ribosomal subunits, only 5 were within a sumo consensus sequence. On the other hand, 
65% of sumo-acceptor lysines found on proteins involved in ribosome biogenesis were 
within a sumo consensus sequence. This might indicate a very different biological 
significance of sumoylation on these two groups of proteins.   
 
 
 
	   170	  
6.7. What next? 
 
 
Possible future work has been suggested in previous sections regarding a more 
detailed study of the function of the Smc5-Smc6 complex in sister chromatid 
recombination and of the role of complex’s subunit Mms21.  
 
Our findings also open the door to a more intensive study of sumoylation itself. 
The large number of sumo-acceptor lysines detected in our study allowed a 
comprehensive study of the occurrence of the different sumo sites motifs, of the 
subcellular distribution of sumoylated proteins and of the cellular pathways with which 
sumoylation is most involved. I observed patterns in the subcellular distribution of 
sumoylated proteins, and in the sites of sumoylation. These patterns might reflect 
differences in the nature and function of sumoylation (i.e. regulatory or degradation 
function, site-specific or random).  
 
However, more work can be done to verify and describe a correlation between 
the local context of the sumo-acceptor lysine (sumo motif) and the nature of the 
sumoylation. Our technique for detection of sumo-acceptor lysines by mass 
spectrometry can be standardized and repeated in different cellular conditions in order 
to obtain a wider description of sumoylation.  
 
A different extraction technique (i.e. high pressure lysis), or purification method 
(i.e. copper ion-based HIS-tag purification) might be applied. Different conditions 
during the cell lysis and purification of Smt3 might allow the detection of sumo-
acceptor lysines not found in our study.  
 
The data obtained could be used to create a public proteome-wide database of 
sumoylation sites and substrates. Standard procedures and free access would allow 
different laboratories to compare and verify the data.  
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SUMO is the best well known of all ubiquitin-like (UBL) modifiers. However, 
recent studies suggest that two other UBLs, Urm1 and Nedd8 (urmylation and 
neddylation respectively when conjugated), also play an important role in the cell 
metabolism of eukaryotes, from budding yeast to humans.  
 
The NEDD8 gene is essential in S. pombe, C. elegans, D. melanogaster. and M. 
musculus (Jones and Candido 2000; Osaka, Saeki et al. 2000; Tateishi, Omata et al. 
2001; Ou, Lin et al. 2002). Neddylation has been described for cullin proteins (Tomoko 
Hori 1999; Osaka, Saeki et al. 2000; Laplaza, Bostick et al. 2004), ribosomal proteins 
(Kraft, Deplazes et al. 2008; Xirodimas, Sundqvist et al. 2008) and the anti-
oncoproteins p53 and p73 (Xirodimas, Saville et al. 2004; Oved, Mosesson et al. 2006; 
Watson, Blanch et al. 2006). Due to its influence on the p53 pathway, neddylation is 
being studied as a new target in cancer treatment. However, many other substrates of 
neddylation remain unknown, as well as any specific role of neddylation in human 
oncogenesis. 
 
The Urm1 modifier functions as a sulfur carrier in tRNA thiolation and has an 
important role in the regulation of genes involved in controlling levels of amino acids 
(Goehring, Rivers et al. 2003; Nakai, Nakai et al. 2008). Urm1 becomes attached to 
lysines residues at target proteins (like SUMO and Nedd8) and oxidative stress 
enhances protein urmylation in both Saccharomyces cerevisiae and mammalian cells 
(Van der Veen, Schorpp et al. 2011). However, the role of Urm1 as UBL modifier is 
completely unknown. 
 
 The strategy used for the study of in vivo sumoylation can be adapted to the 
study of neddylation and urmylation. The aa sequence of the Nedd8 and Urm1 
modifiers can be changed so the same purification technique and mass spectrometry 
analysis used with Smt3 can be performed with these two modifiers. This approach can 
detect proteome-wide targets of neddylation and urmylation and map the acceptor-
sites within these substrates. The identification of new targets and the mapping of the 
sites of modification would allow the generation of mutant protein variants to be used 
in functional studies to uncover the role of Nedd8 and Urm1.    
	   172	  
R E F E R E N C E S  
 
Altieri, F., C. Grillo, et al. (2008). "DNA damage and repair: from molecular 
mechanisms to health implications." Antioxid Redox Signal 10(5): 891-937. 
Ampatzidou, E., A. Irmisch, et al. (2006). "Smc5/6 Is Required for Repair at Collapsed  
Replication Forks." Molecular and Cellular Biology 26(24): 9387-9401. 
Anderson, D. B., K. A. Wilkinson, et al. (2009). "Protein SUMOylation in 
neuropathological conditions." Drug News Perspect 22(5): 255-65. 
Andersson, C.-O. (1958). Acta. Chem. Scand 12(1353). 
Andrews, E. A., J. Palecek, et al. (2005). "Nse2, a Component of the Smc5-6 
Complex, Is a SUMO Ligase Required for the Response to DNA Damage." Mol. Cell. 
Biol. 25(1): 185-196. 
Apionishev, S., D. Malhotra, et al. (2001). "The Drosophila UBC9 homologue 
lesswright mediates the disjunction of homologues in meiosis I." Genes Cells 6(3): 
215-24. 
Arnaudeau, C., C. Lundin, et al. (2001). "DNA double-strand breaks associated with 
replication forks are predominantly repaired by homologous recombination involving 
an exchange mechanism in mammalian cells." Journal of Molecular Biology 307(5): 
1235-1245. 
Azuma, Y., A. Arnaoutov, et al. (2005). "PIASy mediates SUMO-2 conjugation of 
Topoisomerase-II on mitotic chromosomes." EMBO J 24(12): 2172-82. 
Bachant, J., A. Alcasabas, et al. (2002). "The SUMO-1 Isopeptidase Smt4 Is Linked to 
Centromeric Cohesion through SUMO-1 Modification of DNA Topoisomerase II." 
Molecular Cell 9(6): 1169-1182. 
Baek, S. H. (2006). "A Novel Link Between SUMO Modification and Cancer 
Metastasis." Cell Cycle 5(14): 1492-1495. 
Bartek, J. and Z. Hodny (2010). "SUMO boosts the DNA damage response barrier 
against cancer." Cancer Cell 17(1): 9-11. 
Bayer, P., A. Arndt, et al. (1998). "Structure determination of the small ubiquitin-
related modifier SUMO-1." J Mol Biol 280(2): 275-86. 
Benson, M. D., Q. J. Li, et al. (2007). "SUMO modification regulates inactivation of 
the voltage-gated potassium channel Kv1.5." Proc Natl Acad Sci U S A 104(6): 1805-
10. 
Bernier-Villamor, V., D. A. Sampson, et al. (2002). "Structural Basis for E2-Mediated 
SUMO Conjugation Revealed by a Complex between Ubiquitin-Conjugating Enzyme 
Ubc9 and RanGAP1." Cell 108(3): 345-356. 
	   173	  
Bischof, O. and A. Dejean (2007). "SUMO is Growing Senescent." Cell Cycle 6(6): 
677-681. 
Blomster, H. A., Imanishi, Susumu Y., et al. (2010). "In Vivo Identification of 
Sumoylation Sites by a Signature Tag and Cysteine-targeted Affinity Purification." 
Journal of Biological Chemistry 285(25): 19324-19329. 
Bossis, G., C. E. Malnou, et al. (2005). "Down-regulation of c-Fos/c-Jun AP-1 dimer 
activity by sumoylation." Mol Cell Biol 25(16): 6964-79. 
Bouras, T., M. Fu, et al. (2005). "SIRT1 Deacetylation and Repression of p300 
Involves Lysine Residues 1020/1024 within the Cell Cycle Regulatory Domain 1." 
Journal of Biological Chemistry 280(11): 10264-10276. 
Branzei, D. and M. Foiani (2005). "The DNA damage response during DNA 
replication." Curr Opin Cell Biol 17(6): 568-75. 
Branzei, D. and M. Foiani (2008). "Regulation of DNA repair throughout the cell 
cycle." Nat Rev Mol Cell Biol 9(4): 297-308. 
Branzei, D., J. Sollier, et al. (2006). "Ubc9- and mms21-mediated sumoylation 
counteracts recombinogenic events at damaged replication forks." Cell 127(3): 509-22. 
Branzei, D., F. Vanoli, et al. (2008). "SUMOylation regulates Rad18-mediated 
template switch." Nature 456(7224): 915-20. 
Bylebyl, G. R., I. Belichenko, et al. (2003). "The SUMO Isopeptidase Ulp2 Prevents 
Accumulation of SUMO Chains in Yeast." Journal of Biological Chemistry 278(45): 
44113-44120. 
Cadet, J., M. Berger, et al. (1997). "Oxidative damage to DNA: formation, 
measurement, and biological significance." Rev Physiol Biochem Pharmacol 131: 1-
87. 
Caldecott, K. W. (2008). "Single-strand break repair and genetic disease." Nat Rev 
Genet 9(8): 619-631. 
Carter, S., O. Bischof, et al. (2007). "C-terminal modifications regulate MDM2 
dissociation and nuclear export of p53." Nat Cell Biol 9(4): 428-35. 
Chen, X. L., H. R. Silver, et al. (2007). "Topoisomerase I-Dependent Viability Loss in 
Saccharomyces cerevisiae Mutants Defective in Both SUMO Conjugation and DNA 
Repair." Genetics 177(1): 17-30. 
Cheng, C.-H., Y.-H. Lo, et al. (2006). "SUMO modifications control assembly of 
synaptonemal complex and polycomplex in meiosis of Saccharomyces cerevisiae." 
Genes & Development 20(15): 2067-2081. 
Cheng, J., T. Bawa, et al. (2006). "Role of desumoylation in the development of 
prostate cancer." Neoplasia 8(8): 667-76. 
Choudhary, C., C. Kumar, et al. (2009). "Lysine Acetylation Targets Protein 
Complexes and Co-Regulates Major Cellular Functions." Science 325(5942): 834-840. 
	   174	  
Cohen, P. (2001). "The role of protein phosphorylation in human health and disease.  
" European Journal of Biochemistry 268(19): 5001-5010. 
Colaert, N., K. Helsens, et al. (2009). "Improved visualization of protein consensus 
sequences by iceLogo." Nat Meth 6(11): 786-787. 
Conzelmann, A., H. Riezman, et al. (1988). "A major 125-kd membrane glycoprotein 
of Saccharomyces cerevisiae is attached to the lipid bilayer through an inositol-
containing phospholipid." EMBO J 7(7): 2233-40. 
Cortes-Ledesma, F. and A. Aguilera (2006). "Double-strand breaks arising by 
replication through a nick are repaired by cohesin-dependent sister-chromatid 
exchange." EMBO Rep 7(9): 919-926. 
Cox, J., I. Matic, et al. (2009). "A practical guide to the MaxQuant computational 
platform for SILAC-based quantitative proteomics." Nat. Protocols 4(5): 698-705. 
Cox, J., N. Neuhauser, et al. (2011). "Andromeda: A Peptide Search Engine Integrated 
into the MaxQuant Environment." Journal of Proteome Research 10(4): 1794-1805. 
Dadke, S., S. Cotteret, et al. (2007). "Regulation of protein tyrosine phosphatase 1B by 
sumoylation." Nat Cell Biol 9(1): 80-85. 
Dai, X. Q., J. Kolic, et al. (2009). "SUMOylation regulates Kv2.1 and modulates 
pancreatic beta-cell excitability." J Cell Sci 122(Pt 6): 775-9. 
de Godoy, L. M., J. V. Olsen, et al. (2006). "Status of complete proteome analysis by 
mass spectrometry: SILAC labeled yeast as a model system." Genome Biol 7(6): R50. 
de Godoy, L. M. F., J. V. Olsen, et al. (2008). "Comprehensive mass-spectrometry-
based proteome quantification of haploid versus diploid yeast." Nature 455(7217): 
1251-1254. 
De Piccoli, G., F. Cortes-Ledesma, et al. (2006). "Smc5-Smc6 mediate DNA double-
strand-break repair by promoting sister-chromatid recombination." Nat Cell Biol 8(9): 
1032-4. 
Denison, C., A. D. Rudner, et al. (2005). "A proteomic strategy for gaining insights 
into protein sumoylation in yeast." Mol Cell Proteomics 4(3): 246-54. 
Desterro, J. M., M. S. Rodriguez, et al. (1998). "SUMO-1 modification of IκKα 
inhibits NF-κB activation." Mol Cell 2(2): 233-9. 
Di Marcotullio, L., E. Ferretti, et al. (2007). "Multiple ubiquitin-dependent processing 
pathways regulate hedgehog/gli signaling: implications for cell development and 
tumorigenesis." Cell Cycle 6(4): 390-3. 
Doyle, J. M., J. Gao, et al. (2010). "MAGE-RING Protein Complexes Comprise a  
family of E3 Ubiquitin Ligases." Molecular Cell 39(6): 963-974. 
Duro, E., J. A. Vaisica, et al. (2008). "Budding yeast Mms22 and Mms1 regulate 
homologous recombination induced by replisome blockage." DNA Repair (Amst) 
7(5): 811-8. 
	   175	  
Duwel, M., V. Welteke, et al. (2009). "A20 negatively regulates T cell receptor 
signaling to NF-kappaB by cleaving Malt1 ubiquitin chains." J Immunol 182(12): 
7718-28. 
Edman P. (1949). "A method for the determination of amino acid sequence in 
peptides." Arch Biochem. 22(3):475. 
Eng, J., A. McCormack, et al. (1994). "An approach to correlate tandem mass spectral 
data of peptides with amino acid sequences in a protein database." Journal of The 
American Society for Mass Spectrometry 5(11): 976-989. 
Fenn, J., M. Mann, et al. (1989). "Electrospray ionization for mass spectrometry of 
large biomolecules." Science 246(4926): 64-71. 
Fishman-Lobell, J., N. Rudin, et al. (1992). "Two alternative pathways of double-
strand break repair that are kinetically separable and independently modulated." 
Molecular and Cellular Biology 12(3): 1292-1303. 
Fraser, A. G., R. S. Kamath, et al. (2000). "Functional genomic analysis of C. elegans 
chromosome I by systematic RNA interference." Nature 408(6810): 325-30. 
Friedberg, E. C. (2003). "DNA damage and repair." Nature 421(6921): 436-40. 
Fujioka, Y., Y. Kimata, et al. (2002). "Identification of a novel non-structural 
maintenance of chromosomes (SMC) component of the SMC5-SMC6 complex 
involved in DNA repair." J Biol Chem 277(24): 21585-91. 
Galisson, F., L. Mahrouche, et al. (2010). "A novel proteomics approach to identify 
SUMOylated proteins and their modification sites in human cells." Molecular & 
Cellular Proteomics. 
Gareau, J. R. and C. D. Lima (2010). "The SUMO pathway: emerging mechanisms 
that shape specificity, conjugation and recognition." Nat Rev Mol Cell Biol 11(12): 
861-871. 
Geiss-Friedlander, R. and F. Melchior (2007). "Concepts in sumoylation: a decade on." 
Nat Rev Mol Cell Biol 8(12): 947-956. 
Gill, G. (2005). "Something about SUMO inhibits transcription." Current Opinion in 
Genetics & Development 15(5): 536-541. 
Goehring, A. S., D. M. Rivers, et al. (2003). "Urmylation: A Ubiquitin-like Pathway 
that Functions during Invasive Growth and Budding in Yeast." Mol. Biol. Cell 14(11): 
4329-4341. 
Goldstein, A. L. and J. H. McCusker (1999). "Three new dominant drug resistance 
cassettes for gene disruption in Saccharomyces cerevisiae." Yeast 15(14): 1541-53. 
Golebiowski, F., I. Matic, et al. (2009). "System-wide changes to SUMO 
modifications in response to heat shock." Sci Signal 2(72): ra24. 
Gonzalez-Barrera, S., F. Cortes-Ledesma, et al. (2003). "Equal Sister Chromatid 
Exchange Is a Major Mechanism of Double-Strand Break Repair in Yeast." Molecular 
Cell 11(6): 1661-1671. 
	   176	  
Goodrich-Blair, H. and D. A. Shub (1996). "Beyond homing: competition between 
intron endonucleases confers a selective advantage on flanking genetic markers." Cell 
84(2): 211-21. 
Grenon, M., C. P. Magill, et al. (2006). "Double-strand breaks trigger MRX- and 
Mec1-dependent, but Tel1-independent, checkpoint activation." FEMS Yeast Res 6(5): 
836-47. 
Hanawalt, P. C. and R. H. Haynes (1967). "The repair of DNA." Sci. Am. 216: 36-43. 
Hang, L. E., X. Liu, et al. (2011). "SUMOylation regulates telomere length 
homeostasis by targeting Cdc13." Nat Struct Mol Biol advance online publication. 
Harder, Z., R. Zunino, et al. (2004). "Sumo1 Conjugates Mitochondrial Substrates and 
Participates in Mitochondrial Fission." Current Biology 14(4): 340-345. 
Harrison, J. C. and J. E. Haber (2006). "Surviving the breakup: the DNA damage 
checkpoint." Annu Rev Genet 40: 209-35. 
Harvey, S. H., D. M. Sheedy, et al. (2004). "Coordination of DNA damage responses 
via the Smc5/Smc6 complex." Mol Cell Biol 24(2): 662-74. 
Hay, R. T. (2005). "SUMO: A History of Modification." Molecular Cell 18(1): 1-12. 
Hayashi, T., M. Seki, et al. (2002). "Ubc9 Is Essential for Viability of Higher 
Eukaryotic Cells." Experimental Cell Research 280(2): 212-221. 
Hefferin, M. L. and A. E. Tomkinson (2005). "Mechanism of DNA double-strand 
break repair by non-homologous end joining." DNA Repair (Amst) 4(6): 639-48. 
Heideker, J., J. J. Perry, et al. (2009). "Genome stability roles of SUMO-targeted 
ubiquitin ligases." DNA Repair (Amst) 8(4): 517-24. 
Hietakangas, V., J. Anckar, et al. (2006). "PDSM, a motif for phosphorylation-
dependent SUMO modification." Proc Natl Acad Sci U S A 103(1): 45-50. 
Hochstrasser, M. (2001). "SP-RING for SUMO: new functions bloom for a ubiquitin-
like protein." Cell 107(1): 5-8. 
Hoege, C., B. Pfander, et al. (2002). "RAD6-dependent DNA repair is linked to 
modification of PCNA by ubiquitin and SUMO." Nature 419(6903): 135-41. 
Hoeijmakers, J. H. J. (2001). "Genome maintenance mechanisms for preventing 
cancer." Nature 411(6835): 366-374. 
Hsiang, Y. H., M. G. Lihou, et al. (1989). "Arrest of replication forks by drug-
stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing 
by camptothecin." Cancer Res 49(18): 5077-82. 
Hsiao, H. H., E. Meulmeester, et al. (2009). ""ChopNSpice," a mass spectrometric 
approach that allows identification of endogenous small ubiquitin-like modifier-
conjugated peptides." Mol Cell Proteomics 8(12): 2664-75. 
	   177	  
Hwang, J. Y., S. Smith, et al. (2008). "Smc5-Smc6 complex suppresses gross 
chromosomal rearrangements mediated by break-induced replications." DNA Repair 
(Amst) 7(9): 1426-36. 
Irmisch, A., E. Ampatzidou, et al. (2009). "Smc5/6 maintains stalled replication forks  
in a recombination-competent conformation." EMBO J 28(2): 144-155. 
Isaacson, M. K. and H. L. Ploegh (2009). "Ubiquitination, ubiquitin-like modifiers, 
and deubiquitination in viral infection." Cell Host Microbe 5(6): 559-70. 
Ivanov, D. and K. Nasmyth (2005). "A Topological Interaction between Cohesin Rings 
and a Circular Minichromosome." Cell 122(6): 849-860. 
Jackson, S. P. and J. Bartek (2009). "The DNA-damage response in human biology 
and disease." Nature 461(7267): 1071-8. 
Jacques, C., O. Baris, et al. (2005). "Two-Step Differential Expression Analysis 
Reveals a New Set of Genes Involved in Thyroid Oncocytic Tumors." Journal of 
Clinical Endocrinology & Metabolism 90(4): 2314-2320. 
Janke, C., M. M. Magiera, et al. (2004). "A versatile toolbox for PCR-based tagging of 
yeast genes: new fluorescent proteins, more markers and promoter substitution 
cassettes." Yeast 21(11): 947-62. 
Jiricny, J. (2006). "The multifaceted mismatch-repair system." Nat Rev Mol Cell Biol 
7(5): 335-46. 
Johnson, E. S. (2004). "Protein modification by SUMO." Annu Rev Biochem 73: 355-
82. 
Johnson, E. S. and G. n. Blobel (1999). "Cell Cycle‚ÄìRegulated Attachment of the 
Ubiquitin-Related Protein Sumo to the Yeast Septins." The Journal of Cell Biology 
147(5): 981-994. 
Johnson, E. S., I. Schwienhorst, et al. (1997). "The ubiquitin-like protein Smt3p is 
activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer." EMBO J 
16(18): 5509-19. 
Johnson, R. D. and M. Jasin (2000). "Sister chromatid gene conversion is a prominent 
double-strand break repair pathway in mammalian cells." EMBO J 19(13): 3398-3407. 
Jones, D. and E. P. Candido (2000). "The NED-8 conjugating system in 
Caenorhabditis elegans is required for embryogenesis and terminal differentiation of 
the hypodermis." Dev Biol 226(1): 152-65. 
Kadyk, L. C. and L. H. Hartwell (1992). "Sister Chromatids Are Preferred Over 
Homologs as Substrates for Recombinational Repair in Saccharomyces cerevisiae." 
Genetics 132(2): 387-402. 
Kagey, M. H., T. A. Melhuish, et al. (2003). "The Polycomb Protein Pc2 Is a SUMO 
E3." Cell 113(1): 127-137. 
	   178	  
Kang, X., Y. Qi, et al. "SUMO-Specific Protease 2 Is Essential for Suppression of 
Polycomb Group Protein-Mediated Gene Silencing during Embryonic Development." 
Molecular Cell 38(2): 191-201. 
Karas, M., D. Bachmann, et al. (1987). "Matrix-assisted ultraviolet laser desorption of 
non-volatile compounds." International Journal of Mass Spectrometry and Ion 
Processes 78: 53-68. 
Keller, A., A. I. Nesvizhskii, et al. (2002). "Empirical Statistical Model To Estimate 
the Accuracy of Peptide Identifications Made by MS/MS and Database Search." 
Analytical Chemistry 74(20): 5383-5392. 
Kerscher, O. (2007). "SUMO junction[mdash]what's your function?" EMBO Rep 8(6): 
550-555. 
Knop, M., K. Siegers, et al. (1999). "Epitope tagging of yeast genes using a PCR-based 
strategy: more tags and improved practical routines." Yeast 15(10B): 963-72. 
Kogoma, T. (1996). "Recombination by replication." Cell 85(5): 625-7. 
Kolesar, P., P. Sarangi, et al. (2012). "Dual roles of the SUMO-interacting motif in the 
regulation of Srs2 sumoylation." Nucleic Acids Research. 
Kraft, C., A. Deplazes, et al. (2008). "Mature ribosomes are selectively degraded upon 
starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease." 
Nat Cell Biol 10(5): 602-610. 
Kuzminov, A. (1999). "Recombinational repair of DNA damage in Escherichia coli 
and bacteriophage lambda." Microbiol Mol Biol Rev 63(4): 751-813, table of contents. 
Lake, A. N. and M. T. Bedford (2007). "Protein methylation and DNA repair." 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 
618(1‚Äì2): 91-101. 
Laplaza, J. M., M. Bostick, et al. (2004). "Saccharomyces cerevisiae ubiquitin-like 
protein Rub1 conjugates to cullin proteins Rtt101 and Cul3 in vivo." Biochem J 377(Pt 
2): 459-67.Lee, K. M. and M. J. O'Connell (2006). "A new SUMO ligase in the DNA 
damage response." DNA Repair 5(1): 138-141. 
Lettier, G., Q. Feng, et al. (2006). "The role of DNA double-strand breaks in 
spontaneous homologous recombination in S. cerevisiae." PLoS Genet 2(11): e194. 
Lewis, L. K., J. M. Kirchner, et al. (1998). "Requirement for End-Joining and 
Checkpoint Functions, but NotRAD52-Mediated Recombination, after EcoRI 
Endonuclease Cleavage of Saccharomyces cerevisiaeDNA." Molecular and Cellular 
Biology 18(4): 1891-1902. 
Lewis, L. K., J. W. Westmoreland, et al. (1999). "Repair of endonuclease-induced 
double-strand breaks in Saccharomyces cerevisiae: essential role for genes associated 
with nonhomologous end-joining." Genetics 152(4): 1513-29. 
	   179	  
Lindroos, H. B., L. Strom, et al. (2006). "Chromosomal association of the Smc5/6 
complex reveals that it functions in differently regulated pathways." Mol Cell 22(6): 
755-67. 
Lisby, M., J. H. Barlow, et al. (2004). "Choreography of the DNA damage response: 
spatiotemporal relationships among checkpoint and repair proteins." Cell 118(6): 699-
713. 
Lois, L. M. and C. D. Lima (2005). "Structures of the SUMO E1 provide mechanistic 
insights into SUMO activation and E2 recruitment to E1." EMBO J 24(3): 439-451. 
Mahajan, R., C. Delphin, et al. (1997). "A Small Ubiquitin-Related Polypeptide 
Involved in Targeting RanGAP1 to Nuclear Pore Complex Protein RanBP2." Cell 
88(1): 97-107. 
Makarov, A. (2000). "Electrostatic Axially Harmonic Orbital Trapping: A High-
Performance Technique of Mass Analysis." Analytical Chemistry 72(6): 1156-1162. 
Mann, M. and M. Wilm (1994). "Error-tolerant identification of peptides in sequence 
databases by peptide sequence tags." Anal Chem 66(24): 4390-9. 
Mannini, L., S. Menga, et al. (2010). "The expanding universe of cohesin functions: a 
new genome stability caretaker involved in human disease and cancer." Hum Mutat 
31(6): 623-30. 
Martin, S., A. Nishimune, et al. (2007). "SUMOylation regulates kainate-receptor-
mediated synaptic transmission." Nature 447(7142): 321-5. 
Matic, I., J. Schimmel, et al. (2010). "Site-Specific Identification of SUMO-2 Targets 
in Cells Reveals an Inverted SUMOylation Motif and a Hydrophobic Cluster 
SUMOylation Motif." Molecular Cell 39(4): 641-652. 
McKay, et al. (2005). "A proline-90 residue unique to SUMO-4 prevents maturation 
and sumoylation." Biochem Biophys Res Commun 337(2): 517-20. 
Meulmeester, E. and F. Melchior (2008). "Cell biology: SUMO." Nature 452(7188): 
709-11. 
Mimitou, E. P. and L. S. Symington (2008). "Sae2, Exo1 and Sgs1 collaborate in DNA 
double-strand break processing." Nature 455(7214): 770-4. 
Mossessova, E. and C. D. Lima (2000). "Ulp1-SUMO crystal structure and genetic 
analysis reveal conserved interactions and a regulatory element essential for cell 
growth in yeast." Mol Cell 5(5): 865-76. 
Müller, S., M. Berger, et al. (2000). "c-Jun and p53 Activity Is Modulated by SUMO-1 
Modification." Journal of Biological Chemistry 275(18): 13321-13329. 
Nacerddine, K., F. Lehembre, et al. (2005). "The SUMO Pathway Is Essential for 
Nuclear Integrity and Chromosome Segregation in Mice." Developmental Cell 9(6): 
769-779. 
	   180	  
Nakai, Y., M. Nakai, et al. (2008). "Thio-modification of Yeast Cytosolic tRNA 
Requires a Ubiquitin-related System That Resembles Bacterial Sulfur Transfer 
Systems." Journal of Biological Chemistry 283(41): 27469-27476. 
Nathan, D., K. Ingvarsdottir, et al. (2006). "Histone sumoylation is a negative regulator 
in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone 
modifications." Genes & Development 20(8): 966-976. 
Nelson, J. D., O. Denisenko, et al. (2006). "Protocol for the fast chromatin 
immunoprecipitation (ChIP) method." Nat Protoc 1(1): 179-85. 
Nesvizhskii, A. I. and R. Aebersold (2004). "Analysis, statistical validation and 
dissemination of large-scale proteomics datasets generated by tandem MS." Drug 
Discov Today 9(4): 173-81. 
Nesvizhskii, A. I., A. Keller, et al. (2003). "A statistical model for identifying proteins 
by tandem mass spectrometry." Anal Chem 75(17): 4646-58. 
Nielsen, I., I. B. Bentsen, et al. (2009). "A Flp-nick system to study repair of a single 
protein-bound nick in vivo." Nat Methods 6(10): 753-7. 
Nishimura, K., T. Fukagawa, et al. (2009). "An auxin-based degron system for the 
rapid depletion of proteins in nonplant cells." Nat Methods 6(12): 917-22. 
Ong, S.-E., I. Kratchmarova, et al. (2002). "Properties of 13C-Substituted Arginine in 
Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)." Journal of 
Proteome Research 2(2): 173-181. 
Osaka, F., M. Saeki, et al. (2000). "Covalent modifier NEDD8 is essential for SCF 
ubiquitin-ligase in fission yeast." EMBO J 19(13): 3475-3484Owerbach, D., E. M.  
Ou, C. Y., Y. F. Lin, et al. (2002). "Distinct protein degradation mechanisms mediated 
by Cul1 and Cul3 controlling Ci stability in Drosophila eye development." Genes Dev 
16(18): 2403-14. 
Oved, S., Y. Mosesson, et al. (2006). "Conjugation to Nedd8 instigates ubiquitylation 
and down-regulation of activated receptor tyrosine kinases." J Biol Chem 281(31): 
21640-51. 
Pal, S., A. Santos, et al. (2011). "Influenza A virus interacts extensively with the 
cellular SUMOylation system during infection." Virus Res 158(1-2): 12-27. 
Panse, V. G., D. Kressler, et al. (2006). "Formation and nuclear export of preribosomes 
are functionally linked to the small-ubiquitin-related modifier pathway." Traffic 7(10): 
1311-21. 
Paques, F. and J. E. Haber (1999). "Multiple pathways of recombination induced by 
double-strand breaks in Saccharomyces cerevisiae." Microbiol Mol Biol Rev 63(2): 
349-404. 
Parker, J. L., A. Bucceri, et al. (2008). "SUMO modification of PCNA is controlled by  
DNA." EMBO J 27(18): 2422-31. 
	   181	  
Pebernard, S., J. J. P. Perry, et al. (2008). "Nse1 RING-like Domain Supports Functions 
of the Smc5-Smc6 Holocomplex in Genome Stability." Molecular Biology of the Cell 
19(10): 4099-4109. 
Pebernard, S., L. Schaffer, et al. (2008). "Localization of Smc5/6 to centromeres and 
telomeres requires heterochromatin and SUMO, respectively." EMBO J 27(22): 3011-
23. 
Pedrioli, P. G., B. Raught, et al. (2006). "Automated identification of SUMOylation 
sites using mass spectrometry and SUMmOn pattern recognition software." Nat 
Methods 3(7): 533-9. 
Peng, J., J. E. Elias, et al. (2002). "Evaluation of Multidimensional Chromatography 
Coupled with Tandem Mass Spectrometry (LC/LC‚àíMS/MS) for Large-Scale Protein 
Analysis:‚Äâ The Yeast Proteome." Journal of Proteome Research 2(1): 43-50. 
Perkins, D. N., D. J. C. Pappin, et al. (1999). "Probability-based protein identification 
by searching sequence databases using mass spectrometry data." Electrophoresis 
20(18): 3551-3567. 
Pfander, B., G. L. Moldovan, et al. (2005). "SUMO-modified PCNA recruits Srs2 to 
prevent recombination during S phase." Nature 436(7049): 428-33. 
Pichler, A., A. Gast, et al. (2002). "The Nucleoporin RanBP2 Has SUMO1 E3 Ligase 
Activity." Cell 108(1): 109-120. 
Potts, P. R., M. H. Porteus, et al. (2006). "Human SMC5/6 complex promotes sister 
chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to 
double-strand breaks." EMBO J 25(14): 3377-88. 
Potts, P. R. and H. Yu (2005). "Human MMS21/NSE2 Is a SUMO Ligase Required 
for DNA Repair." Mol. Cell. Biol. 25(16): 7021-7032. 
Prakash, L. and S. Prakash (1977). "Isolation and characterization of MMS-sensitive 
mutants of Saccharomyces cerevisiae." Genetics 86(1): 33-55. 
Prakash, S. and L. Prakash (1977). "Increased spontaneous mitotic segregation in 
MMS-sensitive mutants of Saccharomyces cerevisiae." Genetics 87(2): 229-36. 
Prakash, S. and L. Prakash (2000). "Nucleotide excision repair in yeast." Mutat Res 
451(1-2): 13-24. 
Rai, R., S. P. M. V. Varma, et al. (2011). "Small Ubiquitin-related Modifier Ligase 
Activity of Mms21 Is Required for Maintenance of Chromosome Integrity during the 
Unperturbed Mitotic Cell Division Cycle in Saccharomyces cerevisiae." Journal of 
Biological Chemistry 286(16): 14516-14530. 
Regad, T. and M. K. Chelbi-Alix (2001). "Role and fate of PML nuclear bodies in 
response to interferon and viral infections." Oncogene 20(49): 7274-86. 
Riedel, M., O. Goldbaum, et al. "Membrane lipid modification by docosahexaenoic 
acid (DHA) promotes the formation of alpha-synuclein inclusion bodies 
	   182	  
immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress." J Mol 
Neurosci 43(3): 290-302. 
Riezman, H., T. Hase, et al. (1983). "Import of proteins into mitochondria - a 70 
kilodalton outer-membrane protein with a large carboxy-terminal deletion is still 
transported to the outer-membrane." Embo Journal 2(12): 2161-2168. 
Rodriguez, M. S., C. Dargemont, et al. (2001). "SUMO-1 conjugation in vivo requires 
both a consensus modification motif and nuclear targeting." J. Biol. Chem. 276: 
12654-12659. 
Rodriguez, M. S., C. Dargemont, et al. (2001). "SUMO-1 Conjugation in Vivo 
Requires Both a Consensus Modification Motif and Nuclear Targeting." Journal of 
Biological Chemistry 276(16): 12654-12659. 
Rog, O., K. M. Miller, et al. (2009). "Sumoylation of RecQ helicase controls the fate 
of dysfunctional telomeres." Mol Cell 33(5): 559-69. 
Ronen, O., J. P. Malone, et al. (2009). "Expression of a novel marker, Ubc9, in 
squamous cell carcinoma of the head and neck." Head & Neck 31(7): 845-855. 
Rosonina, E., S. M. Duncan, et al. (2010). "SUMO functions in constitutive 
transcription and during activation of inducible genes in yeast." Genes Dev 24(12): 
1242-52. 
Rothenbusch, U., M. Sawatzki, et al. (2012). "Sumoylation regulates Kap114-mediated 
nuclear transport." EMBO J 31(11): 2461-2472. 
Rouse, J. (2004). "Esc4p, a new target of Mec1p (ATR), promotes resumption of DNA 
synthesis after DNA damage." EMBO J 23(5): 1188-1197. 
Rudin, N. and J. E. Haber (1988). "Efficient repair of HO-induced chromosomal 
breaks in Saccharomyces cerevisiae by recombination between flanking homologous 
sequences." Molecular and Cellular Biology 8(9): 3918-3928. 
Sacher, M., B. Pfander, et al. (2006). "Control of Rad52 recombination activity by 
double-strand break-induced SUMO modification." Nat Cell Biol 8(11): 1284-90. 
Saitoh, H. and J. Hinchey (2000). "Functional heterogeneity of small ubiquitin-related 
protein modifiers SUMO-1 versus SUMO-2/3." J Biol Chem 275(9): 6252-8. 
Sapetschnig, A., G. Rischitor, et al. (2002). "Transcription factor Sp3 is silenced 
through SUMO modification by PIAS1." EMBO J 21(19): 5206-5215. 
Saracco, S. A., M. J. Miller, et al. (2007). "Genetic Analysis of SUMOylation in 
Arabidopsis: Conjugation of SUMO1 and SUMO2 to Nuclear Proteins Is Essential." 
Plant Physiology 145(1): 119-134. 
Sato, Y., K. Miyake, et al. (2006). "Sumoylation of CCAAT/enhancer-binding protein 
alpha and its functional roles in hepatocyte differentiation." J Biol Chem 281(31): 
21629-39. 
	   183	  
Seeler, J. S., O. Bischof, et al. (2007). "SUMO, the three Rs and cancer." Curr Top 
Microbiol Immunol 313: 49-71. 
Seeler, J. S. and A. Dejean (2003). "Nuclear and unclear functions of SUMO." Nat 
Rev Mol Cell Biol 4(9): 690-9. 
Seiler, M., A. Mehrle, et al. (2006). "The 3of5 web application for complex and 
comprehensive pattern matching in protein sequences." BMC Bioinformatics 7(1): 
144. 
Seo, J. and K. J. Lee (2004). "Post-translational modifications and their biological  
functions: proteomic analysis and systematic approaches." J Biochem Mol Biol 37(1):  
35-44. 
Shalizi, A., B. Gaudilliere, et al. (2006). "A Calcium-Regulated MEF2 Sumoylation 
Switch Controls Postsynaptic Differentiation." Science 311(5763): 1012-1017. 
Sharrocks, A. D. (2006). "PIAS proteins and transcriptional regulation‚Äîmore than 
just SUMO E3 ligases?" Genes & Development 20(7): 754-758. 
Shen, B. W., M. Landthaler, et al. (2004). "DNA binding and cleavage by the HNH 
homing endonuclease I-HmuI." J Mol Biol 342(1): 43-56. 
Shen, T. H., H. K. Lin, et al. (2006). "The mechanisms of PML-nuclear body 
formation." Mol Cell 24(3): 331-9. 
Shen, Z., P. E. Pardington-Purtymun, et al. (1996). "Associations of UBE2I with 
RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system." Genomics 
37(2): 183-6. 
Shen, Z., P. E. Pardington-Purtymun, et al. (1996). "UBL1, a human ubiquitin-like 
protein associating with human RAD51/RAD52 proteins." Genomics 36(2): 271-9. 
Shiio, Y. and R. N. Eisenman (2003). "Histone sumoylation is associated with 
transcriptional repression." Proceedings of the National Academy of Sciences 100(23): 
13225-13230. 
Shiloh, Y. (2003). "ATM and related protein kinases: safeguarding genome integrity." 
Nat Rev Cancer 3(3): 155-68. 
Shinohara, A. and T. Ogawa (1998). "Stimulation by Rad52 of yeast Rad51-mediated 
recombination." Nature 391(6665): 404-7. 
Silver, H. R., J. A. Nissley, et al. (2011). "A role for SUMO in nucleotide excision 
repair." DNA Repair 10(12): 1243-1251. 
Sjogren, C. and K. Nasmyth (2001). "Sister chromatid cohesion is required for 
postreplicative double-strand break repair in Saccharomyces cerevisiae." Current 
Biology 11(12): 991-995. 
Stade, K., F. Vogel, et al. (2002). "A Lack of SUMO Conjugation Affects cNLS-
dependent Nuclear Protein Import in Yeast." Journal of Biological Chemistry 277(51): 
49554-49561. 
	   184	  
Stankovic-Valentin, N., S. Deltour, et al. (2007). "An Acetylation/Deacetylation-
SUMOylation Switch through a Phylogenetically Conserved {psi}KXEP Motif in the 
Tumor Suppressor HIC1 Regulates Transcriptional Repression Activity." Mol. Cell. 
Biol. 27(7): 2661-2675. 
Stehmeier, P. and S. Muller (2009). "Phospho-regulated SUMO interaction modules 
connect the SUMO system to CK2 signaling." Mol Cell 33(3): 400-9. 
Sterner, D. E., D. Nathan, et al. (2005). "Sumoylation of the Yeast Gcn5 Protein." 
Biochemistry 45(3): 1035-1042. 
Strunnikov, A. V., E. Hogan, et al. (1995). "SMC2, a Saccharomyces cerevisiae gene 
essential for chromosome segregation and condensation, defines a subgroup within the 
SMC family." Genes & Development 9(5): 587-599. 
Subramaniam, S., K. M. Sixt, et al. (2009). "Rhes, a Striatal Specific Protein, Mediates 
Mutant-Huntingtin Cytotoxicity." Science 324(5932): 1327-1330. 
Tanaka, K., H. Waki, et al. (1988). "Protein and polymer analyses up to m/z 100 000 
by laser ionization time-of-flight mass spectrometry." Rapid Communications in Mass 
Spectrometry 2(8): 151-153. 
Tateishi, K., M. Omata, et al. (2001). "The NEDD8 system is essential for cell cycle 
progression and morphogenetic pathway in mice." The Journal of Cell Biology 155(4): 
571-580. 
Tatham, M. H., M. S. Rodriguez, et al. (2009). "Detection of protein SUMOylation in 
vivo." Nat. Protocols 4(9): 1363-1371. 
Tomoko Hori, F. O., Tomoki Chiba, Chikara Miyamoto, Ken Okabayashi, Naoki 
Shimbara, Seishi Kato and Keiji Tanaka (1999). "Covalent modification of all 
members of human cullin family proteins by NEDD8." Oncogene 18(48): 6829-6834. 
Torres-Rosell, J., G. De Piccoli, et al. (2007). "Anaphase Onset Before Complete DNA 
Replication with Intact Checkpoint Responses." Science 315(5817): 1411-1415. 
Torres-Rosell, J., F. Machin, et al. (2005). "SMC5 and SMC6 genes are required for 
the segregation of repetitive chromosome regions." Nat Cell Biol 7(4): 412-9. 
Ulrich, H. D. (2005). "Mutual interactions between the SUMO and ubiquitin systems: 
a plea of no contest." Trends in Cell Biology 15(10): 525-532. 
Ulrich, H. D. (2005). "SUMO modification: wrestling with protein conformation." 
Curr Biol 15(7): R257-9. 
Ulrich, H. D. (2009). "Preface. Ubiquitin, SUMO and the maintenance of genome 
stability." DNA Repair (Amst) 8(4): 429. 
Urnov, F. D., J. C. Miller, et al. (2005). "Highly efficient endogenous human gene 
correction using designed zinc-finger nucleases." Nature 435(7042): 646-651. 
Van der Veen, A. G., K. Schorpp, et al. (2011). "Role of the ubiquitin-like protein 
Urm1 as a noncanonical lysine-directed protein modifier." Proceedings of the National 
Academy of Sciences 108(5): 1763-1770. 
	   185	  
Van Hoof, D., J. Munoz, et al. (2009). "Phosphorylation dynamics during early 
differentiation of human embryonic stem cells." Cell Stem Cell 5(2): 214-26. 
Verger, A., J. Perdomo, et al. (2003). "Modification with SUMO. A role in 
transcriptional regulation." EMBO Rep 4(2): 137-42. 
Vertegaal, A. C., J. S. Andersen, et al. (2006). "Distinct and overlapping sets of 
SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics." Mol Cell 
Proteomics 5(12): 2298-310. 
Wagner, S. A., P. Beli, et al. (2011). "A proteome-wide, quantitative survey of in vivo 
ubiquitylation sites reveals widespread regulatory roles." Mol Cell Proteomics. 
Wagner, S. A., P. Beli, et al. (2011). "A proteome-wide, quantitative survey of in vivo 
ubiquitylation sites reveals widespread regulatory roles." Mol Cell Proteomics 10(10): 
M111 013284. 
Walsh, C. T., S. Garneau-Tsodikova, et al. (2005). "Protein Posttranslational 
Modifications: The Chemistry of Proteome Diversifications." Angewandte Chemie 
International Edition 44(45): 7342-7372. 
Wang, Q.-E., Q. Zhu, et al. (2005). "DNA repair factor XPC is modified by SUMO-1 
and ubiquitin following UV irradiation." Nucleic Acids Research 33(13): 4023-4034. 
Wang, Y., A. Abu Irqeba, et al. (2009). "Sumoylation of Transcription Factor Tec1 
Regulates Signaling of Mitogen-Activated Protein Kinase Pathways in Yeast." PLoS 
One 4(10): e7456. 
Watson, I. R., A. Blanch, et al. (2006). "Mdm2-mediated NEDD8 modification of 
TAp73 regulates its transactivation function." J Biol Chem 281(45): 34096-103. 
Watts, F. Z. (2006). "Sumoylation of PCNA: Wrestling with recombination at stalled 
replication forks." DNA Repair (Amst) 5(3): 399-403. 
Weger, S., E. Hammer, et al. (2005). "Topors acts as a SUMO-1 E3 ligase for p53 in 
vitro and in vivo." FEBS Letters 579(22): 5007-5012. 
Wei, F., H. R. Schöler, et al. (2007). "Sumoylation of Oct4 Enhances Its Stability, 
DNA Binding, and Transactivation." Journal of Biological Chemistry 282(29): 21551-
21560. 
Wilkinson, K. A. and J. M. Henley (2010). "Mechanisms, regulation and consequences 
of protein SUMOylation." Biochemical Journal 428(2): 133-145. 
Wilkinson, K. A., Y. Nakamura, et al. (2010). "Targets and consequences of protein 
SUMOylation in neurons." Brain Res Rev 64(1): 195-212. 
Wilm, M., A. Shevchenko, et al. (1996). "Femtomole sequencing of proteins from  
polyacrylamide gels by nano-electrospray mass spectrometry." Nature 379(6564): 466- 
9.  
 
Windecker, H. and H. D. Ulrich (2008). "Architecture and assembly of poly-SUMO 
chains on PCNA in Saccharomyces cerevisiae." J Mol Biol 376(1): 221-31. 
	   186	  
 
Wohlschlegel, J. A. (2009). "Identification of SUMO-conjugated proteins and their 
SUMO attachment sites using proteomic mass spectrometry." Methods Mol Biol 497: 
33-49. 
Wohlschlegel, J. A., E. S. Johnson, et al. (2004). "Global analysis of protein 
sumoylation in Saccharomyces cerevisiae." J Biol Chem 279(44): 45662-8. 
Wohlschlegel, J. A., E. S. Johnson, et al. (2006). "Improved identification of SUMO 
attachment sites using C-terminal SUMO mutants and tailored protease digestion 
strategies." J Proteome Res 5(4): 761-70. 
Wu, F., S. Zhu, et al. (2009). "MicroRNA-mediated Regulation of Ubc9 Expression in 
Cancer Cells." Clinical Cancer Research 15(5): 1550-1557. 
Xiong, Y. and K.-L. Guan (2012). "Mechanistic insights into the regulation of  
metabolic enzymes by acetylation." The Journal of Cell Biology 198(2): 155-164. 
Xirodimas, D. P., M. K. Saville, et al. (2004). "Mdm2-mediated NEDD8 conjugation 
of p53 inhibits its transcriptional activity." Cell 118(1): 83-97. 
Xirodimas, D. P., A. Sundqvist, et al. (2008). "Ribosomal proteins are targets for the 
NEDD8 pathway." EMBO Rep 9(3): 280-6. 
Yan, D., F. J. Davis, et al. (2010). "Emerging roles of SUMO modification in 
arthritis." Gene 466(1-2): 1-15. 
Yan, Y., S. Zhang, et al. (2011). "Applications of graph theory in protein structure 
identification." Proteome Science 9(Suppl 1): S17. 
Yang, S. H., A. Galanis, et al. (2006). "An extended consensus motif enhances the 
specificity of substrate modification by SUMO." EMBO J 25(21): 5083-93. 
Yang, X. J. and S. Gregoire (2006). "A recurrent phospho-sumoyl switch in 
transcriptional repression and beyond." Mol Cell 23(6): 779-86. 
Yunus, A. A. and C. D. Lima (2009). "Structure of the Siz/PIAS SUMO E3 Ligase  
Siz1 and Determinants Required for SUMO Modification of PCNA." Molecular Cell  
35(5): 669-682. 
Yurchenko, V., Z. Xue, et al. (2008). "Ku70 is stabilized by increased cellular 
SUMO." Biochemical and Biophysical Research Communications 366(1): 263-268. 
Yurchenko, V., Z. Xue, et al. (2006). "SUMO Modification of Human XRCC4 
Regulates Its Localization and Function in DNA Double-Strand Break Repair." Mol. 
Cell. Biol. 26(5): 1786-1794. 
Zavec, A. B., A. Comino, et al. (2008). "Ecm11 protein of yeast Saccharomyces 
cerevisiae is regulated by sumoylation during meiosis." FEMS Yeast Research 8(1): 
64-70. 
	   187	  
Zhang, Y.-Q. and K. D. Sarge (2008). "Sumoylation regulates lamin A function and is 
lost in lamin A mutants associated with familial cardiomyopathies." The Journal of 
Cell Biology 182(1): 35-39. 
Zhao, X. and G. Blobel (2005). "A SUMO ligase is part of a nuclear multiprotein 
complex that affects DNA repair and chromosomal organization." Proceedings of the 
National Academy of Sciences of the United States of America 102(13): 4777-4782. 
Zhao, X. and G. n. Blobel (2005). "A SUMO ligase is part of a nuclear multiprotein 
complex that affects DNA repair and chromosomal organization." Proceedings of the 
National Academy of Sciences of the United States of America 102(13): 4777-4782. 
Zhao, X., T. Sternsdorf, et al. (2005). "Regulation of MEF2 by Histone Deacetylase 4- 
and SIRT1 Deacetylase-Mediated Lysine Modifications." Mol. Cell. Biol. 25(19): 
8456-8464. 
Zhou, W., J. J. Ryan, et al. (2004). "Global analyses of sumoylated proteins in 
Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses." J 
Biol Chem 279(31): 32262-8. 
Zhu, Z., W. H. Chung, et al. (2008). "Sgs1 helicase and two nucleases Dna2 and Exo1 
resect DNA double-strand break ends." Cell 134(6): 981-94. 
Zunino, R., A. Schauss, et al. (2007). "The SUMO protease SENP5 is required to 
maintain mitochondrial morphology and function." Journal of Cell Science 120(7): 
1178-1188. 
 
 
 
	   188	  
	   189	  
S U P P L E M E N T A R Y  D A T A  
 
 
 
 
Table 8. Sumo-acceptor lysines detected under MMS-induced DNA damage (0.05%MMS). Database-
matched with Mascot. The GENE column displays the Standard Name of the gene encoding the 
protein to which the sumoylated peptide belongs. The SCORE column displays the Mascot peptide 
score, an estimation of the quality of the peptide spectra. The MODIFIED SEQUENCE column 
displays the sequence of the sumoylated peptide. The SUMO acceptor Lysine is denoted with “(gl)”.  
 
Gene Score Modified Sequence  Gene  Score Modified Sequence 
AOS1 26.6 MDMK(gl)VEK  HPC2 37.3 MQTQTDTNAEVLNTDNSIK(gl)K 
ARB1 24.8 DAK(gl)K(gl)AER  HTA1 22.4 ATK(gl)ASQEL 
ARP5 27.7 LNK(gl)LIK  HTB1 38.3 AVTK(gl)YSSSTQA 
BAF1 48.7 QQGVTIK(gl)NDTEDDSINK  IES4 76.5 SQESSVLSESQEQLANNPK(gl)IEDTSPPSANSR 
BDF2 23.4 K(gl)NNNNSK  IKI1 30.2 DIK(gl)DENR 
BDP1 31.2 DK(gl)LLNADIPESDRK  ISW2 24.2 RVK(gl)ADVEK 
BDP1 30.2 K(gl)GSGGIMTNDLK(gl)VYR  KAR2 20.8 NK(gl)LENYAHSLK 
BFR1 27.0 EMQSLNK(gl)LIK  KAR2 21.3 QLIK(gl)AFK(gl)K 
BIR1 24.8 ILEDVSVK(gl)NETPNNEMLLFETGTPIASQENK  KIP3 24.2 ATK(gl)ATASSINNSNATNK 
BIR1 31.0 VIK(gl)PEFEPVPSVAR  LSM12 28.6 K(gl)QQIK 
BNI1 31.9 K(gl)LDEINR  LST4 21.3 FPLK(gl)NVELK 
BNI1 20.4 MLK(gl)NSGSK  LTV1 22.5 MSK(gl)K(gl)FSSK 
BOP3 90.6 IGASAVAALNDNISIK(gl)EEDVAR  MLP2 27.5 SLK(gl)NVTEK(gl)NR 
BSP1 23.1 K(gl)VELMK(gl)K  MRP8 40.5 EFK(gl)DIPDLK 
BUD3 36.5 FFEIEEELK(gl)EELK  MRPL11 43.8 IK(gl)QTGGKLTK 
BUD3 24.2 TGNEDVGNNNPSNSIPK(gl)IEKPPAFK  MRPL40 21.6 NPIPK(gl)K 
CBF2 24.4 IFEK(gl)LEMK  MRPS18 28.3 MFELIK(gl)EK 
CDC11 31.2 EAKIK(gl)QEE  MTW1 25.3 K(gl)NEMLLK 
CDC3 44.7 SLK(gl)EEQVSIK  NBP35 21.0 K(gl)NLLIK 
CDC3 60.0 EEQVSIK(gl)QDPEQEER  NET1 48.4 K(gl)SQAEPSGIVEPK 
CDC3 56.5 FEAAESDVK(gl)VEPGLGMGITSSQSEK  NET1 28.1 VADLK(gl)SANIGGEDLNK 
CDC48 51.9 EVK(gl)VEGEDVEMTDEGAK  NFI1 39.6 NENQGTVK(gl)QEQDYDSR 
CKI1 22.8 K(gl)NGSACWQK  NHA1 23.2 QK(gl)SAAVK 
CRZ1 55.3 IESGIVNIK(gl)NELDDTSK  NMD4 27.7 LK(gl)NLLK 
DAD2 26.5 K(gl)ELQSLQK  NOP12 20.8 LLNEEAEAEDDK(gl)PTVTK 
DBP1 26.9 MADLPQK(gl)VSNLSINNK  NOP14 21.5 NAEAEEK(gl)K 
DCD1 21.6 LSLLEK(gl)LEK  NST1 27.9 K(gl)ELEEREMR 
DEP1 32.5 LSSLVK(gl)QETLTESLK  NUC1 27.6 QSK(gl)DVK 
EBP2 53.5 SQELK(gl)KEEPTIVTASNLK  PDR1 26.6 TSLEGTTVQVK(gl)EETDSSSTSFSNPQR 
ECM5 26.1 DEEEPLHK(gl)K  PEX25 20.1 FNK(gl)TR 
EMC2 21.0 TELLEK(gl)ALK  PFK26 23.6 VDEK(gl)LSMLK(gl)NK 
ENP1 28.9 ILLDK(gl)K  PGK1 23.8 YGVTDK(gl)ISHVSTGGGASLELLEGK 
ERG10 31.7 AGAK(gl)FGQTVLVDGVER  PLC1 20.3 K(gl)VEYMIK(gl)DK 
ERG11 23.5 LMEQK(gl)K  POB3 28.3 KEESSNEVVPK(gl)K(gl)EDGAEGEDVQMAVEEK 
ERG27 22.3 K(gl)K(gl)LEWDEK  POL30 91.1 DLSQLSDSINIMITK(gl)ETIK 
FRE6 24.3 SEILELK(gl)NSR  POL30 38.6 LMDIDADFLK(gl)IEELQYDSTLSLPSSEFSK 
FSH3 21.3 MSEK(gl)K(gl)K  PRE2 54.0 VK(gl)EEEGSFNNVIG 
GCN4 24.4 FIK(gl)TEEDPIIK  PRP45 35.9 PK(gl)K(gl)QTSTVAR 
GCN5 47.3 RVK(gl)LENNVEEIQPEQAETNK  PSD2 23.1 NK(gl)K(gl)PTLILK 
GON7 27.0 MELAK(gl)NK(gl)K(gl)K  QCR2 27.9 K(gl)IVADLK(gl)K 
HAL9 25.5 YDPTSQELK(gl)K  QDR1 24.3 FSHK(gl)QK 
HAS1 22.4 LDLAK(gl)VAK  RAD52 48.3 NLVK(gl)IENTVSR 
HHF1 22.5 GLGK(gl)GGAK  RCK1 24.9 LMDFGLAK(gl)K 
HMO1 27.6 TTDPSVK(gl)LK  RED1 23.4 PK(gl)SIK(gl)VSK 
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Gene Score Modified Sequence  Gene  Score Modified Sequence 
RLI1 23.9 ILAGK(gl)QK  TFB2 25.1 LEK(gl)K(gl)LELDPNCK 
ROM1 25.6 QTIK(gl)LSTHK  TFG1 40.5 GSLVK(gl)K(gl)DDPEYAEER 
RPC53 70.9 GFIK(gl)SEGSGSSLVQK  TFG1 22.6 VK(gl)DEDPNEYNEFPLR 
RPC53 47.5 PAVK(gl)EEK(gl)EDMETQASDPSK  TIF6 23.1 NSLPDSVK(gl)IQR 
RPC53 28.6 VK(gl)LEEESK  TOA1 68.8 IEVK(gl)PEIELTINNANITTVENIDDESEK 
RPL13A 48.4 GFTLAEVK(gl)AAGLTAAYAR  TOP1 24.1 AK(gl)EEEEEYK 
RPL16B 25.1 YEDVVAK(gl)LEDK  TOP2 23.3 TPSVSETK(gl)TEEEENAPSSTSSSSIFDIK(gl)
KEDK RPL18A 55.3 ALK(gl)QEGAANK  TRI1 30.5 EIK(gl)LENESLPNLSG 
RPL18A 33.7 APK(gl)GQNTLILR  TUP1 30.2 LQNQK(gl)DYDFK 
RPL18A 66.8 VVLK(gl)ALFLSK  TYE7 20.6 LQQIIPWVASEQTAFEVGDSVK(gl)K 
RPL25 46.9 LDSYK(gl)VIEQPITSETAMK  UBA2 33.4 IK(gl)QETNELYELQK 
RPL7A 31.5 VTK(gl)ATLELLK  UBC9 72.0 KVLLQAK(gl)QYSK 
RPS0B 39.1 TWEK(gl)LVLAAR  UBC9 67.4 VLLQAK(gl)QYSK 
RPS10A 25.4 HEEIDTK(gl)NLYVIK  UBI1 58.8 LIFAGK(gl)QLEDGR 
RPS21 37.6 ADDHASVQINVAK(gl)VDEEGR  UBI1 49.1 TLSDYNIQK(gl)ESTLHLVLR 
RPS3 39.2 ALPDAVTIIEPK(gl)EEEPILAPSVK  ULP2 27.5 TQIK(gl)MK 
RPS8A 42.1 NVK(gl)EEETVAK  UTP8 25.1 QEMK(gl)K(gl)LSK 
RPS9B 25.2 DLLTRDEK(gl)DPK  VAC14 21.7 K(gl)ADGALIAEK 
RRP9 27.7 LK(gl)YAK(gl)GGAK  VMA10 25.8 QAK(gl)TDAAK 
RSC1 27.7 IK(gl)NILK  VPS45 21.5 YYK(gl)LK 
RSC8 51.1 LENNGNSVK(gl)K  VPS70 34.2 K(gl)NIDIEDK 
RSM23 22.2 DYK(gl)FSNANPK  VPS72 40.2 VNSDELK(gl)PTALPDVTLDAIANK 
RTT107 24.7 ASFPVVDSK(gl)K  YAP5 21.4 QK(gl)LETLTLK 
RVB1 64.6 K(gl)EIVVNDVNEAK  YDL156W 58.4 LSDLIK(gl)DEDESALLEK 
SCC2 26.5 K(gl)SEIVSRPEAK  YDR109C 24.3 K(gl)VRSVISLAK 
SEF1 26.7 DSK(gl)VSVQTYLSR  YDR333C 23.9 K(gl)TDILK 
SHS1 43.6 EIK(gl)QENENLIR  YHR031C 20.8 MK(gl)EIYK 
SHS1 35.9 SIK(gl)TESSPK  YHR097C 26.4 TSVPVTATQGSGHEDVVK(gl)K 
SIP2 24.4 AK(gl)EASGGPSEIK  YIL161W 26.4 NGNK(gl)K 
SIR3 29.1 IK(gl)IEPSADDDVNNGNIPSQR  YLR247C 31.3 K(gl)LEEADDK 
SIR4 21.1 K(gl)TIQNPLNK  YLR255C 28.2 PYSSGNK(gl)K 
SKO1 33.1 DTNVVK(gl)SENAGYPSVNSRPIILDK  YMR111C 27.9 IK(gl)PEPGLSDFENGEYDGNESDENATTR 
SLH1 22.4 EEESK(gl)ELK  YOR114W 23.0 K(gl)LQVWRAK 
SMC1 30.5 K(gl)ELEQK  YPR089W 27.2 FLNNK(gl)IK 
SMC5 53.2 LDDIVSK(gl)ISAR  YRR1 32.0 YLK(gl)LTR 
SOD1 28.4 GDAGVSGVVK(gl)FEQASESEPTTVSYEIAGNSPNAER  ZEO1 28.4 NEATPEAEQVK(gl)K(gl)EEQNIADGVEQK 
SOD1 43.3 K(gl)THGAPTDEVR     
SPP41 25.6 GVTTPIK(gl)IEDSDANVPPVSIAVSTIEPSQDK     
SPP41 64.1 RPQIK(gl)PEVSVINLVQNLVNTK     
SPT15 20.9 DGTK(gl)PATTFQSEEDIKR     
SPT7 25.1 QK(gl)IEQNSIMK     
SSM4 31.3 LSPK(gl)DLK     
STP1 31.0 IK(gl)SEVNAK     
SUM1 21.4 IK(gl)NEIPINSLLPSSK     
SWA2 41.7 YLEILK(gl)SK     
SWR1 43.1 AGGEQDLADLK(gl)FR     
SXM1 20.1 NK(gl)IHR     
TAF14 74.3 TGSASTVK(gl)GSVDLEK     
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Table 9. Sumo-acceptor lysines detected by SILAC-based mass spectrometry under MMS-induced 
DNA damage (0.05%MMS). Database-matched with Andromeda. 
 
GENE SCORE SEQUENCE  GENE SCORE SEQUENCE 
ABD1 96.7 NISPIIK(gl)IR  IES4 138.7 QRGSEFTASDVK(gl)GSDDK ABF1 130.6 MDK(gl)IVVNYYEYK  INO80 146.0 SIAVIINKEDK(gl)DISDFSK ABF1 141.5 QQGVTIK(gl)NDTEDDSINK  ISW1 106.7 DIISPLLLNPTK(gl)R ABF1 158.9 VSNDSK(gl)LDFVTDDLEYHLANTHPDD
TNDKVESR 
 ISW1 151.1 AK(gl)IEDTSNVGTEQLVAEK ADH1 81.7 VLGIDGGEGK(gl)EELFR  LIF1 142.4 ISNQSVIK(gl)MEDDDFDDFQFFGLSK AOS1 94.7 SIIEVTTRKDEEDEK(gl)K  MAG1 93.1 IK(gl)REYDEIIK AOS1 126.2 MDMK(gl)VEKISEDEIAIYDRQIR  MCD1 73.7 TRNEQTTIQTEK(gl)VRPTPGEVASK ASG1 99.4 IISNIK(gl)TER  MCD1 145.3 ELSEEK(gl)EVIFTDVLK ATG2 98.0 DEPVSQK(gl)ISK  MET12 98.0 MEMLRNTGLEK(gl) BDP1 111.0 ARQEFK(gl)PLHSLTKEEQEEEEEK  MET28 137.6 VAATTAVVVK(gl)EEEAPVSTSNELDK BDP1 113.7 KGSGGIMTNDLK(gl)VYR  MET4 61.5 MK(gl)QEQSHEGDSYSTEFINIFGK BDP1 128.7 DK(gl)LLNADIPESDRK  MLP1 155.9 KIK(gl)TEDEEEKETDK BDP1 176.8 NTAK(gl)EEDQTAQRLNDANLNK  MLP2 176.1 RVK(gl)EEYDIWQSRDQGNDSLNDDLNK BIR1 117.1 VIK(gl)PEFEPVPSVAR  MPP10 134.3 VK(gl)LDLFADEEDEPNAEGVGEASDK BIR1 164.8 ILEDVSVK(gl)NETPNNEMLLFETGTPIA
SQENK 
 MRP8 176.6 EFK(gl)DIPDLK BOP3 311.9 IGASAVAALNDNISIK(gl)EEDVAR  MSP1 78.2 GFSGSDIK(gl)EICREAAIDAAK BRE1 106.0 KIK(gl)LELSDPSEPLTQSDVIAFQK  MZM1 121.7 K(gl)VDGSSTKEPR BUD3 126.8 NK(gl)QENINSSSNLFPEGK  NCB2 148.6 SRLHHNSVSDPVK(gl)SEDSS CBF2 118.4 FIRDNQPIK(gl)KEENIVNEDGPNTSR  NET1 90.2 DIDNSK(gl)PDPR CBF5 162.8 SKEDFVIK(gl)PEAAGASTDTSEWPIIIK  NET1 94.4 ISEIEK(gl)ELKEGPSSPASILPAK CDC11 187.6 EAKIK(gl)QEE  NET1 125.7 NEIDLDDSAPVSLYK(gl)SVK CDC12 74.5 IFTPPIDADSK(gl)EDAK  NET1 133.7 K(gl)IKSSIVEEDIVSR CDC12 167.7 IRLNGDLEEIQGK(gl)VK  NET1 143.4 KIK(gl)SSIVEEDIVSR CDC3 79.5 GQVLPDQPEIK(gl)FIR  NET1 157.6 NESAQIDRQQK(gl)ETTSR CDC3 201.3 FEAAESDVK(gl)VEPGIGMGITSSQSEK
GQVIPDQPEIK 
 NET1 164.7 K(gl)VRPSLSSLSDLVSR CDC3 216.0 SIKEEQVSIK(gl)QDPEQEERQHDQFND
VQIK 
 NET1 170.7 K(gl)SQAEPSGIVEPK CDC48 223.1 EVK(gl)VEGEDVEMTDEGAKAEQEPEVD
PVPYITK 
 NET1 207.4 VADLK(gl)SANIGGEDLNK CET1 100.9 KIAGNAVGSVVK(gl)KEEEANAAVDNIF
EEK 
 NET1 257.0 SDLFK(gl)MIEGDDTDLPQWFK CIN5 155.2 MTDTAFVPSPPVGFIK(gl)EENK  NOP12 115.2 LLNEEAEAEDDK(gl)PTVTKTDETSVPLTSAAK CMR1 141.5 LSDLIK(gl)DEDESALLEK  NOP12 172.9 SSAIDNIFGNIDEK(gl)KIESSVDK CMR1 241.8 IFLFTDDSGTIK(gl)QEE  NOP14 87.6 IAVGK(gl)PGISK CRZ1 196.8 IESGIVNIK(gl)NELDDTSK  NOP56 80.4 IEFYNTGKPTIK(gl)NEIAIQEAMEIYNK DAD3 121.8 MEHNISPIQQEVIDK(gl)YK  NOP7 80.8 QEDSLLKLDPTEIEEDVK(gl)VESLDASTLK DEP1 247.3 LSSLVK(gl)QETLTESLK  NSR1 153.1 LSWSIDDEWLK(gl)K DUN1 96.0 IVFGK(gl)SCSFIFK  NTG1 108.6 IK(gl)QEEVVPQPVDIDWVK EBP2 166.0 SQELKK(gl)EEPTIVTASNLK  NTG1 153.2 RPLVK(gl)TETGPESELLPEK FBA1 131.9 DYIMSPVGNPEGPEK(gl)PNK  PAA1 200.5 ELIK(gl)EEYDN FLP1 120.9 EMIALK(gl)DETNPIEEWQHIEQLK  PDC1 100.9 LTQDK(gl)SFNDNSK GCN4 140.9 FIK(gl)TEEDPIIKQDTPSNLDFDFALPQT
ATAPDAK 
 PGK1 130.0 VLENTEIGDSIFDK(gl)AGAEIVPK GCN4 140.9 TEEDPII (gl)QDTPSNLDFDFALPQTAT
APDAK 
 PGK1 172.9 VK(gl)ASKEDVQK GCN5 156.7 VK(gl)LENNVEEIQPEQAETNKQEGTDK  POB3 145.6 KEESSNEVVPKK(gl)EDGAEGEDVQMAVEEK GPD1 203.5 PFK(gl)VTVIGSGNWGTTIAK  POL30 226.8 LMDIDADFLK(gl)IEELQYDSTLSLPSSEFSK GPM1 92.3 GLVK(gl)HLEGISDADIAK  POL30 278.4 IVRDLSQLSDSINIMITK(gl)ETIK GSH1 99.8 ASGEIPTTAK(gl)FFR  PRE2 113.2 VK(gl)EEEGSFNNVIG GZF3 96.4 AISNVK(gl)TETTPPHFIPFLQSSK  PRP45 131.1 K(gl)QTSTVAR HAP1 110.4 VK(gl)QESSDELKK  PRP45 132.6 LDEAVNVK(gl)SEGASGSHGPIQFTK HDA1 103.8 MDSVMVK(gl)KEVIENPDHDIK  PTA1 129.1 KIK(gl)METEPLAEEPEEPEDDDRMQK HHF1 167.3 K(gl)ILRDNIQGITKPAIR  RAD52 171.9 NLVK(gl)IENTVSR HHT1 112.8 YK(gl)PGTVAIR  RAD59 143.0 NEANTNYNLLSATNSKPTFIK(gl)LEDAK HHT1 119.8 STGGK(gl)APRK  REB1 268.9 ELVDYFSSNISMK(gl)TEN HHT1 129.7 RFQK(gl)STELLIR  REP2 128.6 NLTVK(gl)AR HMO1 166.5 TTDPSVK(gl)LK  REP2 252.2 MDDIETAK(gl)NITVK HPC2 285.9 MQTQTDTNAEVLNTDNSIK(gl)K  RHR2 168.7 TYDAIAK(gl)FAPDFADEEYVNKLEGEIPEK HSC82 131.1 KPK(gl)LEEVDEEEEEK  RLP7 131.2 SSTQDSK(gl)AQTINSNPEIIIRK HSP82 79.6 KVK(gl)EEVQEIEEINK  RNR2 99.0 DSK(gl)SNLNK HTA1 133.6 ATK(gl)ASQEL  RNR2 229.8 STK(gl)QEAGAFTFNEDF HTA2 127.1 TAK(gl)ASQEL  RPA34 81.8 VEGLK(gl)LEHFATGYDAEDFHVAEEVK HTB1 177.8 AVTK(gl)YSSSTQA  RPB4 151.0 HLK(gl)HENANDETTAVEDEDDDLDEDDVNADDD
DFMHSETREK HTB2 137.0 KPASK(gl)APAEK  RPC53 236.3 VK(gl)L EES  HTB2 175.2 SSAAEK(gl)KPASK  RPC53 266.4 RGFIK(gl)SEGSGSSLVQK 
HTB2 177.8 AVTK(gl)YSSSTQA  RPC82 99.5 KLK(gl)TEDGFVIPALPAAVSK 
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RPL18B 124.2 VVLK(gl)ALFLSK  SSE1 88.3 GK(gl)LEEEYAPFASDAEK RPL20A 107.6 DIK(gl)FPIPHR  STB3 95.8 EVSPPQAISVK(gl)SEASSSIFSKPISTSSPAGLAAA
QR RPL25 108.4 AVK(gl)ELYEVDVLK  STH1 71.3 VFREDIEEHFK(gl)KEDSEPIGR RPL34A 155.1 AFLIEEQK(gl)IVK  STP1 122.5 IK(gl)SEVNAK RPL4B 171.9 LNPYAK(gl)VFAAEK  SUM1 216.9 SDASNRIK(gl)NEIPINSLLPSSK RPL8B 92.5 LVSTIDANFADK(gl)YDEVKK  SWI3 151.3 IQKEEEPENNTVIEGVK(gl)EESQPDENTK RPL8B 177.6 NFGIGQAVQPK(gl)R  TAF14 218.1 TGSASTVK(gl)GSVDLEK RPP1B 130.3 ALEGK(gl)DLK  TDH2 104.2 VVDLVEHVAK(gl)A RPP2A 128.8 VSSVLSALEGK(gl)SVDELITEGNEK  TFG1 103.2 ENESPVK(gl)KEEDSDTLSK RPS0 161.2 TWEK(gl)LVLAAR  TFG1 112.9 AVDSSNNASNTVPSPIK(gl)QEEGLNSTVAEREETP
APTITEK RPS10
A 
162.7 HEEIDTK(gl)NLYVIK  TFG1 150.1 GSLVK(gl)KDDPEYAEEREK RPS17
B 
170.5 YYPK(gl)LTLDFQTNK  TFG1 189.1 K(gl)DDPEYAEEREK RPS1B 108.7 VSGFK(gl)DEVLETV  TFG1 199.1 VK(gl)DEDPNEYNEFPLRAIPK RPS20 139.5 RYIDLEAPVQIVK(gl)R  TIF463
1 
97.6 SAEPEVK(gl)QETPAEEGEQGEK 
RPS20 191.4 SDFQK(gl)EKVEEQEQQQQQIIK  TOF2 99.8 LHQSQGK(gl)EALFR RPS24
B 
99.3 TQFGGGK(gl)SVGFGLVYNSVAEAK  TOF2 105.9 LVEKEFPDK(gl)SLGAASSTSHAK RPS28
B 
195.3 MDSK(gl)TPVTIAK  TOF2 128.8 FKPTGETK(gl)VQK RPS3 176.9 ALPDAVTIIEPK(gl)EEEPILAPSVK  TOP1 197.3 KIK(gl)KEDGDVK RPS31 133.3 TLSDYNIQK(gl)ESTLHLVLR  TOP2 79.2 TEEEENAPSSTSSSSIFDIK(gl)KEDKDEGELSK RPS31 133.3 LIFAGK(gl)QLEDGRTLSDYNIQK  TOP2 88.7 IK(gl)IEDKNFER RPS8B 170.5 NVK(gl)EEETVAK  TRI1 72.0 VIIPK(gl)NDIISRDQEISIR RPS9A 77.7 DIITRDEK(gl)DPK  TRI1 78.4 HLFNPDEIVK(gl)HEEEQKQTPEK RPT6 90.1 K(gl)IEFPPPSVAAR  TRI1 185.3 VLLSAPLQK(gl)FLGSEELPR RRG9 133.6 RIIK(gl)SNWKR  TRI1 193.7 EIK(gl)LENESLPNLSG RRP9 179.1 ERTIDEYNNFDAGDLDK(gl)DIIASR  TRX1 150.7 FSEQYPQADFYK(gl)LDVDELGDVAQK RSC2 159.7 TSVK(gl)RESEPGTDTNNDEDYEATDMD
IDNPK 
 TUP1 119.7 APESTLK(gl)ETEPENNNTSK RSC58 203.3 KVK(gl)QEELLNTNEEGINRK  TUP1 155.1 DAYEEEIK(gl)HLK RSC8 123.4 PFLPENVIK(gl)QEVEGGDGAEPQVKK  TUP1 163.6 LQNQK(gl)DYDFK RTF1 140.3 NAEHVK(gl)KEDSNNFDSK  TYE7 185.3 SSETTLIK(gl)PESEFDNWLSDENDGASHINVNK SDC1 204.5 SVTNQNVK(gl)IEESSSTNSVIEESSEPK  UBA2 109.0 SHIFNIPMK(gl)SVFDIK SHS1 91.6 SIK(gl)TESSPK  UBA2 127.4 LLAIENLWK(gl)TR SHS1 95.4 FLNSPDLPERTK(gl)LR  UBA2 151.7 RIK(gl)QETNELYELQK SHS1 192.1 EIK(gl)QENENLIR  UBC9 200.1 VLLQAK(gl)QYSK SIR4 151.5 APFIK(gl)SESKPFSSDALSK  UME1 136.3 STIDIAEDNKIK(gl)NEEFK SIZ1 94.4 VIPEYLGNSSSYIGK(gl)QLPNILGK  UME6 130.3 DREITDPNVK(gl)LDENESK SIZ1 119.6 STNTDILTEK(gl)GSSAPSR  VBA5 108.5 AENK(gl)GIIQQIK SIZ1 131.6 NFLQNALVVGK(gl)SDPYRVQAVK  VHR1 207.7 NLFNIINK(gl)NK SIZ1 208.1 TLDPK(gl)SYNIVASETTTPVTNR  VIP1 199.7 SGIK(gl)KEPIESDEVPQQETK SKO1 225.5 DTNVVK(gl)SENAGYPSVNSRPIILDK  VMA1 103.4 AIK(gl)EESQSIYIPR SLI15 133.1 NNVYMNTLK(gl)YEDK  VPS16 85.1 VTISSRGFICIYNMKDNK(gl)IQIFR SOD1 156.6 K(gl)THGAPTDEVRHVGDMGNVK  VPS3 143.6 K(gl)TEDDSLR SPA2 116.5 TIK(gl)REEEDEDFDRVNHNIQITGAYTK  YLR455
W 
116.5 NSISIK(gl)EDPEDNQK 
SPC24 96.3 LLK(gl)DLDGLER  YSH1 127.6 IEPIK(gl)EENEDNLDSQAEK SPP41 110.8 GVTTPIK(gl)IEDSDANVPPVSIAVSTIEP
SQDKLELTK 
 YTA7 165.5 VGYETQIK(gl)DENGIIHTTTR SPP41 129.0 ILSRPK(gl)SEDHEWPLSDSSASQNYDA
HLK 
 ZEO1 109.0 AETAAQDVQQK(gl)LEETK SPP41 135.4 VK(gl)QQLDK  ZEO1 138.8 NEATPEAEQVK(gl)KEEQNIADGVEQK SPP41 174.2 IPEIK(gl)NESVDLGSNITDILSSTITNILP
EITATDVK 
    SPP41 196.7 RPQIK(gl)PEVSVINLVQNLVNTK     SPT15 151.3 PATTFQSEEDIK(gl)R     
 
 
 
 
 
 
. 
. 
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Table 10. Summary of all sumo-acceptor lysines detected by mass spectrometry. 
 
   Gene Andro. 
Score 
Mascot 
Score 
Modified Sequence sumo-site 
 mms  ABD1 97  NISPIIK(gl)IR No Consensus 
 mms oxi ABF1 163  MDK(gl)IVVNYYEYK No Consensus 
non mms oxi ABF1 160 45 QQGVTIK(gl)NDTEDDSINK Core Consen. 
non mms oxi ABF1 159 73 VSNDSK(gl)LDFVTDDLEYHLANTHPDDTNDK Inverse Consen. 
non   ADE1  81 SITK(gl)TELDGILPLVAR No Consensus 
non   AIM44  46 LNMEK(gl)DIK No Consensus 
non   ALY2 149 36 FAPLDK(gl)VTLHR No Consensus 
 mms  AOS1 126 27 MDMK(gl)VEKISEDEIAIYDRQIR Inverse Consen. 
 mms  AOS1 95  SIIEVTTRKDEEDEK(gl)K No Consensus 
non   AOS1 157 41 VEK(gl)LSEDEIALYDR No Consensus 
  oxi APA1 167  ALTFFQDWLNENPELK(gl)K No Consensus 
  oxi APC5 109  K(gl)K(gl)TDELLESLSVEEDR No Consensus 
non  oxi ARP7 79 24 LAPLIK(gl)EENDMENMADEQK Core Consen. 
non mms  ARP8  26 LTK(gl)EIKDLEGHYVNAPDK No Consensus 
 mms oxi ASG1 161  LLSNIK(gl)TER Core Consen. 
 mms  ATG2 98  DEPVSQK(gl)ISK No Consensus 
 mms  BAF1  49 QQGVTIK(gl)NDTEDDSINK Core Consen. 
 mms  BDP1 111 34 ARQEFK(gl)PLHSLTKEEQEEEEEK Inverse Consen. 
non mms  BDP1 129 31 DK(gl)LLNADIPESDRK No Consensus 
non   BDP1  41 K(gl)AHTAIQLK No Consensus 
  oxi BDP1 186  K(gl)TEVVLGTIDDLK No Consensus 
 mms oxi BDP1 160 46 KGSGGIMTNDLK(gl)VYR Inverse Consen. 
 mms oxi BDP1 153 62 NTAK(gl)EEDQTAQR No Consensus 
  oxi BFR2 93   SIADQISDIAIK(gl)PVNK No Consensus 
  oxi BIR1 177   EISGIK(gl)KETDDGK Core Consen. 
 mms oxi BIR1 165 25 ILEDVSVK(gl)NETPNNEMLLFETGTPIASQENK Core Consen. 
non mms oxi BIR1 140 41 VIK(gl)PEFEPVPSVAR Core Consen. 
  oxi BMH2 162   IVSSIEQK(gl)EESKEK No Consensus 
non mms  BNI1  32 K(gl)LDEINR No Consensus 
non mms oxi BOP3 312 103 IGASAVAALNDNISIK(gl)EEDVAR Core Consen. 
 mms  BRE1 106 49 KIK(gl)LELSDPSEPLTQSDVIAFQK Phospho Consen. 
non   BRX1  28 AEAAVERK(gl)IK Inverse Consen. 
  oxi BSP1 145  NIK(gl)KEEEDSIPEAIK Acidic Consen. 
non   BUD27 104  LEDFK(gl)EYNK No Consensus 
non mms  BUD3 186 41 FFEIEEELK(gl)EELK Core Consen. 
non mms  BUD3 127 34 NK(gl)QENINSSSNLFPEGK No Consensus 
non mms  BUD3 87 24 TGNEDVGNNNPSNSIPK(gl)IEKPPAFK Core Consen. 
  oxi BUD4 109  AGNK(gl)QENNEINIKAEEEIEPMTQQETDGLK No Consensus 
  oxi BUD4 149  QENNEINIK(gl)AEEEIEPMTQQETDGIK Acidic Consen. 
 mms oxi CBF2 103 40 DNQPIK(gl)KEENIVNEDGPNTSR Core Consen. 
non mms  CBF5 137 43 EDFVIK(gl)PEAAGASTDTSEWPLLLK Core Consen. 
non   CBF5  47 VNENTPEQWK(gl)K No Consensus 
non mms  CDC11 188 31 EAKIK(gl)QEE Core Consen. 
 mms  CDC12 168  IRLNGDLEEIQGK(gl)VK No Consensus 
non   CDC12 131 33 K(gl)YFTDQVK No Consensus 
non   CDC12 94 28 YK(gl)EEENALK No Consensus 
  oxi CDC19 105  IIVK(gl)IENQQGVNNFDEILK Core Consen. 
non mms  CDC3 208 81 FEAAESDVK(gl)VEPGLGMGITSSQSEK Inverse Consen. 
non   CDC3 172 80 KLQK(gl)SETELFAR No Consensus 
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non mms  CDC3  45 SLK(gl)EEQVSIK Phospho Consen. 
non mms oxi CDC3 312 74 SLKEEQVSIK(gl)QDPEQEER Core Consen. 
non mms oxi CDC48 237 54 EVK(gl)VEGEDVEMTDEGAK Inverse Consen. 
 mms oxi CET1 101 47 KIAGNAVGSVVK(gl)KEEEANAAVDNIFEEK Acidic Consen. 
non mms  CIN5 156 68 MTDTAFVPSPPVGFIK(gl)EENK Core Consen. 
  oxi CMD1 114  SSNITEEQIAEFK(gl)EAFAIFDK No Consensus 
non mms oxi CMR1 245 54 IFIFTDDSGTIK(gl)QEE Core Consen. 
non mms oxi CMR1 178 58 LSDLIK(gl)DEDESALLEK Acidic Consen. 
non mms oxi CRZ1 352 95 IESGIVNIK(gl)NELDDTSK Core Consen. 
non   CRZ1 108  PK(gl)IESGIVNIK Core Consen. 
 mms  CWC15  22 NK(gl)VEDK No Consensus 
non   CYC8  29 QPTHAIPTQAPATGITNAEPQVK(gl)K No Consensus 
 mms  DAD3 122  MEHNISPIQQEVIDK(gl)YK No Consensus 
non mms oxi DEP1 296 58 LSSLVK(gl)QETLTESLK Core Consen. 
 mms  DUN1 96  IVFGK(gl)SCSFIFK No Consensus 
non   EAF7 113  EVK(gl)FEDEEK Acidic Consen. 
 mms oxi EBP2 212 53 SQELK(gl)KEEPTIVTASNLK Core Consen. 
 mms  ENO2 86 26 IEEELGDK(gl)AVYAGENFHHGDKL No Consensus 
 mms  ERG10  32 AGAK(gl)FGQTVLVDGVER No Consensus 
  oxi ESC1 68  VNEGEEPEHQAVDIPVKVEVK(gl)EEQEEMPSK Core Consen. 
 mms oxi FBA1 132  DYIMSPVGNPEGPEK(gl)PNK No Consensus 
  oxi FHL1 148  HPQNTTTDIENEVENPVTDDNGNLK(gl)LELPDNLDNADFSK Core Consen. 
non mms oxi FLP1 121 25 EMIALK(gl)DETNPIEEWQHIEQLK Core Consen. 
non   GCN2 101  LMIDSPHLK(gl)K No Consensus 
non mms oxi GCN4 150 38 FIK(gl)TEEDPIIK Acidic Consen. 
 mms oxi GCN4 141  TEEDPIIK(gl)QDTPSNLDFDFALPQTATAPDAK Phospho Consen. 
non mms oxi GCN5 201 75 VK(gl)LENNVEEIQPEQAETNKQEGTDK Core Consen. 
 mms  GPD1 204  PFK(gl)VTVIGSGNWGTTIAK No Consensus 
 mms  GPM1 92  GLVK(gl)HLEGISDADIAK No Consensus 
 mms  GSH1 100  ASGEIPTTAK(gl)FFR No Consensus 
non mms oxi GZF3 126 24 AISNVK(gl)TETTPPHFIPFLQSSK Core Consen. 
  oxi HAA1 129  IGSQENSVK(gl)QENYSK Phospho Consen. 
non mms oxi HAP1 110 28 VK(gl)QESSDELKK Phospho Consen. 
non mms  HDA1 104 41 MDSVMVK(gl)K Core Consen. 
 mms  HHF1 167 36 K(gl)ILRDNIQGITKPAIR No Consensus 
 mms  HHT1 130 47 RFQK(gl)STELLIR No Consensus 
 mms  HHT1 120 33 STGGK(gl)APRK No Consensus 
 mms  HHT1 113  YK(gl)PGTVAIR No Consensus 
non   HMO1 124 30 DAIIAAPVK(gl)AVR No Consensus 
non mms oxi HMO1 174 43 TTDPSVK(gl)IK No Consensus 
  oxi HMS1 153  DSSLLSAASIVK(gl)KEQLSGFENFLPLSK Phospho Consen. 
non mms oxi HPC2 286 37 MQTQTDTNAEVLNTDNSIK(gl)K Phospho Consen. 
 mms oxi HSC82 252 30 KPK(gl)IEEVDEEEEEK Core Consen. 
non mms oxi HTA1/2 134 36 ATK(gl)ASQEL No Consensus 
non mms oxi HTB1/2 178 42 AVTK(gl)YSSSTQA No Consensus 
 mms  HTB1/2 137  KPASK(gl)APAEK No Consensus 
 mms  HTB2 175  SSAAEK(gl)KPASK No Consensus 
non mms  IES4 163 32 EPADEDPEVK(gl)QLEK No Consensus 
 mms oxi IES4 214  GSEFTASDVK(gl)GSDDK No Consensus 
  oxi IES4 117  K(gl)KEPADEDPEVK No Consensus 
 mms  IES4  76 SQESSVLSESQEQLANNPK(gl)IEDTSPPSANSR Phospho Consen. 
 mms  IKI1  30 DIK(gl)DENR Core Consen. 
 mms oxi INO80 146  SIAVIINKEDK(gl)DISDFSK No Consensus 
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 mms  IRC20  31 K(gl)LEEADDK No Consensus 
non mms oxi ISW1 151 51 AK(gl)IEDTSNVGTEQLVAEK No Consensus 
non mms oxi ISW1 160 30 DIISPLLLNPTK(gl)R No Consensus 
non   ISW1  20 LK(gl)EEGSR Phospho Consen. 
non   KAP123 106 25 TSLLQTAFSEPK(gl)ENVR No Consensus 
non   KRR1 105 28 DFIAPEEEAYK(gl)PNQN No Consensus 
 mms oxi LIF1 147  ISNQSVIK(gl)MEDDDFDDFQFFGISK Acidic Consen. 
 mms  MAG1 93  IK(gl)REYDEIIK Core Consen. 
non mms  MCD1 145 20 ELSEEK(gl)EVIFTDVLK No Consensus 
  oxi MCM1 58  QQPQQQQPQQQQQVINAHANSIGHINQDQVPAGAIK(gl)QEVK Phospho Consen. 
 mms  MET12 98  MEMLRNTGLEK(gl) No Consensus 
 mms oxi MET28 223 52 VAATTAVVVK(gl)EEEAPVSTSNEIDK Core Consen. 
 mms  MET4 61  MK(gl)QEQSHEGDSYSTEFINIFGK No Consensus 
non   MGA2 97 27 ALK(gl)EEEEDEHENK Acidic Consen. 
 mms  MLP1 156 26 KIK(gl)TEDEEEKETDK Acidic Consen. 
non mms  MLP2 155 55 RVK(gl)EEYDIWQSR Core Consen. 
 mms  MPP10 134  VK(gl)LDLFADEEDEPNAEGVGEASDK Core Consen. 
non mms oxi MRP8 177 40 EFK(gl)DIPDLK No Consensus 
non mms  MRPL11  43 IK(gl)QTGGKLTK No Consensus 
 mms  MRPL22  33 SSMK(gl)KATLLLR No Consensus 
 mms  MZM1 122  K(gl)VDGSSTKEPR No Consensus 
non mms oxi NCB2 176 56 LHHNSVSDPVK(gl)SEDSS Phospho Consen. 
 mms  NET1 90  DIDNSK(gl)PDPR No Consensus 
 mms oxi NET1 182  EKEDTNDK(gl)LLEK No Consensus 
non mms  NET1 149 21 IK(gl)SSIVEEDIVSR No Consensus 
 mms  NET1 94  ISEIEK(gl)ELKEGPSSPASILPAK No Consensus 
 mms  NET1 134 36 K(gl)IKSSIVEEDIVSR No Consensus 
 mms  NET1 171 48 K(gl)SQAEPSGIVEPK No Consensus 
 mms  NET1 165  K(gl)VRPSLSSLSDLVSR No Consensus 
 mms  NET1 126  NEIDLDDSAPVSLYK(gl)SVK No Consensus 
 mms  NET1 158  NESAQIDRQQK(gl)ETTSR No Consensus 
non mms oxi NET1 257 37 SDLFK(gl)MIEGDDTDLPQWFK No Consensus 
  oxi NET1 121  SQAEPSGIVEPK(gl)R No Consensus 
non mms  NET1 207 31 VADLK(gl)SANIGGEDLNK No Consensus 
non mms oxi NFI1 157 40 NENQGTVK(gl)QEQDYDSR Core Consen. 
  oxi NHP10 213  KISNIDADDDKEENEQK(gl)IK Inverse Consen. 
  oxi NHP10 132  VADSK(gl)GGEDGSIVSSN No Consensus 
non mms oxi NOP12 126 49 LLNEEAEAEDDK(gl)PTVTK Inverse Consen. 
non mms oxi NOP12 173 29 SSAIDNIFGNIDEK(gl)KIESSVDK No Consensus 
non mms  NOP56 183  PTLK(gl)NELAIQEAMELYNK Core Consen. 
non mms oxi NOP7 122 35 LDPTEIEEDVK(gl)VESLDASTLK Inverse Consen. 
non mms  NSR1 153  LSWSIDDEWLK(gl)K Core Consen. 
 mms oxi NTG1 109  IK(gl)QEEVVPQPVDIDWVK Core Consen. 
non   NTG1 146 42 LENDISVK(gl)VED Core Consen. 
 mms oxi NTG1 166 40 RPLVK(gl)TETGPESELLPEK Core Consen. 
non   NUM1  18 ESLSDK(gl)IEELTNQKK No Consensus 
non mms oxi PAA1 231 32 ELIK(gl)EEYDN Core Consen. 
 mms oxi PDC1 142  LTQDK(gl)SFNDNSK No Consensus 
 mms  PDR1  27 TSLEGTTVQVK(gl)EETDSSSTSFSNPQR Phospho Consen. 
non   PGI1 178 33 TLSVK(gl)QEFQK Core Consen. 
non mms oxi PGK1 173 27 VK(gl)ASKEDVQK No Consensus 
 mms  PGK1 130 33 VLENTEIGDSIFDK(gl)AGAEIVPK No Consensus 
non mms oxi POB3 127 41 KEESSNEVVPK(gl)KEDGAEGEDVQMAVEEK Core Consen. 
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non mms oxi POL30 255 91 DLSQLSDSINIMITK(gl)ETIK No Consensus 
non mms oxi POL30 227 50 LMDIDADFLK(gl)IEELQYDSTLSLPSSEFSK Core Consen. 
non mms oxi PRE2 113 63 VK(gl)EEEGSFNNVIG Phospho Consen. 
non   PRP45 143 42 DVSEK(gl)IILGAAK No Consensus 
 mms  PRP45 131 34 K(gl)QTSTVAR No Consensus 
non mms oxi PRP45 157 81 LDEAVNVK(gl)SEGASGSHGPIQFTK Phospho Consen. 
 mms  PTA1 129  KIK(gl)METEPLAEEPEEPEDDDRMQK Core Consen. 
non   PUS1 108  K(gl)ADFDDEK(gl)DKK No Consensus 
non   RAD16 127 36 NDNDEIIEIK(gl)EER Core Consen. 
  oxi RAD52 88  K(gl)PVFGNHSEDIQTKLDK Inverse Consen. 
non mms oxi RAD52 172 48 NLVK(gl)IENTVSR Core Consen. 
 mms oxi RAD59 143 45 NEANTNYNLLSATNSKPTFIK(gl)LEDAK Core Consen. 
non mms  RAP1 170 79 DSIRPK(gl)TEIISTNTNGATEDSTSEK Phospho Consen. 
  oxi RBA50 133  DVHFIK(gl)EESQNEINIEKIDINDPNFNDK Core Consen. 
 mms  REB1 92 30 AIIDADSITQHPDFQQYINTAADTDDNEK(gl)IK No Consensus 
non mms oxi REB1 269 59 ELVDYFSSNISMK(gl)TEN No Consensus 
 mms  REH1 98  KGMK(gl)KMQQIEK No Consensus 
non   REP2 184 43 GAYK(gl)LQNTITEGPK No Consensus 
non mms oxi REP2 252 70 MDDIETAK(gl)NITVK No Consensus 
non mms  REP2 129 28 NLTVK(gl)AR No Consensus 
 mms oxi RHR2 169  TYDAIAK(gl)FAPDFADEEYVNKLEGEIPEK No Consensus 
 mms  RLP7 131  SSTQDSK(gl)AQTINSNPEIIIRK No Consensus 
 mms oxi RNR2 99 25 DSK(gl)SNLNK No Consensus 
non mms oxi RNR2 254 34 STK(gl)QEAGAFTFNEDF No Consensus 
 mms  RPA34 82  VEGLK(gl)LEHFATGYDAEDFHVAEEVK Core Consen. 
 mms oxi RPB4 151  HLK(gl)HENANDETTAVEDEDDDLDEDDVNADDDDFMHSETREK Core Consen. 
non  oxi RPC37 222  SEEVK(gl)AEDDTGEEEEDDPVIEEFPLK Acidic Consen. 
non   RPC37  44 SIDNK(gl)LFVTEEDEEDRTQDR Inverse Consen. 
non  oxi RPC53 123 54 EPTPSVK(gl)TEPVGTGLQSYLEER Core Consen. 
non mms oxi RPC53 235 83 GFIK(gl)SEGSGSSIVQK Phospho Consen. 
 mms oxi RPC53 173  LPAFERPAVKEEK(gl)EDMETQASDPSK No Consensus 
non   RPC53  62 MAK(gl)YLNNTHVISSGPLAAGNFVSEK No Consensus 
non mms oxi RPC53 181 47 PAVK(gl)EEKEDMETQASDPSK Core Consen. 
non mms oxi RPC53 236 39 VK(gl)LEEESK Acidic Consen. 
non mms oxi RPC82 167 63 LK(gl)TEDGFVIPALPAAVSK Core Consen. 
non   RPD3 122 31 DAEDLGDVEEDSAEAK(gl)DTK No Consensus 
non mms  RPL13A/B 135 46 GFTLAEVK(gl)AAGLTAAYAR No Consensus 
 mms  RPL18A  34 APK(gl)GQNTLILR No Consensus 
 mms  RPL18A/B 124 55 ALK(gl)QEGAANK Core Consen. 
non mms  RPL18A/B 138 67 VVLK(gl)ALFLSK No Consensus 
 mms  RPL20A 108  DIK(gl)FPIPHR No Consensus 
 mms  RPL20A  40 TADVK(gl)R No Consensus 
  oxi RPL25 122  APK(gl)YASK No Consensus 
non mms  RPL25 123 29 AVK(gl)ELYEVDVLK No Consensus 
non mms oxi RPL25 175 69 LDSYK(gl)VIEQPITSETAMK No Consensus 
non   RPL28 111 33 FVSK(gl)LAEEK No Consensus 
non   RPL28 124 46 IPNVPVIVK(gl)AR No Consensus 
non mms oxi RPL34A/B 155 49 AFLIEEQK(gl)IVK Inverse Consen. 
  oxi RPL35B 104  EQIASQIVDIK(gl)K Core Consen. 
non mms oxi RPL4A/B 182 53 LNPYAK(gl)VFAAEK No Consensus 
non   RPL5 133 37 VAAK(gl)IAALAGQQ No Consensus 
 mms  RPL7A  32 VTK(gl)ATLELLK No Consensus 
non mms oxi RPL8A/B 230 47 NFGIGQAVQPK(gl)R No Consensus 
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 mms  RPL8B 92  LVSTIDANFADK(gl)YDEVKK No Consensus 
non   RPO21 119  VDLLNTDHTLDPSLLESGSEILGDLK(gl)LQVLLDEEYK Inverse Consen. 
non mms  RPP1B 154 36 ALEGK(gl)DLK No Consensus 
 mms  RPP2A 129  VSSVLSALEGK(gl)SVDELITEGNEK No Consensus 
non mms oxi RPS0A/B 161 60 TWEK(gl)LVLAAR No Consensus 
non   RPS1 128 32 VSGFK(gl)DEVLETV No Consensus 
non mms oxi RPS10A 163 24 HEEIDTK(gl)NLYVIK No Consensus 
non   RPS13 118 33 K(gl)GLTPSQIGVLLR No Consensus 
non mms  RPS17A/B 99 21 GISFK(gl)LQEEER No Consensus 
non mms oxi RPS17A/B 171 41 YYPK(gl)ITIDFQTNK No Consensus 
 mms oxi RPS1A 136 26 VTGFK(gl)DEVLETV No Consensus 
 mms  RPS20 139  RYIDLEAPVQIVK(gl)R No Consensus 
 mms  RPS20 191  SDFQK(gl)EKVEEQEQQQQQIIK No Consensus 
  oxi RPS20 161  SDFQKEK(gl)VEEQEQQQQQIIK No Consensus 
non mms  RPS21A 115 35 ADDHASVQINVAK(gl)VDEEGR No Consensus 
 mms  RPS24A/B 99  TQFGGGK(gl)SVGFGIVYNSVAEAK No Consensus 
 mms  RPS28A/B 195  MDSK(gl)TPVTIAK No Consensus 
non mms oxi RPS3 177 61 ALPDAVTIIEPK(gl)EEEPILAPSVK Core Consen. 
non mms  RPS31 189 31 LIFAGK(gl)QLEDGR No Consensus 
 mms  RPS31 133  TLSDYNIQK(gl)ESTLHLVLR No Consensus 
non   RPS6A 89 24 K(gl)GEQELEGLTDTTVPK No Consensus 
non mms oxi RPS8A/B 170 42 NVK(gl)EEETVAK Core Consen. 
non   RPS9B 130  K(gl)AEASGEAAEEAEDEE No Consensus 
 mms  RPT6 90  K(gl)IEFPPPSVAAR Inverse Consen. 
  oxi RPT6 112  YGEPQK(gl)VVLK No Consensus 
 mms  RRG9 134  RIIK(gl)SNWKR No Consensus 
  oxi RRP15 142  IFNAIIATQVK(gl)TEK Core Consen. 
non mms  RRP9 179 79 TIDEYNNFDAGDLDK(gl)DIIASR No Consensus 
 mms oxi RSC2 160  TSVK(gl)RESEPGTDTNNDEDYEATDMDIDNPK Core Consen. 
non   RSC4 109  LIAKPETVQSEVK(gl)NER Phospho Consen. 
non mms oxi RSC58 235 72 VK(gl)QEELLNTNEEGINR Core Consen. 
 mms  RSC8  51 LENNGNSVK(gl)K No Consensus 
 mms  RSC8 123  PFLPENVIK(gl)QEVEGGDGAEPQVKK Core Consen. 
 mms oxi RTF1 140  NAEHVK(gl)KEDSNNFDSK Phospho Consen. 
non mms  RVB1 160 64 K(gl)EIVVNDVNEAK No Consensus 
non   SAT4  20 DLK(gl)PENLLLTHDGVLK Inverse Consen. 
non mms  SCC2  27 K(gl)SEIVSRPEAK No Consensus 
non   SCM4 111 23 TLK(gl)PESER Core Consen. 
non mms oxi SDC1 205 69 SVTNQNVK(gl)IEESSSTNSVIEESSEPK Phospho Consen. 
 mms  SEF1 108 31 DSK(gl)VSVQTYLSR Inverse Consen. 
non   SGS1  23 QLENDIK(gl)LEVIR Core Consen. 
non mms oxi SHS1 233 43 EIK(gl)QENENLIR Core Consen. 
 mms  SHS1 95  FLNSPDLPERTK(gl)LR No Consensus 
non mms oxi SHS1 129 36 SIK(gl)TESSPK Phospho Consen. 
  oxi SIC1 94  LTDEEK(gl)R No Consensus 
non   SIR2 111 34 IK(gl)VAQPDSLR No Consensus 
non mms oxi SIR3 140 29 K(gl)IK(gl)IEPSADDDVNNGNIPSQR Phospho Consen. 
non mms oxi SIR4 152 34 APFIK(gl)SESKPFSSDALSK Core Consen. 
non mms oxi SIZ1 154 53 NFLQNALVVGK(gl)SDPYR No Consensus 
 mms oxi SIZ1 120  STNTDILTEK(gl)GSSAPSR No Consensus 
 mms oxi SIZ1 208 56 TLDPK(gl)SYNIVASETTTPVTNR No Consensus 
non mms oxi SIZ1 94 24 VIPEYLGNSSSYIGK(gl)QLPNILGK No Consensus 
non mms oxi SKO1 226 71 DTNVVK(gl)SENAGYPSVNSRPIILDK Core Consen. 
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  oxi SLI15 101  EVK(gl)NYYQSPVR No Consensus 
non mms oxi SLI15 227 22 NNVYMNTLK(gl)YEDK Core Consen. 
non mms  SMC5  53 LDDIVSK(gl)ISAR No Consensus 
non   SNF2 84  DIGAELK(gl)R Phospho Consen. 
 mms  SOD1  28 GDAGVSGVVK(gl)FEQASESEPTTVSYEIAGNSPNAER Phospho Consen. 
non mms  SOD1 175 45 K(gl)THGAPTDEVR No Consensus 
 mms oxi SPA2 116  TIK(gl)REEEDEDFDRVNHNIQITGAYTK Acidic Consen. 
 mms  SPC24 96  LLK(gl)DLDGLER No Consensus 
non mms oxi SPP41 111 39 GVTTPIK(gl)IEDSDANVPPVSIAVSTIEPSQDK Phospho Consen. 
 mms oxi SPP41 174 69 IPEIK(gl)NESVDLGSNITDILSSTITNILPEITATDVK Core Consen. 
non mms  SPP41 131 44 PK(gl)SEDHEWPLSDSSASQNYDAHLK Core Consen. 
non mms oxi SPP41 197 64 RPQIK(gl)PEVSVINLVQNLVNTK Phospho Consen. 
non mms oxi SPP41 135  VK(gl)QQLDK No Consensus 
non mms oxi SPT15 187 33 DGTKPATTFQSEEDIK(gl)R No Consensus 
  oxi SPT7 56  NGFGTVIK(gl)QEDDDQIQFHNDHSINGNEAFEK Acidic Consen. 
 mms  SSE1 88  GK(gl)LEEEYAPFASDAEK No Consensus 
 mms  SSM4  31 LSPK(gl)DLK No Consensus 
non mms oxi STB3 96  EVSPPQAISVK(gl)SEASSSIFSK Phospho Consen. 
non   STH1 134 26 LIQLDELPK(gl)VFR No Consensus 
non mms oxi STH1 187 37 VFREDIEEHFK(gl)KEDSEPIGR No Consensus 
 mms oxi STP1 157 31 IK(gl)SEVNAK Core Consen. 
non   SUM1 145 68 IITIK(gl)SSSENSGNNTTNNNNTDNVIK No Consensus 
non mms oxi SUM1 212 66 IK(gl)NEIPINSLLPSSK Core Consen. 
non  oxi SUM1 135 28 K(gl)TPGDEETTTFVPLENSQPSDTIRK No Consensus 
non   SUM1 141 41 LPSGPK(gl)DDVDTLALTSAQNQANSLR Core Consen. 
non   SUM1 100  VNVEENK(gl)TEK No Consensus 
non   SUM1 79 19 YFVEPSTK(gl)QESLLLSAPSSSR No Consensus 
 mms  SWA2  42 YLEILK(gl)SK No Consensus 
non mms oxi SWC3 187 41 TTAESTQVDVK(gl)K Acidic Consen. 
 mms oxi SWI3 151  IQKEEEPENNTVIEGVK(gl)EESQPDENTK Core Consen. 
non mms  SWR1  43 AGGEQDLADLK(gl)FR No Consensus 
non   SWR1 141 43 LLAQAEDEDDVK(gl)AANLAMR No Consensus 
non   SWR1 140  YDHIAK(gl)VEEPSEAFTIK No Consensus 
  oxi TAF12 111  SAIFK(gl)QTEPAIPISENISTK No Consensus 
non mms oxi TAF14 218 74 TGSASTVK(gl)GSVDLEK No Consensus 
non   TAH11  34 EK(gl)MPDSQANLMDRLR No Consensus 
non mms oxi TDH1/2/3 105 33 TASGNIIPSSTGAAK(gl)AVGK No Consensus 
 mms oxi TDH2/3 104 29 VVDLVEHVAK(gl)A No Consensus 
non   TEC1  20 K(gl)IENFIK Inverse Consen. 
non   TEF1  35 LPLQDVYK(gl)IGGIGTVPVGR No Consensus 
non mms oxi TFG1 125 63 AVDSSNNASNTVPSPIK(gl)QEEGLNSTVAER Core Consen. 
 mms  TFG1 103  ENESPVK(gl)KEEDSDTLSK Acidic Consen. 
non mms oxi TFG1 236 45 GSLVK(gl)KDDPEYAEEREK Core Consen. 
non mms oxi TFG1 214 74 VK(gl)DEDPNEYNEFPLR Core Consen. 
non   TFP1  17 AIK(gl)EESQSIYIPR Phospho Consen. 
 mms  TIF4631 98  SAEPEVK(gl)QETPAEEGEQGEK Core Consen. 
 mms  TOA1  69 IEVK(gl)PEIELTINNANITTVENIDDESEK Inverse Consen. 
 mms  TOF2 129  FKPTGETK(gl)VQK Inverse Consen. 
non mms  TOF2 138 52 LHQSQGK(gl)EALFR No Consensus 
 mms  TOF2 106  LVEKEFPDK(gl)SLGAASSTSHAK No Consensus 
non   TOP1 99 29 IK(gl)TEPVQSSSLPSPPAK Core Consen. 
 mms  TOP1 197 22 KIK(gl)KEDGDVK Core Consen. 
 mms oxi TOP2 121  KIK(gl)IEDK Core Consen. 
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non mms oxi TOP2 174 18 TEEEENAPSSTSSSSIFDIK(gl)KEDK Core Consen. 
 mms  TOP2  23 TPSVSETK(gl)TEEEENAPSSTSSSSIFDIKKEDK No Consensus 
non mms oxi TRI1 194 35 EIK(gl)LENESLPNLSG Inverse Consen. 
 mms  TRI1 78  HLFNPDEIVK(gl)HEEEQKQTPEK Acidic Consen. 
 mms oxi TRI1 115  VIIPK(gl)NDIISRDQEISIR Phospho Consen. 
 mms oxi TRI1 185 38 VLLSAPLQK(gl)FLGSEELPR No Consensus 
 mms  TRX1 151 50 FSEQYPQADFYK(gl)LDVDELGDVAQK No Consensus 
 mms  TUP1 120 21 APESTLK(gl)ETEPENNNTSK No Consensus 
 mms oxi TUP1 155  DAYEEEIK(gl)HLK No Consensus 
non   TUP1 183 48 DYDFK(gl)MNQQLAEMQQIR No Consensus 
non  oxi TUP1 169 49 ETTTLPSVK(gl)APESTLK No Consensus 
  oxi TUP1 58  INDTGSATTATTTTATETEIK(gl)PK(gl)EEDATPASLHQDHYLVPYNQR Inverse Consen. 
  oxi TUP1 97  IWNIQNANNK(gl)SDSK No Consensus 
non mms oxi TUP1 202 54 LQNQK(gl)DYDFK No Consensus 
  oxi TYE7 127  K(gl)QDEDGAETAATTPIPSAAATSTK No Consensus 
non mms  TYE7 108 24 LQQIIPWVASEQTAFEVGDSVK(gl)K No Consensus 
non mms oxi TYE7 185 70 SSETTLIK(gl)PESEFDNWLSDENDGASHINVNK Core Consen. 
  oxi TYE7 145  TNIDAK(gl)ETK No Consensus 
non mms oxi UBA2 144 32 IK(gl)QETNELYELQK Core Consen. 
non mms oxi UBA2 133 33 LLAIENLWK(gl)TR No Consensus 
 mms  UBA2 109  SHIFNIPMK(gl)SVFDIK No Consensus 
 mms  UBC9 90 41 EGTNWAGGVYPITVEYPNEYPSK(gl)PPKVK No Consensus 
non mms oxi UBC9 297 72 VLLQAK(gl)QYSK No Consensus 
non mms  UBI1  74 LIFAGK(gl)QLEDGR No Consensus 
non mms  UBI1  49 TLSDYNIQK(gl)ESTLHLVLR No Consensus 
non  oxi UBI4 181  LIFAGK(gl)QLEDGR No Consensus 
non   UBI4 129  TLSDYNIQK(gl)ESTLHLVLR No Consensus 
 mms  UME1 136  STIDIAEDNKIK(gl)NEEFK Core Consen. 
non mms  UME6 130 22 DREITDPNVK(gl)LDENESK Core Consen. 
non   UPC2 96  ADGSVESDSSVDLPPTIK(gl)K Core Consen. 
non   UTP7 105 28 TNSDIPDVK(gl)PDVK Inverse Consen. 
 mms  VBA5 108  AENK(gl)GIIQQIK No Consensus 
non mms oxi VHR1 258  NLFNIINK(gl)NK No Consensus 
non  oxi VHR2 165 48 LQK(gl)FDIEDQPLESEQEYDFIAK No Consensus 
 mms oxi VIP1 200  SGIK(gl)KEPIESDEVPQQETK Core Consen. 
non mms oxi VMA1 152  AIK(gl)EESQSIYIPR Phospho Consen. 
 mms  VPS3 144  K(gl)TEDDSLR No Consensus 
  oxi VPS72 158  SDIK(gl)RDETTNEDSDDQVR Core Consen. 
non mms  VPS72 120 47 VNSDELK(gl)PTALPDVTLDAIANK Inverse Consen. 
non mms  YAP5 116 21 QK(gl)LETLTLK No Consensus 
non   YJR129C 106  IK(gl)IEETPNLISAASTTGFR Core Consen. 
non mms oxi YLR455W 206  NSISIK(gl)EDPEDNQK Core Consen. 
 mms  YMR111C  28 IK(gl)PEPGLSDFENGEYDGNESDENATTR Core Consen. 
 mms  YRR1  32 YLK(gl)LTR No Consensus 
non mms oxi YSH1 166 72 IEPIK(gl)EENEDNLDSQAEK Core Consen. 
 mms  YTA7 165 45 VGYETQIK(gl)DENGIIHTTTR Core Consen. 
 mms  ZEO1 109  AETAAQDVQQK(gl)LEETK No Consensus 
 mms oxi ZEO1 100 23 GQEVK(gl)EQAEASIDNIK No Consensus 
non mms oxi ZEO1 196 30 NEATPEAEQVK(gl)K Core Consen. 
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